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Abstract 
Tenascin-C, the founding member of the matricellular tenascin family, is a large 
multifunctional hexameric extracellular matrix (ECM) glycoprotein. It is abundantly 
expressed in the developing embryo but its expression becomes tightly regulated in 
the adult. However, during inflammatory responses tenascin-C becomes highly 
upregulated where it acts to create a local pro-inflammatory ‘niche’. In this pro-
inflammatory role tenascin-C has been implicated in the pathogenesis of a variety of 
chronic inflammatory diseases including rheumatoid arthritis (RA) and inflammatory 
bowel disease (IBD), both of which are characterised by upregulated tenascin-C 
locally and systemically. 
The work of this thesis has looked to expand upon this earlier work, identifying 
tenascin-C as a key driver as well as marker of inflammation, and further probe its 
mechanistic role in the inflammatory response and utility as a biomarker of 
inflammatory disease.  
To answer the first question regarding tenascin-C’s role in pathological inflammation 
a murine Dextran Sulphate Sodium (DSS) model of chemically induced colitis was 
utilised. This thesis details the spatial and temporal expression of tenascin-C in the 
colon under basal conditions as well as the inflammatory state of the DSS model. 
Tenascin-C demonstrated a marked upregulation within the inflamed mucosa 
coinciding with the upregulation of other pro-inflammatory mediators and immune 
cell infiltration.  
Following this descriptive characterisation, subsequent studies probed the 
mechanistic relevance of this upregulation utilising the same model in combination 
with a tenascin-C knockout mouse.  These studies showed a protective effect of 
tenascin-C’s genetic ablation on the severity of the colitis induced. This included 
reductions in gross pathology as well as histopathology including lower 
inflammation and tissue damage observed during the acute stage. 
Finally, with this mechanistic link clearly established between tenascin-C and the 
inflammatory diseased state this thesis aimed to explore tenascin-Cs utility as a 
   
disease marker, with a focus on RA. To this end, a number of novel immunoassays 
were established and validated for the measurement of tenascin-C and autoantibodies 
against in human serum samples. Screening of serum samples with these assays 
showed significantly higher levels of tenascin-C or autoantibodies against it in the 
serum of RA patients compared to healthy controls. These changes were not entirely 
RA specific however with a number of other inflammatory diseases tested also 
showing higher serum tenascin-C levels.  
The work described herein has utilised the DSS colitis model in combination with 
tenascin-C knockout mice to demonstrate the role of tenascin-C as a driver of 
inflammatory disease and has further shown translational relevance as a disease 
marker in human patients.  
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Chapter 1 Introduction 
1.1 Inflammation 
1.1.1 The inflammatory response 
Inflammation, from the Latin inflammare (to set on fire), was first clinically described 
in the first century AD by the scholar Celsus in his medical encyclopaedia ‘De 
Medicina’. He classified inflammation symptomatically which formed the basis of its 
diagnosis, still in use today, using the five cardinal signs; redness, swelling, increased 
heat, pain, and loss of function (Scott et al., 2004). In more modern medical terms’ 
inflammation is defined as the non-specific and largely immunovascular response 
launched by the body in response to a challenge to homeostasis, such as that caused 
by infection or tissue injury. The purpose of this response is to ultimately restore 
normal tissue function by repelling the threat, such as by eliminating an invading 
pathogen, and subsequently initiating tissue remodelling and repair (Medzhitov, 
2008). The exact course of the response is complex and varied, reflecting the wide 
variety of insults which may present as a challenge and the accompanying variety of 
responses the body can deploy to counteract them. In its simplest terms however, a 
model acute inflammatory response can still be subdivided into three broad categories; 
initiation, propagation, and resolution (Chen et al., 2018).  
1.1.2 Initiation  
Inflammation begins with the initiation stage where the response is triggered by 
detection of either an extreme deviation of a homeostatic variable, eliciting a stress 
response, or a threat which could disrupt homeostasis, eliciting a defence response. 
This detection utilises a variety of mechanisms and can be carried out by the majority 
of cells although specialised sensory cells, such as sentinel innate immune cells, are 
the key orchestrators (Chovatiya and Medzhitov, 2014). 
The defence response encompasses the classical inflammatory induction pathway with 
its sensors the pattern recognition receptors (PRRs). PRRs encompass several families 
of intra- and extracellular receptors which bind a wide variety of exogenous and 
endogenous ligands from nucleic acids to lipids and proteins (Takeuchi and Akira, 
2010). The first of these, recognising exogenous ligands, follow Charles Janeway’s 
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theory of the ‘Infectious Non-self’ and rely on recognition of non-self derived 
pathogen associated molecular patterns (PAMPs). PAMPs constitute conserved 
elements of pathogens which are distinguishable from the self and thus their presence 
within a normally sterile tissue would suggest a barrier breakdown or pathogenic 
invasion (Janeway, 1992, Broggi and Granucci, 2015). A prototypical example of this 
type of inducer and sensor would be lipopolysaccharide (LPS), a bacterial outer-
membrane component not found on eukaryotic cells, which is recognised by the PRR 
Toll-like receptor 4 (TLR4) (Bryant et al., 2015). The second set of patterns recognised 
by PRRs are the endogenous damage associated molecular patterns (DAMPs) which 
follow Polly Matzinger’s ‘Danger Theory’. This theory correctly proposed the 
existence of a variety of  endogenously derived patterns recognised by PRRs which 
only become available for detection upon cellular or tissue damage (Matzinger, 1994, 
Broggi and Granucci, 2015). DAMPs can be derived from a variety of cellular and 
tissue matrix sources which when damaged release detectable DAMPs as breakdown 
products or due to loss of compartmentalisation or sequestration away from sensors 
(Medzhitov, 2008). As their name would suggest the presence of these patterns signals 
that cellular or tissue injury has occurred and thus activates the inflammatory response 
in response to this. A prototypical example in this case is the protein High mobility 
group box 1 (HMGB1) which normally functions to stabilise nucleosomes and thus in 
healthy cells is safely sequestered in the nucleus (Celona et al., 2011). However, in the 
case of necrosis membrane integrity is lost and HMGB1 is released extracellular where 
it can act in a pro-inflammatory manner. This includes by acting as a ligand for the 
PRR TLR4 and demonstrates the cross-talk between these two arms of the PRR system 
(Broggi and Granucci, 2015). 
In contrast to the defence response the stress response is triggered by sensing a direct 
deviation of a variable from a homeostatic set point. This deviation is detected by the 
sensors in the variety of homeostatic regulatory systems, for example elevated 
temperature detected by heat-shock factors (Buchman, 2002). This stress can be extra- 
or intracellular in nature and if it is extreme or persistent enough it can likewise lead 
to induction of inflammation in an attempt to restore homeostasis (Chovatiya and 
Medzhitov, 2014).  
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1.1.3 Propagation and effector function  
Having initiated the response following inducer detection the inflammatory response 
is first propagated by the production, release, or activation of a range of pro-
inflammatory mediators. These can be classified into seven broad groups which 
encompass; cytokines, chemokines, lipid mediators, vasoactive amines, vasoactive 
peptides, complement components, and proteolytic enzymes (Medzhitov, 2008). 
These mediators can be produced by many cell types under inflammatory conditions 
although they are primarily produced by immune cells such as resident macrophages 
early in the response. These mediators can act both locally and systemically on target 
effector cells to induce and activate a range of functions resulting in development of 
inflammation (Medzhitov, 2008). 
As a primarily immunovascular response the immune system and vasculature are key 
effectors of inflammation. Mediators act to activate the local vasculature to dilate and 
increase in permeability resulting in localised oedema. This delivers a range of 
circulating plasma components which aid in both pathogen removal, such as 
complement and antibodies, and tissue repair, such as fibrin and coagulation factors, 
to the site of challenge (Medzhitov, 2008). These vascular changes additionally 
facilitate the recruitment of leukocytes from the blood with upregulation of expression 
of leukocyte adhesion molecules on the endothelium occurring as well. These changes 
synergise with the immune cell mobilising and chemotactic action of other mediators 
resulting in leukocyte extravasation and infiltration into the inflamed site (Medzhitov, 
2008).  
Immune cell recruitment initially consists primarily of neutrophils, followed by other 
myeloid cells such as monocytes, and finally the lymphocytes. The initial innate 
response functions primarily to eliminate pathogens, clear tissue debris, and release 
further inflammatory mediators to fine tune the response and local tissue to the threat 
being faced. This paves the way for the later arrival of lymphocytes which, further 
aided by antigen-presentation, mount the adaptive immune response alongside 
production of their own repertoires of pro-inflammatory mediators (Barton, 2008). 
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1.1.4 Resolution 
As a correctional response to challenge the ultimate goal of the inflammatory response 
is to successful resolve with resumption of homeostasis and normal tissue function. 
This was once thought to be simply a passive process whereby elimination of the 
original threat resulted in the loss of pro-inflammatory inducers and thus the 
downregulation and eventual cessation of the response. It is now appreciated however 
that inflammatory resolution is in fact an active process with its own inducers, drivers, 
and regulators (Buckley et al., 2013).  
The inducers of resolution are still being elucidated although it has been shown that 
they appear based on feedback loops from the initial signals and effectors of the 
inflammatory response (Serhan and Savill, 2005). The best example of this to date has 
been the discovery that efferocytosis of spent neutrophils, key early inflammatory 
effectors, by macrophages results in a promotion of a pro-resolution macrophage 
polarisation (Ortega-Gomez et al., 2013). In addition to induced pro-resolution cell 
types there are also intrinsic populations of immunomodulatory cell types such as 
myeloid derived suppressor cells (MDSCs) (Budhwar et al., 2018) and T regulatory 
(Treg) cells (Qiao et al., 2017). The recruitment of these anti-inflammatory cells to 
sites of inflammation therefore might likewise help promote resolution as the 
inflammatory response progresses. 
Much like the initial pro-inflammatory response resolution likewise has a variety of its 
own, and even shared in some pleiotropic cases, signalling mediators. These include 
anti-inflammatory cytokines, such as interleukin (IL)-10, lipid mediators, such as 
resolvins, and hormones such as glucocorticoids (Headland and Norling, 2015). These 
mediators act to counteract their pro-inflammatory counterparts by supressing their 
signalling and production. They also act to promote immune cell deactivation via 
apoptosis or egress via vasculature and block further recruitment. Furthermore, they 
actively promote downregulation of damaging anti-microbial and degradative 
processes in favour of those of repair such as production of growth factors to promote 
parenchymal and stromal cell regeneration (Headland and Norling, 2015). Thus, with 
repair and resumption of normal function this stage successfully ends the model acute 
inflammatory response, the stages of which are finally summarised in figure 1.1.  
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1.1.5 Chronic inflammation and disease 
The inflammatory response clearly plays a positive role in normal physiology as a 
mechanism to counteract challenges. This is evidenced by the evolutionary 
conservation of the process (Straub and Schradin, 2016) and the increased morbidity 
and mortality, from infection and other complications, seen in those in which the 
process is deficient (Nathan, 2002). However, the inflammatory response is not always 
positive for health with a dysregulated response potentially severely damaging. This 
can be exemplified in the case of sepsis whereby a hyperactive response to a 
particularly potent pathogen derived inflammatory inducer causes rapid organ failure 
and subsequent death in the host (Cohen, 2002). This starkly demonstrates the severity 
of damage inflammation can self-inflict, far in excess of the original pathogen 
challenge, and thus the need to tightly regulate the process.  
In recent decades a different type of inflammatory dysregulation has come to 
prominence however grouped under the umbrella term of chronic inflammatory 
diseases. Chronic inflammation as its name suggests is characterised by a continuous 
or recurrent response occurring over prolonged periods, from many months to years, 
far outlasting the classical acute response detailed above (Nathan and Ding, 2010). 
Chronic inflammation can occur simply due to a failure to eliminate the offending 
insult with persistent infection, such as that caused by Mycobacterium tuberculosis, or 
repeated irritation, such as that caused by silica dust inhalation, classic examples 
(Pahwa and Jialal, 2019). An increasing number of chronic inflammatory conditions 
have been characterised by the absence of obvious pathological challenge and instead 
appear a direct result of immune dysregulation and a failure of inflammatory resolution 
(Nathan and Ding, 2010).  
These wide varying diseases, covering a range of organ systems and presentations, are 
broadly classified as immune-mediated inflammatory diseases (IMIDs) (Rahman et 
al., 2010). Matching their variety, a range of shared mechanisms can drive these 
disorders which can be sub-classified on a spectrum ranging from autoimmune to 
autoinflammatory mediated. Autoimmunity is characterised by a loss of tolerance with 
the development of a pathological immune response against the self (Doria et al., 
2012). The disease systemic lupus erythematosus (SLE) is a classic example, being 
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characterised by the development of disease driving autoantibodies against a range of 
nuclear derived autoantigens (Rekvig et al., 2012). Autoinflammation in comparison 
is characterised by a breakdown in immune regulation with either overactivation of 
pro-inflammatory pathways or deficiencies in anti-inflammatory ones (Doria et al., 
2012). A paradigm of these diseases would be familial Mediterranean fever (FMF) in 
which a deactivating mutation in a negative regulator of the inflammasome leads to 
spontaneous overproduction of the pro-inflammatory cytokine IL-1β and thus disease 
(Papin et al., 2007).  
The rise to prominence of the IMIDs has been in part spurred by epidemiological 
changes with many of the diseases of rising prevalence globally. Indeed, prevalence 
while varying substantially by population studied is already high in the western world 
with estimates of an average prevalence between 5-7% (Kuek et al., 2007, El-
Gabalawy et al., 2010). Their threat to health is further compounded by their usually 
high burden on both patients and society. For patients this is reflected in both their 
significantly impaired quality of life due to pain, disability, depression, and anxiety 
(Russell et al., 2011, Enns et al., 2018), as well as their heightened incidence of 
mortality and other comorbidities (El-Gabalawy et al., 2010). In terms of society the 
conditions chronic duration and disabling nature lead to high socioeconomic costs due 
to decreased work-related productivity (Jacobs et al., 2011) as well as the need for 
expensive extended health and social care (Baumgart et al., 2019).  
The reasons for the increase in prevalence of IMIDs is an area of active research in 
which several theories have been posited. Most rest on a common base theory, 
stemming from the field of evolutionary biology, which proposes that humans are 
maladapted to their modern environment which leads to disease (Okin and Medzhitov, 
2012). Sociological changes in recent decades which have hastened or are a result of 
these environmental factors have thus led to increased disease prevalence. The increase 
in lifespans due to modern medicine and resulting aging populations seen in most 
industrialised countries is one such sociological factor. IMID incidence increases with 
age and ageing is characterised by a gradual increase in systemic inflammation, termed 
inflammaging (Franceschi and Campisi, 2014). This is hypothesised to occur due to 
positive selection for pro-inflammatory systems occurring due to their ability to help 
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fend off challenge, such as infection, early in life. As the subsequent long term 
detrimental effects of these systems mainly become apparent at post-reproductive ages 
they are thus selected for in the population as they result in an increase in reproductive 
fitness (Straub and Schradin, 2016). Environmental sociological factors are also 
implicated in IMID pathogenesis with the comparative cleanliness of modern living 
conditions implicated. The detriments of this lifestyle is summarised in the hygiene 
hypothesis that states that the immune system is adapted to function in an unsterile 
environment and thus in the absence of microbial challenge becomes dysregulated 
resulting in IMIDs (Okada et al., 2010). In addition, modern environmental stressors 
are another factor implicated in IMID development with exposure to irritants from 
smoking and via pollution both associated with inflammatory diseases (Gawda et al., 
2017). Finally, diet is another potential stressor with the western diet associated with 
IMIDs due to its propensity to lead to obesity and dysbiosis of the gut microbiota 
which can both cause inflammation aggravating stress (Versini et al., 2014).  
In summary the chronic inflammatory IMIDs represent a growing threat to global 
health and already represent a large burden on both patients and societies as a whole. 
Their threat is further amplified by their often complex and uncertain aetiology which 
negatively impacts their medical management by for example hindering development 
of effective curative therapies. Going forward the work of this thesis will 
predominantly focus on the archetypal IMID inflammatory bowel disease, an umbrella 
term for inflammatory diseases of the gastrointestinal tract.  
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1.2 Inflammatory bowel disease (IBD) 
Before delving into the pathology of IBD it is pertinent to first assess the context in 
which the disease arises in the gastrointestinal (GI) system, considering this major 
organ systems overall function as well as its immune components. 
1.2.1 The gastrointestinal system 
The human GI system is a major organ system responsible for the digestion of ingested 
foodstuffs so that nutrients can be extracted and adsorbed into the body. Multiple 
organs co-ordinate to achieve this goal and make up the GI tract, through which 
ingested food passes, as well as the accessory organs which aid digestion. The GI tract 
begins at the mouth where food first enters the tract and is mechanical broken down 
by mastication and by digestive enzymes produced by the salivary glands. Food is then 
passed through the pharynx and oesophagus to the stomach where it is mixed with 
gastric acid and digestive enzymes for further digestion. The digestate, called chyme, 
then passes, via the pyloric sphincter, into the duodenum, the first segment of the small 
intestine. In the small intestine the chyme is mixed with digestive enzymes and other 
secretions produced in the liver, gall bladder, and pancreas. This results in further 
breakdown and release of nutrients, including saccharides, amino acids, vitamins, and 
lipids, which are absorbed into the body across the intestinal epithelium. This process 
of digestion and absorption continue as the digestate passes through the remaining 
sections of the small intestine, the jejunum and ileum, before reaching the large 
intestine. Upon reaching the large intestine digestion has largely run its course and the 
digestate, now termed faeces, is prepared for excretion from the body. This largely 
involves the absorption of any remaining water and minerals from the faeces before it 
is finally excreted from the tract via the rectum and anus (Greenwood-Van Meerveld 
et al., 2017). A summary diagrammatic overview of the GI systems anatomy 
highlighting these key organs and their arrangement in the human body can be found 
in figure 1.2. 
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1.2.2 The intestinal tract 
The intestinal tract is composed of both the small and large intestine which form a 
continuous tube, approximately eight metres long in an adult human, from the outlet 
of the stomach to the anus (Mowat and Agace, 2014). The small intestine is narrow in 
diameter but long, at approximately six and a half metres in length, and is responsible 
for handling the majority of the digestion and nutrient absorption process. The large 
intestine in contrast is wider in diameter but shorter, at approximately one and a half 
metres in length, and is composed of the caecum, colon, and rectum (Mowat and 
Agace, 2014). The caecum is a blind-ended pouch present at the start of the large 
intestine at its junction with the small intestine. The caecum’s function is as a store for 
the commensal microbiota, which is in highest numbers in the large intestine, which 
ferment foodstuffs not able to be digested by the small intestine. This function is 
mainly pertinent to herbivores, such as the house mouse Mus musculus, due to the need 
for fermentation to efficiently breakdown plant material and as such the caecum is 
largely vestigial in humans (Smith et al., 2009). The colon makes up the majority of 
the large intestine and carries out its primarily water reabsorption functions in 
preparation for excretion which occurs via the rectum an anal canal ending in 
expulsion through the anus (Greenwood-Van Meerveld et al., 2017).  
In terms of histology a common layout of the intestinal wall is maintained along the 
length of the tract. This consists of an outer muscularis externa, which overlies the 
submucosa, which in turn overlies the inner luminal facing mucosa (Mowat and Agace, 
2014). The muscularis externa is primarily composed of smooth muscle and functions 
in motility and segmentation of luminal contents ensuring their proper mixing and 
propulsion in an anterograde manner (Greenwood-Van Meerveld et al., 2017). The 
submucosa separating the muscularis externa from the mucosa serves a mainly 
connective tissue role containing major vascular vessels and nerves and thus is also an 
important site of interface with the rest of the body (Greenwood-Van Meerveld et al., 
2017). The final layer is the mucosa which serves as the interface with the lumen from 
which it absorbs nutrients and fluid and secretes into a variety of protective and 
digestive factors. In terms of structure at its base the mucosa separates itself from the 
submucosa with a layer of smooth muscle termed the muscularis mucosae. Above this 
lies the connective tissue of the mucosa, the lamina propria, which contains a variety 
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of stromal cells, such as fibroblasts, and immune cells, such as macrophages as well 
as the mucosal vascular network. Covering the lamina propria and separating it from 
the lumen is the intestinal epithelium, composed primarily of a single layer of 
columnar epithelial cells, which displays a structure characterised by crypts, tubular 
invaginations which extend down into the mucosa (Mowat and Agace, 2014). At the 
base of these crypts are epithelial stems cells which replicate and differentiate moving 
up the crypt to replace epithelial cells which are shed into the lumen at the luminal 
surface at the tops of the crypts. Other fully differentiated epithelial cell types include 
goblet cells, which secrete mucus into the lumen, and a variety of enteroendocrine and 
immune related cell types with secretory, as well as sensing and signalling roles 
(Garrett et al., 2010).  The major histological difference between the mucosa of the 
small and large intestine are the presence of intestinal villi which are present in the 
former and absent in the latter. Villi are long thin mucosal extensions, extending from 
the epithelium at the top of the crypts out further into the lumen. Villi serve to further 
increase the surface area of the small intestine to aid nutrient absorption (Mowat and 
Agace, 2014). To summarise a diagrammatic representation of histological layout of 
the colon wall in transverse cross section, as well as a labelled histological section of 
murine colon in the same orientation, are presented in figure 1.3. 
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1.2.3 The mucosal immune system 
As a major interface with the external environment, with a surface area of 
approximately 100m2, the intestines are a major site of immunological challenge 
(Artis, 2008). As such, humans have evolved a robust GI mucosal immune system 
consisting of resident immune cell populations as well as distinct specialised lymphoid 
tissues which together make up the largest compartment of the body’s immune system 
(Mowat and Agace, 2014). 
The majority of the immune cells of the intestines reside diffusely distributed within 
the lamina propria of the mucosa and vary in number and variety along its length based 
on immunological function and need (Mowat and Agace, 2014). Macrophages of the 
innate immune mononuclear phagocytic system are the most abundant in the lamina 
propria and present along the entire length of the intestine (Mowat and Agace, 2014). 
Macrophages play a key local immunomodulatory role in managing maintenance of 
tolerance to the commensal microbiota while also acting as important immune 
sentinels for pathogenic threats (Bain and Schridde, 2018). In their first role intestinal 
resident macrophages help maintain tolerance via their secretion of the 
immunoregulatory cytokines IL-10 and transforming growth factor β (TGFβ) which 
help dampen local immune responses (Hadis et al., 2011). In their second major role 
macrophages act as a second line of defence following microbial breach of the 
epithelium with potent bactericidal phagocytic activity (Bujko et al., 2018). They also 
act to monitor the luminal microbiota, via extension of antigen sampling transepithelial 
dendrites, for potential threats which they can then present antigens of to the adaptive 
immune system (Niess et al., 2005). Macrophages are helped in this last role by 
dendritic cells (DCs), also of the mononuclear phagocytic system, which are also 
present along length of the intestine although at much lower abundance (Mowat and 
Agace, 2014). DCs play an important role in progressing the adaptive immune 
response via uptake of antigens, including those sampled from the lumen by 
macrophages, before migrating to local lymphoid tissues for antigen presentation to 
lymphocytes (Persson et al., 2013). 
In terms of lymphocytes both cytotoxic and helper T cells are also present within the 
lamina propria although the latter predominates (Mowat and Agace, 2014). These cells 
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are predominantly of a resident effector memory phenotype which are primed to 
respond to a previously encountered antigen (Sathaliyawala et al., 2013). They 
additionally come in a variety of functional subtypes including the pro-inflammatory 
Th1 and Th17 polarisations which can function to counteract local pathogens (Tato 
and O'Shea, 2006). In addition, immunomodulatory Treg cells are also present and 
along with macrophages play an important role in dampening the local immune 
response via production of cytokines such as IL-10 (Zigmond et al., 2014). Alongside 
T cells B lymphocytes are also present in the lamina propria along the length of the 
intestinal tract largely as plasma cells which predominantly produce IgA class 
antibodies (Mowat and Agace, 2014). These antibodies are then trafficked into the 
lumen via overlying epithelial cells and act as another line of defence against microbial 
encroachment (Brandtzaeg, 1974).  
In addition to their presence in the lamina propria lymphocytes are also reside within 
the organised lymphoid tissues of the intestine, termed gut associated lymphoid tissue 
(GALT). GALT exist as subepithelial lymphoid aggregates embedded in the mucosa 
and submucosa of the gut wall where, like other secondary lymphoid tissues, they 
function to aid the co-ordination of the immune response (Mowat and Agace, 2014). 
They carry out this role by acting as specialised collecting sites for mucosal derived 
antigens which are then efficiently presented to lymphocytes in a lymph node-like 
environment that supports the adaptive immune response (Randall and Mebius, 2014). 
In the intestinal tract GALT can be developmentally derived, as is the case for Peyer’s 
patches in the small intestine (Veiga-Fernandes et al., 2007) and colonic patches in the 
large (Baptista et al., 2013). In addition, solitary intestinal lymphoid tissues (SILT), 
which includes the cryptopatch and isolated lymphoid follicle (ILF) GALTs, develop 
postnatally in response to antigenic challenge and inflammation (Buettner and 
Lochner, 2016).  
The mucosal immune system must not only be able to efficiently mount a response 
against a perceived threat but must also exist in balance with the basal external 
environment. In doing this it must contend with a high load of innocuous foreign 
antigens derived from food and commensal organism which must be tolerated. When 
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this system of regulation is disrupted disease arises as in the case of IBD (Garrett et 
al., 2010). 
1.2.4 Pathophysiology of IBD 
IBD is the name given to a group of IMIDs characterised by idiopathic non-infectious 
pathological inflammation of gastrointestinal tract. The two main clinical 
subgroupings of IBD are ulcerative colitis (UC) and Crohn’s Disease (CD) which 
while sharing some similarities both have their own distinct disease presentations and 
pathophysiology (de Souza and Fiocchi, 2016). 
UC is clinically defined as a condition that causes non-infectious chronic mucosal 
inflammation that affects the rectum and colon in a continuous lesion and has a 
relapsing and remitting disease course (Magro et al., 2017). UC can be further 
subclassified based on the disease’s distribution along the large intestine, as assessed 
by endoscopy, which produces the three subgroups of proctitis, left-sided, or extensive 
UC. These reflect the extension of the disease proximally, with proctitis affecting 
solely the rectum, left-sided UC restricted to the distal colon, and extensive UC 
extending even further proximally from the distal colon (Silverberg et al., 2005).  
Additionally, UC can also be sub-classified based on disease activity and severity as 
assessed by several clinical parameters. These include measures of systemic 
inflammation and toxicity including, erythrocyte sedimentation rate (ESR), body 
temperature, haemoglobin concentration, and pulse rate, as well as frequency of 
passing stools and presence of blood in faeces. This produces four subclasses of 
increasing severity from, asymptomatic remission, to mild, moderate, and severe 
disease activity (Silverberg et al., 2005). In terms of macroscopic pathology UC is 
characterised by an inflammatory vascular pattern, including erythema and loss of 
vascularity, as well as mucosal damage including bleeding and the presence of the 
eponymous superficial ulceration (Travis et al., 2012). Histologically UC pathology is 
generally superficial being restricted to the mucosa with only occasional extension into 
the submucosa. Mucosal damage presents in a continuous nature with widespread 
distortion of crypt architecture, including atrophy and branching, alongside luminal 
mucus depletion. Additionally, infiltrating neutrophils invade the crypt epithelium, 
termed cryptitis, as well as the crypt lumen forming crypt abscesses. This accompanies 
 Tenascin-C: A marker and driver of inflammation 
Chapter 1 – Introduction 17 
the general diffuse inflammatory infiltration of the lamina propria which is primarily 
composed of neutrophils and lymphocytes, including plasma cells which are 
characteristically found around the base of the crypts (Magro et al., 2013).  
Crohn’s disease in contrast to UC is a more clinically heterogenous disease 
characterised by chronic non-infectious discontinuous granulomatous inflammation 
which may affect anywhere along the entire length of the GI tract (Gomollon et al., 
2017). Like UC disease is also subclassified based on number of features which 
include age of diagnosis, location of disease, and disease behaviour. Age of diagnosis 
splits patients into three subgroups of early, common, and late onset CD based on the 
cut offs of 16 years or younger, 17-40 years, and over 40 years of age respectively 
(Silverberg et al., 2005). Disease location splits patients into a further four 
subcategories centred primarily on the most commonly affected areas of the ileum and 
colon. These categories include terminal ileum, colon, ileocolon in which disease 
affects both the colon and ileum, and upper GI tract. Additionally, the first three 
categories are not entirely mutually exclusive with the potential for upper GI 
involvement in each of these categories as well (Silverberg et al., 2005). Finally, 
disease can also be subclassified based on its behaviour which splits patients into an 
additional three groups. These include stricturing, in which constant obstructive 
luminal narrowing occurs, penetrating, in which intraabdominal fistulas or 
inflammatory masses and abscesses are present, and uncomplicated non-stricturing 
non-penetrating disease (Silverberg et al., 2005). In terms of macroscopic pathology 
CD is characterised by skip lesions whereby inflammation presents as patchily 
distributed lesions interspersed between areas of unaffected tissue, commonly giving 
a cobblestone like appearance. In addition, longitudinal serpinginous ulcers, fistulae, 
and strictures can also all potentially be present (Annese et al., 2013). Matching its 
macroscopic presentation histopathologically CD presents as focal discontinuous 
tissue damage and or inflammatory infiltration. Unlike UC this infiltrate and tissue 
damage is not restricted to the superficial mucosa and may extended through the entire 
width of the gut wall. Tissue damage typically presents as abnormal crypt architecture, 
including distortions in crypt morphology and branching, and in the small intestine 
irregular villous architecture. In terms of immune infiltration lymphocytes and plasma 
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cells are found diffusely infiltrating the tissue alongside granulomas consisting of 
monocytes and macrophages (Magro et al., 2013). 
To summarise these two major IBD clinical groupings a diagrammatic overview of the 
common histopathological features of both UC and CD is presented in figure 1.4. 
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1.2.5 Epidemiology of IBD 
Like other IMIDs IBD is growing problem globally with increased incidence observed 
especially in countries with emerging economies and associated societal 
westernisation (Ng et al., 2018). In western countries, in which IBD is well established, 
prevalence is also high, around or exceeding 0.3% in many countries (Ng et al., 2018), 
including in the UK where prevalence has been estimated at 261 per 100,000 
population (Lewis et al., 2002). Much like other IMIDs as well IBD has a high patient 
and societal burden. For patients this burden manifests as reduced quality of life due 
to abdominal pain, incontinence, GI bleeding, fatigue, and the associated impacts of 
these symptoms on their ability to function in society (Lonnfors et al., 2014). In terms 
of society, the loss of productivity and need for social care due to the disabling nature 
of these symptoms impacts social safety nets, with for example 20% of European IBD 
patients requiring disability benefits (Burisch et al., 2013). In addition, costs of 
treatment have risen in recent decades, primarily due to the introduction of highly 
costly biologic therapies, which combined with the need for long-term medical 
management has led to high IBD related health care expenditure (Click et al., 2019). 
This can be seen in Europe’s IBD costs which have been estimated to account for the 
significant sum of €4.6-5.6 billion in direct healthcare expenditure per year (Burisch 
et al., 2013).  
In terms of IBD patient demographics there is considerable geographic variation, as 
would be expected by the diverse array of potentially geographically influenced factors 
which are implicated in this multi-factorial disease (Cosnes et al., 2011). Typically 
though, in contrast to some other IMIDs, disease onset usually occurs in early to mid-
life with peak occurrences from 20-30 and 30-40 years for CD and UC respectively 
(Ruel et al., 2014). In terms of sex UC occurs more frequently in men and CD more 
frequently in women, although these associations can be lost of reversed when looking 
at different subgroups categorised based on factors such as on age of onset (Cosnes et 
al., 2011). Patients suffering from IBD additionally often present with initially or 
develop other IMIDs as comorbidities at a higher incidence rate than the population 
average (Halling et al., 2017). IMID comorbidity in IBD is associated with worse 
quality of life for the patient as well as more severe IBD which often requires more 
intensive therapies (Conway et al., 2017, Burisch et al., 2019).  
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1.2.6 Aetiology of IBD 
Like most IMIDs IBD is a complex multi-factorial disease with no definitive 
aetiological mechanisms defined, although a number of factors have been identified 
and theories based on them proposed (de Souza and Fiocchi, 2016).  
As has been suggested for IMIDs in general and as the epidemiological data, showing 
geographic heterogeneity, would suggest a range of environmental factors have been 
proposed to influence the development of IBD (Bernstein, 2017). Of these it has been 
diet, antibiotic use, and by extension the gut microbiota these can alter which have 
received the most attention, with a potential microbial infectious origin of disease 
proposed since the diseases first medical description (Bosca-Watts et al., 2015). 
Indeed, dysbiosis of the GI microbiota is well characterised in IBD patients with 
reduced commensal diversity and higher number of mucosa associated pathogenic 
species (Chassaing and Darfeuille-Michaud, 2011). Furthermore, animal models have 
shown that transplant of IBD patient derived microbiotas can exacerbate colitis 
susceptibility (Britton et al., 2019). However, due in part to the immense diversity 
between and within individuals’ microbiotas, a definitive causative microbe or 
microbes has so far remained elusive. Additionally, some argue that dysbiosis rather 
than a causative factor of IBD is actually just a secondary by-product of intrinsic 
inflammatory pathology of the gut (Chassaing and Darfeuille-Michaud, 2011).  
Looking to host factors, similarly to other IMIDs, IBD has been shown by familial 
aggregation and genetic association studies to also be underpinned by a genetic 
component to disease (Ye and McGovern, 2016). Some of the first gene variants 
identified to predispose to IBD were for the PRR receptor caspase recruitment domain-
containing protein 15 (CARD15), with predicted implications on its activation (Hugot 
et al., 2001). Since then a plethora of risk genes across different populations have been 
identified which are known to be involved in a range of diverse processes from HLA 
genes, involved in antigen presentation, to ATG genes, involved in autophagy (Liu et 
al., 2015). Additionally, some of these factors have been further linked to specific 
subtypes of disease, such as disease location in CD, further suggesting they play a role 
in specific aspects of disease pathogenesis (Cleynen et al., 2016). However, it should 
be noted that IBD is very much a polygenic disease with individual variants only 
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providing a minor contribution to disease heritability which even when combined only 
explain between 15-19% and 19-26% heritability for UC and CD respectively (Ye and 
McGovern, 2016). As such, current theories centre around the interactions of host 
genetics and the microbiota in combination. In these models genetic variants 
predisposes to auto-inflammatory overactivation of immunity and defective 
interactions with the microbiota. Combined with other complex environmental factors 
in reciprocal interactions it is theorised these factors jointly lead to the development of 
the inflammatory pathology and dysbiosis of IBD (de Souza and Fiocchi, 2016). 
Despite these theories, which have in some cases have helped guide clinical practice, 
lack of a clarity in IBDs aetiology is still problematic from a clinical management and 
therapeutic development point of view. In particular, this knowledge gap prevents the 
development of causal therapies which, in targeting the cause of the disease, unlike all 
current treatments could prove to be potentially curative (de Souza and Fiocchi, 2016). 
As such, further work is needed to further identify and better understand the 
pathological mechanism in play in IBD. Regarding this aim, the work of this thesis 
will focus on dissecting the role of one such pathogenic mechanism based on the 
protein tenascin-C, which will potentially have broad applicability to other IMIDs as 
well. 
1.3 Tenascin-C  
1.3.1 The extracellular matrix (ECM) 
The ECM, of which tenascin-C is a component, is the three-dimensional non-cellular 
macromolecular network found within all tissues of multicellular metazoan organisms. 
The ECM varies substantially by tissue type and sub-localisation, reflecting the 
different requirements of each site, and in most tissue is primarily composed of 
proteins and carbohydrates, often in combination as glycoproteins (Theocharis et al., 
2016). 
In terms of function the ECM has a clear integral role as a structural and mechanical 
component of tissues. This is exemplified by the fibrillar collagens, such as collagen 
type 1, which provide tensile strength to a range of tissues (Frantz et al., 2010). The 
ECM in this structural role also functions as a scaffold substrate for cells to adhere to, 
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with the basement membrane, which underlies all epitheliums and acts as an anchorage 
point for epithelial cells, a clear example (Jayadev and Sherwood, 2017). In addition 
to these structural roles it has also become appreciated in recent decades that the ECM 
can also act as an important modulator of cellular behaviour and tissue function. In the 
first instance this can be achieved by the ECMs function as a storage reservoir for a 
variety of biochemical and biological factors, including minerals and growth factors, 
whose controlled release can affect cells in a myriad of ways. Secondly, ECM 
components can carry out this role through their own direct or indirect interactions 
with cells.  This includes their ability to function as co-receptors to a range of soluble 
signalling factors, as well as their ability to directly bind and activate a range of cell 
surface receptors (Hynes, 2009). 
In regard to the matrix as a direct signalling modulator of cellular behaviour the 
matricellular family of proteins are probably the best-known example. A diverse 
family they were classically defined by their de-adhesive properties and non-structural 
roles in a range of processes from embryogenic cell differentiation to tissue 
remodelling in response to wounding. The family consists of several sub-families with 
a variety of distinct and overlapping structures, functions, and expression patterns. 
This includes the tenascin family of proteins of which tenascin-C is a member 
(Murphy-Ullrich and Sage, 2014).  
1.3.2 The tenascin family of proteins 
The tenascin family of proteins is composed of four members in mammals; tenascin-
C, tenascin-R, tenascin-W, and tenascin-X. The family is believed to have evolved 
early in the chordate lineage with a single precursor tenascin gene present. This gene 
was subsequently conserved in future lineages and duplicated in vertebrates to produce 
the four members of the family found in tetrapods today (Tucker et al., 2006, Adams 
et al., 2015). The family is not unified by expression patterns or function which, while 
in some cases overlapping, overall differ substantial. Instead the family are 
characterised by their common unique domain structure consisting of, from N to C 
terminus, tenascin assembly (TA) domain, a series of epidermal growth factor-like 
(EGF-L) repeats, a series of fibronectin type 3 (FNIII)-like repeats, and finally a 
terminal fibrinogen-like globe (FBG) domain (Chiovaro et al., 2015).  
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1.3.3 Molecular structure of tenascin-C 
Tenascin-C, originally just called tenascin among other names, was the founding 
member of the family, being first described in 1983 by Bourdon and colleagues 
(Bourdon et al., 1983), and is no exception from this domain structural organisation. 
The human tenascin-C polypeptide consists of an N terminal TA domain followed by 
14.5 EGF-L repeats, up to 17 FNIII-like repeats, and a terminal FBG domain (Mighell 
et al., 1997). This domain structure for tenascin-C, as well as its amino acid sequence, 
is further conserved evolutionarily between organisms, including between humans and 
the common house mouse, Mus musculus. This can be revealed by aligning the protein 
sequences of human (UniProt identifier P24821) and mouse (UniProt identifier 
Q80YX1) using the multiple sequence alignment tool Clustal Omega (Sievers et al., 
2011). Such an alignment shows the orthologs overall share a high amino acid 
sequence identity of approximately 88%, with the most major difference between the 
proteins being the presence of three fewer FNIII-like repeats in the murine version.  
Indeed, the FNIII-like repeats are of particular note in tenascin-C as they are known to 
produce significant isoform diversity due to alternative splicing. In mice and humans 
eight of the FNIII-like repeats are constitutively expressed while six and nine, in 
humans and mice respectively, are subject to alternative splicing (Giblin and 
Midwood, 2015). In the tenascin-C gene each FNIII-like repeat is encoded individually 
by one or two exons with, from the N to C terminal, five constitutive repeats followed 
by all of the alternatively spliced repeats, before the sequence is finished by the three 
remaining constitutive repeats. As each repeat is encoded by separate exons, and thus 
able to be spliced independently, this allows for a wide range of potential alternative 
splicing combinations which are realised as a wide range of tenascin-C isoforms that 
have been found (Giblin and Midwood, 2015). 
As well as being alternatively spliced each tenascin-C polypeptide does not exist in 
isolation with the mature protein secreted into the matrix as a homo-oligomer (Taylor 
et al., 1989). This takes the form of a hexamer with each of the six tenascin-C 
polypeptide monomers joined centrally by disulphide bonding within their N terminal 
TA domains (Kammerer et al., 1998). This adds another area of potential variation 
with the opportunity for homo- and hetero-typic oligomerisation of differentially 
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spliced or otherwise modified tenascin-C monomers (Giblin and Midwood, 2015), and 
even theoretically other tenascin family members (Jones and Jones, 2000).  
A summary overview of the molecular structure of a tenascin-C monomer and its 
arrangement in its mature hexameric form are shown in figure 1.5a and 1.5b 
respectively. 
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1.3.4 Post-translation modification (PTM) of tenascin-C 
Further diversity is added, to the already described variability of tenascin-C, through 
a variety of known post-translational modifications. The best described of these is 
glycosylation, with tenascin-C shown to be a glycoprotein, like many ECM proteins, 
shortly after its first identification. These early studies proved tenascin-C’s 
glycosylated status by treating the purified protein with different glycosidases, such as 
endoglycosidase F and neuraminidase. The proteins molecular weight was then 
determined and the loss weight, due to the loss of the carbohydrate moieties, assessed. 
This, along with other more indirect methods such as caesium chloride equilibrium 
sedimentation, demonstrated that tenascin-C had a significant carbohydrate 
component and was thus significantly glycosylated (Vaughan et al., 1987, Taylor et 
al., 1989). Subsequent studies using protein sequence interrogation and bioinformatic 
resources has revealed human tenascin-C has 26 and 34 predicted N-glycosylation and 
O-glycosylation sites respectively (Gulcher et al., 1989, Giblin and Midwood, 2015). 
Of these for the N-glycosylation sites the predominant number were found in the 
FNIII-repeat domains with 21 sites identified, including many within alternatively 
spliced domains. Of the remaining sites 2 were found in the TA domain, 2 in the EFG-
L repeat region, 1 in the FBG domain (Giblin and Midwood, 2015). These in silico 
predictions have subsequently been largely validated by glycopeptide mass mapping 
with only two sites, one in the FNIII-like repeat region and one in the FBG domain, 
found not to be glycosylated (Mangan et al., 2019). These studies also confirmed the 
presence of significant variability in tenascin-C N-glycosylation dependent on the 
tissue or cellular source of the protein, including differences in sialyation, mannose 
content, and proportions of processed glycans (Mangan et al., 2019). For O-
glycosylation, while no validating mapping has been undertaken, a similar pattern of 
predicted sites is seen with again the predominant number found in the FNIII-repeat 
domains with 24 sites identified including a number within alternatively spliced 
domains. Of the remaining sites 8 were found in the TA domain and 2 in the EFG-L 
repeat region, with none identified in the FBG domain (Giblin and Midwood, 2015). 
Despite these limited descriptive studies of tenascin-C’s glycosylation status even less 
is known about the functional significance of these modifications with the most work 
to date focused on the human natural killer-1 (HNK-1) carbohydrate epitope. HNK-1 
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is a unique trisaccharide motif found on both O- and N-linked glycoconjugates of a 
number of glycoproteins expressed in the nervous system (Morise et al., 2017), 
including tenascin-C (Kruse et al., 1985, Grumet et al., 1985). While having a number 
of roles in the nervous system tenascin-C specific HNK-1 has been implicated in 
modulating the proliferation of neural stem cells (Yagi et al., 2010).  
Besides glycosylation the other main PTM which has been studied in the case of 
tenascin-C is proteolytic processing. In regard to this a variety of proteases have been 
identified with the ability to cleave tenascin-C which include; matrix 
metalloproteinases (MMP) -1, -2, -3, -7, neutrophil elastase, cathepsins -B, -G, a 
disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) -5, and 
meprinβ (Imai et al., 1994, Siri et al., 1995, Mai et al., 2002, Zhen et al., 2008, Ambort 
et al., 2010). Proteolytic processing, as well as controlling the amounts of proteins in 
its classic degradative role, can also have functional consequences for proteins. This 
can be achieved by processing resulting in the exposure or release a novel functional 
site on the protein, termed a matricryptic site or if released as a fragment a matricryptin 
(Ricard-Blum and Salza, 2014). Such cryptic sites have been found in tenascin-C such 
as an integrin binding site in the third FNIII-like repeat which is only functional when 
presented to cells as part of a small fragment of the total protein (Denda et al., 1998). 
Additional functionality for subdomains, distinct from the full length tenascin-C 
protein, includes; inhibition of fibronectin fibrillogenesis (To and Midwood, 2010), 
syndecan-4 dependent β1 integrin activation (Saito et al., 2007), and induce apoptosis 
in smooth muscle cells (Wallner et al., 2004).  
The combination of all of these PTMs with the post transcriptional splicing tenascin-
C undergoes results in the potential production of a wide range of isoforms. In addition, 
a number of uncharacterised established, as well as yet to be discovered, PTMs may 
add further layers of complexity to tenascin-C. A prime example would be protein 
phosphorylation, with a recent study of publicly available human proteomic data 
finding evidence of four previously unrecognised putative phosphorylation sites in 
tenascin-C, three in the TA domain and one in the FNIII-like repeat region (Klement 
and Medzihradszky, 2017). Furthermore, as was mentioned earlier for glycosylation, 
there is evidence that splicing and PTMs occur in a cell type or tissue specific manner 
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suggesting there is likely multiple potential layers of regulation of tenascin-C function 
in vivo (Giblin, 2018). The functional impacts of much of this variation still remain to 
be determined although both splicing and PTMs are already been shown to impact a 
range of processes from cancer cell invasion to embryonic development (Giblin and 
Midwood, 2015).  
1.3.5 Expression and role of tenascin-C in development  
The first description of tenascin-C, by Bourdon and colleagues, characterised its 
presence in the ECM of human glioma cell lines and tissue (Bourdon et al., 1983). 
Tenascin-C was subsequently determined to be present in not only in the stroma of 
numerous tumour tissue types  but also dynamically in a wide range of locations during 
embryogenesis (Midwood et al., 2016). This dynamic and diverse oncofetal expression 
pattern, as would be expected, was found to be regulated by an equally diverse range 
of transcription factors (TFs) and gene response elements (Chiovaro et al., 2015). 
These include classical developmentally important homeobox containing TFs such as, 
even-skipped homeobox 1 (EVX1) (Jones et al., 1992), orthodenticle homolog 2 
(OTX2) (Briata et al., 1999), and POU domain class 3 transcription factor 2 (POU3F2) 
(Copertino et al., 1997).  
This highly regulated expression provoked widespread research interest, particularly 
in the field of developmental biology, which subsequently attributed a variety of 
functions to tenascin-C based on its locality and findings of in vitro studies. This 
included roles for tenascin-C in embryological cell proliferation, differentiation, and 
migration in a range of tissues from the GI tract to the nervous system (Chiquet, 1992, 
End et al., 1992, Beaulieu et al., 1993, Chiquet and Wehrle-Haller, 1994). However, 
these theories largely fell apart in the early to late 1990s when two independent groups 
published the generation of tenascin-C knockout (Tnc-/-) mice, which both 
demonstrated apparently normal embryonic development (Saga et al., 1992, Forsberg 
et al., 1996). Hopes were further dashed in subsequent studies which found no obvious 
mechanisms of compensation for loss of tenascin-C by other tenascin family members, 
suggesting tenascin-C plays a largely superfluous role in embryogenesis (Mackie and 
Tucker, 1999). 
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At this point in time, aside from in the field of oncology, tenascin-Cs role in mature 
adults had been largely neglected. This was due to the observation that, especially in 
comparison to its embryological expression, tenascin-C seemed sparsely expressed in 
most adult tissues (End et al., 1992). Subsequent studies have identified roles for this 
limited basal expression of tenascin-C in adult tissues, particularly as a component of 
stem cell niches where it can influence cell differentiation (Chiquet-Ehrismann et al., 
2014). The subsequently most studied aspect of adult tenascin-C expression has not 
been this baseline expression however but its reactive expression, with tenascin-C 
shown to be induced by a variety of signals in the adult. Of most interest to this thesis 
was the observation that tenascin-C was found to be induced as part of the 
inflammatory response, it’s expression and roles in which will now be discussed.  
1.4 Tenascin-C and inflammation  
1.4.1 Expression of tenascin-C in the inflammatory response 
The first observation of inflammatory tenascin-C expression was identified in a model 
of dermal wounding where tenascin-C was found significantly upregulated at the 
wound edge and within granulation tissue. Of note was the fact this expression was 
transient and, like the inflammatory response itself, as the wound healed and resolution 
finalised so too did tenascin-C expression subside to negligible basal levels (Mackie 
et al., 1988, Murakami et al., 1989). Subsequent studies in a range of tissue and injury 
types, from human patients as well as animal models, have found similar patterns of 
transient inflammatory upregulation of tenascin-C (Udalova et al., 2011). This 
included in infectious inflammation induced by bacterial; such as tuberculosis 
(Kaarteenaho-Wiik et al., 2000) and H. pylori (Tiitta et al., 1994); viral; such as human 
rhinovirus 16 (Proud et al., 2008) and hepatitis B (Lebensztejn et al., 2006); and fungal; 
such as candidaosis (Tiitta et al., 1995); pathogens. Likewise, tenascin-C was also 
found upregulated in sterile inflammatory responses as well, such as in cases of dermal 
photodamage (Filsell et al., 1999), tendon and joint injury (Riley et al., 1996, 
Chockalingam et al., 2013), and asbestos induced lung damage (Kaarteenaho-Wiik et 
al., 2000).  
This reactive expression has been shown to be driven and regulated by a number of 
different signalling pathways and TFs involved in responses to cellular stress, 
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cytokines, and growth factors (Chiovaro et al., 2015). In regard to cellular stressors a 
range of exogenous derived noxious stimuli, discussed earlier as inducers of the 
inflammatory response, have been found to also induce tenascin-C expression. This 
includes PAMP signalling via PRRs, such as LPS and flagellin signalling via TLR4 
and TLR5, and by extension via DAMPs which engage the same receptors (Goh et al., 
2010). These receptors engage a variety of signalling pathways, with the best described 
for tenascin-C induction being that of inhibitor of κB kinase (IKK) which activates the 
tenascin-C inducing TF nuclear factor κB (NFκB) (Goh et al., 2010). Besides PRR 
signalling other noxious environmental stimuli present in inflammatory lesions can 
also result in tenascin-C expression. This includes hypoxia, with the oxygen sensing 
TF hypoxia inducible factor (HIF)1α able to induce tenascin-C expression 
(Miroshnikova et al., 2016), as well as reactive oxygen species (ROS) which can also 
activate NFκB (Yamamoto et al., 1999).  
In addition to these cellular stressors endogenous pro-inflammatory cytokines and 
other growth factors, induced to propagate and guide the inflammatory response, can 
also induce tenascin-C expression. For example, in the case of pro-inflammatory 
cytokines both IL-1β and tumour necrosis factor (TNF) have been shown to induce 
tenascin-C expression, with the later shown to be in an NFκB dependent manner 
(McCachren and Lightner, 1992, Nakoshi et al., 2008). In terms of growth factors 
TGFβ and platelet derived growth factor (PDGF) have both been shown to induce 
tenascin-C expression in SMAD3/4 and ETS1/2 TF dependent manners respectively 
(Jinnin et al., 2004). These tenascin-C inducing mediators also do not act in isolation 
during the inflammatory response. For example, it has been shown that hypoxia can 
enhance tenascin-C production in response to the pro-inflammatory cytokine IL-1β 
(Tojyo et al., 2008). This reflects the complex network of factors which can interact at 
sites of inflammation to induce tenascin-C’s dynamic spatiotemporal production. 
1.4.2 Tenascin-C as an endogenous pro-inflammatory factor 
Once produced at sites of inflammation tenascin-C has been found to act as a pro-
inflammatory factor with two major classes of receptors thus far identified as 
mediating this function; the PRR TLRs and the adhesion modulating integrins.  
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The best described of these is the former with tenascin identified as a ligand for TLR4 
(Midwood et al., 2009). TLR4 is best known as the PRR for the bacterially derived 
PAMP LPS, although in recent years a number of endogenous molecules alongside 
tenascin-C have been found activate it as well. These include a diverse range of 
proteins from fibrinogen to HMGB1, and biglycan (Bryant et al., 2015). Subsequent 
studies mapped the TLR4 activating site on tenascin-C to the FBG domain with the 
exact interacting site made up of three loops forming a non-contiguous cationic ridge 
(Zuliani-Alvarez et al., 2017). Engagement of the receptor leads to recruitment of the 
adaptor molecule myeloid differentiation factor 88 (MyD88) to the intracellular TIR 
domain of the receptor, followed by the kinases IL-1R-associated kinase (IRAK)4 and 
IRAK1 along with the pseudokinase IRAK2. This signalling complex, termed the 
myddosome, recruits and activates the ubiquitin ligase TNF receptor-associated factor 
6 (TRAF6) which through generation of atypical ubiquitin chains recruits and activates 
the TGF-β activated kinase 1 (TAK1) complex. TAK1 is subsequently responsible for 
the phosphorylation based activation of the mitogen activated protein kinase (MAPK) 
cascade as well as the IKK complex. These pathways both ultimately lead to the 
activation of a pro-inflammatory TF program with the NFκB, AP-1, and CREB factors 
key master regulators (Balka and De Nardo, 2019). Despite these signalling events 
appearing to occur in a broadly similar manner for tenascin-C and LPS some 
differences for tenascin-C have been noted which result in distinct effector outcomes 
(Piccinini et al., 2016). Additionally, also in contrast with LPS it has been shown that 
tenascin-C does not share the requirement for the CD14 and MD-2 co-receptors which 
are essential for LPS stimulation of TLR4 (Midwood et al., 2009).  
Besides TLR4 the other major pro-inflammatory signalling mechanism described for 
tenascin-C is mediated by integrins. Integrins are a family of transmembrane cell 
adhesion receptors best known for their functions in signalling and linking the ECM 
and cytoskeleton, with important roles in development as well as immune responses. 
Integrins exist as heterodimers of one alpha (α) and one beta (β) subunit, with 18 α and 
8 β subunits found in humans which together generate 24 different integrin receptors 
(Barczyk et al., 2010). In terms of tenascin-C pro-inflammatory signalling it is the 
α9β1 and αVβ3 integrins which have been identified as responsible (Kanayama et al., 
2011, Shimojo et al., 2015). The α9β1 binding site has been mapped to the FNIII-like 
 Tenascin-C: A marker and driver of inflammation 
Chapter 1 – Introduction 33 
repeat 3 of tenascin-C (Yokosaki et al., 1994). Binding, and thus recruitment of the 
receptor to a focal adhesion, subsequently results in activation of the intracellular 
adaptor focal adhesion kinase (FAK) complex which can trigger a number of 
downstream signalling pathways. This includes the MAPK and IKK pathways which 
can activate pro-inflammatory TF programs such as that of NFκB (Yokosaki et al., 
1996, Kanayama et al., 2011). In terms of the αVβ3 integrin two binding sites for it in 
tenascin-C have been identified with one, distinct from the α9β1 site, in the FNIII-like 
repeat 3 (Sriramarao et al., 1993) and the other in the FBG domain (Yokoyama et al., 
2000). Similarly to α9β1 the FAK complex was implicated in activating downstream 
signalling pathways which resulted in activation of the pro-inflammatory TF NFκB 
(Shimojo et al., 2015).  
In addition to these pathways which have been validated and most studied there is the 
theoretical possibility for tenascin-C to influence the inflammatory response via a 
variety of other interactions as well. In terms of direct cellular signalling interactions 
the EGF-L repeats of human tenascin-C have been found to bind and activate the EGF 
receptor (EGFR) (Swindle et al., 2001). The functional in vivo relevance of this 
interaction has been further demonstrated with tenascin-C EGF-L able to activated the 
MAPK pathway and protect cells from death induced by pro-apoptotic ligands 
(Rodrigues et al., 2013). While not in the context of tenascin-C stimulation this same 
MAPK EGFR signalling pathway has also been implicated as a driver of both sterile 
(Rayego-Mateos et al., 2018) and infectious (Hardbower et al., 2016) inflammation. 
In both of these cases, which included chronic kidney disease and H. pylori infection, 
these affects were found to be driven by the AP-1 and NFκB TFs and thus this provides 
another potential mechanism by which tenascin-C may activate these factors.  
Aside from these direct receptor interactions tenascin-C can also potentially modulate 
the response via crosstalk and indirect interactions with other pro-inflammatory 
pathways. This could be mediated by the wide range of secreted signalling factors 
tenascin-C has been shown to bind and interact with which include mediators such as 
Wnt ligands, fibroblast growth factors (FGF), and TGFβ (Giblin and Midwood, 2015). 
In the case of Wnt ligands tenascin-C has been shown to directly bind and facilitate 
Wnt3a signalling promoting β-catenin mediated TF programs (Hendaoui et al., 2014). 
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In addition, tenascin-C can further accentuate Wnt signalling by its ability to 
downregulate the Wnt inhibitor Dickkopf-1 (DKK1) by blocking actin stress fibre 
formation (Saupe et al., 2013). Wnt signalling has been shown to have pro-
inflammatory affects as well as displaying crosstalk with numerous other pro-
inflammatory signalling pathways (Moparthi and Koch, 2019). For example Wnt3a 
stimulation is able to directly induce pro-inflammatory cytokine production in some 
cell types (Aumiller et al., 2013). In addition, Wnt3a is known to upregulate signal 
transducer and activator of transcription (STAT)3 expression which functions in IL-6 
signalling (Hao et al., 2006, Fan et al., 2013).  
Together these pro-inflammatory mechanisms, the most well characterised and 
validated of which are summarised in figure 1.6, demonstrate the diverse range of ways 
tenascin-C may act to help drive the inflammatory response. 
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1.4.3 Impact of tenascin-C on innate immune cells  
The innate immune system comprises a range of leukocytes of primarily myeloid 
origin as well as lymphocytic natural killer cells. The myeloid cells comprise of two 
main subgroups which include the mononuclear phagocytes; consisting of monocytes, 
macrophages, and DC; and the granulocytes; consisting of neutrophils, basophils, 
eosinophils, and mast cells. These varied cell types play important roles in pathogen 
recognition and the initiation of the inflammatory responses, as well as acting as key 
effectors through their phagocytic activity and production a myriad of anti-microbials, 
proteases, and ECM molecules (Delves et al., 2006).  
Research on tenascin-Cs impact on the innate immune system have primarily focused 
on its effects on the cells of the mononuclear phagocyte system. This focus has been 
in part because it is this lineage which has been implicated as the primary immune cell 
source of tenascin-C at sites of inflammation with macrophages in particular show to 
be able to secrete significant quantities of the protein (Goh et al., 2010, Giblin, 2018). 
Tenascin-C stimulation has been shown to drive macrophages, which display wide 
ranging phenotypic plasticity (Mosser and Edwards, 2008), to adopt a pro-
inflammatory M1 polarisation classically shown to be induced in response to PAMPs 
(Kimura et al., 2019). In terms of effector outcomes this has been shown to result 
induction of pro-inflammatory cytokine production in both macrophages and DC, 
including the production of TNF, IL-6, IL-1α, IL-1β, and IL-23 (Midwood et al., 2009, 
Kanayama et al., 2011, Machino-Ohtsuka et al., 2014). As well as directly driving 
production, tenascin-C also acts to enhance production with tenascin-C signalling 
upregulating the microRNA miR-155 which is known to aid TNF synthesis by 
stabilising the TNF mRNA transcript (Bala et al., 2011, Piccinini and Midwood, 2012). 
In addition to cytokines tenascin-C also induces macrophages and DC to produce a 
raft of chemokines, including IL-8, chemokine C-C motif ligand (CCL)2, CCL3, 
CCL4, chemokine C-X-C motif ligand (CXCL)2, and CXCL5, which are important 
for the recruitment of various immune cell types to sites of inflammation (Kanayama 
et al., 2009, Midwood et al., 2009). Aside from mediator production tenascin-C can 
also induce the production of tissue remodelling effector molecules. This includes 
proteases such as; MMP1, 3, 9, and 14; as well as ECM molecules such as collagens 
(Tremble et al., 1994, Piccinini et al., 2016) 
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In terms of the granulocytes much less work has been done to characterise the impact 
of tenascin-C stimulation. Indeed, the most numerous granulocyte, the neutrophil, has 
been shown in in vitro studies to be incapable of producing tenascin-C under basal or 
pro-inflammatory stimulated conditions (Giblin, 2018). However, tenascin-C has been 
shown to be able to act on neutrophils via its stimulation of TLR4 which has been 
shown to upregulate production of the extracellular protease MMP9. This is believed 
to aid in immune cell recruitment to sites of inflammation in tissues by helping to 
breakdown ECM barriers in the vasculature during endothelial transmigration 
(Kuriyama et al., 2011, Coito, 2011). Tenascin-C has also been shown to play a role 
in eosinophil biology by acting as a growth factor that promotes eosinophil precursor 
proliferation while also blocking their complete maturation. As such, via these 
mechanisms tenascin-C is implicated in aiding progenitors in the local generation of 
eosinophils at sites of inflammation (Doan et al., 2018). 
Together these studies show a clear pro-inflammatory role for tenascin-C in innate 
immunity, especially for cells within the mononuclear phagocytic system, although 
roles in other innate cell types remains to be properly characterised. 
1.4.4 Impact of tenascin-C on adaptive immune cells 
The cells of the adaptive immune system include T and B cells. T cells are split into 
two broad subgroups of CD4+ helper T (Th) cells, responsible for orchestrating 
immune responses through cytokine production and B cell activation, and CD8+ 
cytotoxic T (Tc) cells, responsible for antigen targeted cell killing. B cells meanwhile 
are primarily responsible for the adaptive humoral immune response through their 
production of antibodies (Delves et al., 2006).  
In terms of tenascin-C signalling there is less literature characterising its interactions 
with the adaptive immune system, and of that which there it has predominantly focused 
on T cells. Indeed, like the neutrophil both the Th and Tc cell subtypes have been 
shown to be incapable of secreting tenascin-C themselves and thus any affects must 
occur in a paracrine rather than autocrine signalling manner (Giblin, 2018). The best 
characterised of these interactions is the ability for tenascin-C to inhibit T cell 
activation in response to a range of activators, including T cell receptor (TCR) specific 
 Tenascin-C: A marker and driver of inflammation 
Chapter 1 – Introduction 38 
activation with tetanus toxoid C fragment, with tenascin-C reducing the proliferative 
response (Ruegg et al., 1989). Most work however has taken place using TCR non-
specific activation methods, utilising either anti-CD3 and anti-CD28 antibodies or the 
mitogen concanavalin A, which similarly showed, irrespective of co-stimulation, 
reduced proliferation as well as reduced IL-2 and interferon (IFN)‐γ production 
(Hemesath et al., 1994, Hibino et al., 1998, Parekh et al., 2005, Mirzaei et al., 2018). 
These affects were mapped to a region spanning the alternatively spliced FNIII-like 
repeats A1 to A3 of tenascin-C (Puente Navazo et al., 2001). Further mechanistic 
studies demonstrated that this inhibition is mediated at least partially by α5β1 and αvβ6 
integrin signalling which results in reduced activation of the key signalling kinases 
mammalian target of rapamycin (mTOR) and protein kinase B (PKB) (Mirzaei et al., 
2018). In the case of α5β1 this was shown to be mediated by inhibiting reorganisations 
of the actin cytoskeletal required for efficient TCR activation (Jachetti et al., 2015) 
In contrast to these findings other studies have shown that attachment of the Jurkat T 
cell line to tenascin-C results in significant calcium ion influx which is known to be 
an important second messenger signal in T cell activation (Weismann et al., 1997, 
Christo et al., 2015). Additionally, while tenascin-C itself may directly inhibit T cell 
activation studies in more physiological co-culture settings with APC myeloid cells 
have shown tenascin-C can promote T cell activation, potentially indirectly via its 
stimulation of the innate immune cells. This includes studies which have shown that 
tenascin-C produced by DCs drives the paracrine production of IL-23 which is needed 
for efficient polarisation of the Th17 T cell subtype which produces the pro-
inflammatory cytokine IL-17 (Ruhmann et al., 2012). In addition, loss of tenascin-C 
in vivo results in decreased numbers of Th1 polarised T cells which are characterised 
by production of the pro-inflammatory cytokine IFN‐γ, during the inflammatory 
response (Momcilovic et al., 2017). Additionally, culture of crudely extracted splenic 
lymphocytes with tenascin-C was shown to result in elevated production of the Th2 T 
cell associated cytokines IL‐5 and IL‐13, as well as IFN‐γ. Additionally in these 
cultures elevated B cell antibody production was observed with tenascin-C treatment 
with increased levels of IgE found in the medium (Nakahara et al., 2006).  
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As well as activation some studies have also investigated tenascin-C ability to 
influence lymphocyte migration and trafficking. The earliest of these identified a role 
for tenascin-C as acting as a ligand supporting lymphocyte rolling adhesion which 
occurs as part of T cells extravasation from the vasculature into an inflammatory site 
(Clark et al., 1997). In contrast to this study another using an in vitro glioblastoma 
model found tenascin-C inhibited T cell migration, in part by activation of FAK by 
integrin signalling (Huang et al., 2010). As such, the current impact of tenascin-C as a 
substrate for lymphocyte migration appears inconclusive.  
Overall these studies show that tenascin-C appears to be pleotropic mediator of 
adaptive immunity able to exert both inhibitory and activating action via direct and 
indirect mechanisms.  
1.4.5 Impact of tenascin-C on non-immune cells  
While not classically considered part of what was thought to be a purely 
immunovascular phenomenon stromal cells have recently become more greatly 
appreciated for their role in the inflammatory response. Of these fibroblasts, spindle 
shaped adherent cells with roles in ECM production and organising, are the most 
common non-immune cell types found in most tissues stroma (Patel et al., 2014). Of 
particular note is that fact that owing to their ECM producing function, fibroblasts 
derived from a variety of sources have been identified as some of the highest tenascin-
C producing cell types to date under both basal as well as pro-inflammatory conditions 
(Goh et al., 2010, Giblin, 2018). As such, a large proportion of the tenascin-C found 
at sites of inflammation is likely to be of fibroblastic origin.   
In regard to the impact of tenascin-C stimulation on fibroblasts a number of pro-
inflammatory and tissue remodelling effector functions have been identified. Firstly, 
as for innate immune cells tenascin-C has been shown to induce pro-inflammatory 
mediator production in fibroblasts, derived from both the synovium and myocardium, 
with  IL-6 and IL-1α both found to be upregulated (Midwood et al., 2009, Kanayama 
et al., 2009, Maqbool et al., 2016). In addition, fibroblast are also able to produce 
chemokines with CCL2, CCL4, CXCL5, and CXCL12 all found to be produced in 
response to tenascin-C stimulation (Kanayama et al., 2009). In terms of tissue 
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remodelling effector functions, as with myeloid cells, tenascin-C can induce 
extracellular protease production, including MMP3 and 9, as well as production of 
ECM components, including type 1 and type 3 collagens (Bhattacharyya et al., 2016, 
Kanayama et al., 2009, Maqbool et al., 2016). 
Besides fibroblasts other non-immune stromal cells have also demonstrated pro-
inflammatory activity in response to tenascin-C. This includes chondrocytes of 
cartilaginous tissue which have been shown to produce IL-6, IL-8, and the protease 
ADAMTS-4 in response to tenascin-C (Patel et al., 2011). It has also been recently 
demonstrated that epithelial cells can also respond to tenascin-C with its stimulation 
of a lung epithelial cell line resulting in production of IL-8 (Mills et al., 2019). 
Together these studies demonstrate the wide range of different cell types which can 
act as pro-inflammatory and tissue remodelling effectors in response to tenascin-C 
stimulation. 
Through all of the cell types discussed in this section tenascin-C is believed to play an 
important pro-inflammatory role in vivo which has been implicated in mediating 
protection from microbial infection (Piccinini and Midwood, 2012). However, while 
tenascin-C may in some instances play a positive role in the acute inflammatory 
response it has been most widely investigated for its apparent and proven roles in 
mediating chronic inflammatory disease.  
1.5 Tenascin-C and inflammatory disease 
1.5.1 Tenascin-C expression is increased in inflammatory 
disease 
After the initial discovery of tenascin-Cs upregulation in response to wounding it was 
not long before tenascin-C was also identified at sites of pathological chronic 
inflammation. The first reported instance in the literature for a bona fide IMID was in 
1991 by Schalkwijk and colleagues who showed by immunohistochemistry elevated 
tenascin-C staining in skin lesions from psoriasis patients (Schalkwijk et al., 1991). 
Since then tenascin-C has been identified as being upregulated in a wide range of 
IMIDs from the inflamed synovia of rheumatoid arthritis (RA) patients (Cutolo et al., 
1992), the ulcerated intestinal mucosa of those with IBD (Geboes et al., 2001). A 
summary of these, as well as a range of other major IMIDs identified thus far in the 
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literature to be characterised by elevated tenascin-C expression is presented in table 
1.1. Additional information is also provided on the functional implications for 
tenascin-C in disease interpreted from either human patient samples or animal models. 
Of particular note is the fact that in these animal models genetic ablation or treatment 
with inhibitors of tenascin-C results in a marked reduction in inflammation and 
associated pathology attesting to tenascin-C’s pro-inflammatory role in vivo.  
Table 1.1: Summary table of published data on tenascin-C’s involvement in a range 
of major immune mediated inflammatory diseases (IMIDs), including the nature of 
its upregulation and, if known, its functional significance to disease pathogenesis. 
References and an indication as to whether the data arises from studies of human 
patients (p) or animal models (am) are also provided.   
 
IMID (Primary site/s 
of disease) 
Nature of upregulation and functional significance 
Ankylosing spondylitis 
(Axial joints) 
Tenascin-C found elevated in the serum and correlated with markers of 




Tenascin-C found elevated surrounding lymphocytic aggregates in the 




Tenascin-C found in immune infiltrated inflammatory muscle lesions by 
IHC (p) (Gullberg et al., 1997, Muller-Felber et al., 1998). 




IBD associated SNP identified in the tenascin-C gene (p) (Brant et al., 
2017) 
Increased tenascin-C observed by IHC within the inflamed mucosa in 
UC, CD, and microscopic colitis. Infliximab treatment of CD results in a 
reduction of this mucosal tenascin-C staining (p) (Geboes et al., 2001, 
Salas et al., 2003, Geboes et al., 2005, Ambort et al., 2010). 
 
Mass spectrometry and western blotting shows increased tenascin-C in 
intestinal epithelial cell extracts from patients with active UC (p) 
(Moriggi et al., 2017) 
 
Tenascin-C found elevated in the serum and correlated with disease 
activity and stricture forming disease. For UC levels decreased in 
response to successful treatment by proctocolectomy surgery or with the 





Tenascin-C found elevated in the serum which correlated with disease 
activity (p) (Shukla et al., 2015) 
Table continued on next page 
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Table 1.1: Table continued from preceding page 
IMID (Primary site/s 
of disease) 




Increased tenascin-C observed by IHC within vascular inflammatory 
lesions which correlated with degree of inflammation (p) (Yokouchi et 
al., 2019) 
 
Tenascin-C found elevated in the serum which correlated with disease 
parameters and poor response to intravenous immunoglobulin (p) 
(Okuma et al., 2016) 
 
Elevated tenascin-C protein in vascular lesions as observed by IHC 
staining in the murine Candida albicans induced Kawasaki disease 
model (am) (Suzuki et al., 2017) 
Multiple sclerosis 
(Brain and spinal cord) 
Tenascin-C IHC staining localises to subacute and chronic plaque lesions 
in the brain and is elevated in serum samples (p) (Gutowski et al., 1999, 
Harada et al., 2015). 
 
Tenascin-C found elevated in the brain at the mRNA level in the murine 
EAE, cuprizone, TMEV MS models. Elevated protein also found in 
brain lesions by IHC in the TMEV model (am) (Haist et al., 2012, 
Harada et al., 2015, Zendedel et al., 2016). 




Increased tenascin-C observed within psoriatic skin lesions by IHC (p) 
(Schalkwijk et al., 1991, Gerritsen et al., 1997, Latijnhouwers et al., 
1998a). 
Psoriatic arthritis 
(Skin and joints) 
Tenascin-C found elevated in the serum (p) (Page et al., 2012). 
Rheumatoid arthritis 
(Appendicular joints) 
Tenascin-C found elevated in the synovium at the mRNA level as 
observed by in situ hybridisation (p) (McCachren and Lightner, 1992). 
Tenascin-C found elevated in the inflamed synovium and cartilage as 
observed by IHC, especially in early disease (p) (Cutolo et al., 1992, 
Salter, 1993, Aungier et al., 2019). 
Tenascin-C found elevated in synovial fluid by WB and ELISA (p) 
(Hasegawa et al., 2007). 
Tenascin-C found elevated in serum by ELISA which correlated with 




Elevated tenascin-C at the mRNA and protein level as observed by IHC 
staining of the joints in a murine collagen antibody induced arthritis 
model. An antibody against tenascin-C reduces it’s expression and 
attenuates disease (am) (Kanayama et al., 2009, Mehta et al., 2018). 
 
Table continued on next page 
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Table 1.1: Table continued from preceding page 
IMID (Primary site/s 
of disease) 
Nature of upregulation and functional significance 
Rheumatoid arthritis 
- List continued from 
previous page 
 
Elevated tenascin-C at the protein level in the joint and serum as 
observed by ELISA in a murine collagen induced arthritis model. Serum 
tenascin-C correlated with clinical score (am) (Kiyeko et al., 2016). 
Murine zymosan and antigen induced arthritis models were both 
attenuated in Tnc-/- mice (am) (Midwood et al., 2009). 
Tenascin-C was found elevated at the mRNA level in the joints of a 
murine cytokine induced arthritis model. Pathology was attenuated with 
administration of antibodies or shRNA against tenascin-C (am) (Harada 
et al., 2015). 
 
Rat CIA arthritis model showed attenuated pathology in a dose 
dependent manner in response to treatment with an antibody against 
tenascin-C (am) (Aungier et al., 2019) 
 
Sarcoidosis 
(Lungs, skin, and 
lymph nodes) 
Tenascin-C observed surrounding cutaneous and pulmonary 
granulomatous lesions by IHC (p) (Kaarteenaho-Wiik et al., 1996, 
Hasibuan et al., 2015). 
Tenascin-C found elevated in serum and lung epithelial lining fluid by 




Tenascin-C increased in dermal and pulmonary lesions observed by IHC. 
This was reduced by methotrexate treatment (p) (Lacour et al., 1992, 
Seyger et al., 2001, Brissett et al., 2012). 
Tenascin-C found elevated in serum (p) (Brissett et al., 2012, Inoue et 
al., 2013, Bhattacharyya et al., 2016).  
Tenascin-C found to drive fibrotic pathology in a variety of murine 
models in which it was also elevated. Disease was attenuated in Tnc-/- 
mice (am) (Bhattacharyya et al., 2016). 
Sjögren’s syndrome 
(Mouth and eye glands) 
Increased subepithelial tenascin-C deposition found in bronchial biopsies 
(p) (Amin et al., 2001). 
Systemic lupus 
erythematosus 
(skin, joints, and 
muscle)  
 
Tenascin-C increased in lupus nephritis kidney lesions as observed by 
IHC (p) (Assad et al., 1993). 
Tenascin-C found elevated in the serum and correlated with disease 
activity (p) (Page et al., 2012, Zavada et al., 2015). 
 
1.5.2 Proposed role of tenascin-C in inflammatory disease 
The collective data in table 1.1, showing that tenascin-C is implicated in inflammatory 
diseases in near all the major organ systems of the human body, suggests that tenascin-
C may play a common pathological role in IMIDs. Indeed, common pathological 
mechanisms have already been proposed to mediate IMIDs due to their shared risk 
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factors, propensity to occur as comorbidities, and responsiveness to similar targeted 
therapies (Kuek et al., 2007).  
For tenascin-C the current mechanism proposed centres on its role in helping drive the 
persistence of pathological chronic inflammation as part of what has been termed the 
pro-inflammatory niche (Ruhmann and Midwood, 2013). The role of the ECM in 
creating specialised microenvironments that locally support and modulates cell 
behaviour is a well-known phenomenon, with the stem cell niche a prime example 
(Hynes, 2009). Tenascin-C’s deposition at sites of inflammation and its ability to drive 
pro-inflammatory signalling pathways suggest it could function similarly to create a 
pro-inflammatory permissive microenvironment at sites of disease (Ruhmann and 
Midwood, 2013). Additionally, certain features of tenascin-C might also make it well 
suited to drive inflammation persistently in comparison to other pro-inflammatory 
factors.  
In regard to this firstly tenascin-C’s simple nature as a relatively large ECM 
glycoprotein might mean that turning off its pro-inflammatory signalling might be 
more difficult than for other mediators. For example, receptor internalisation and 
subsequent intracellular ligand degradation is a well-established mechanism for 
downregulating extracellular signalling pathways, including those for TLRs (Wells et 
al., 2005). Tenascin-C in contrast, due to its bulky and ECM anchored nature, would 
be more resistant to this mechanism and thus could theoretically persist in the local 
ECM continually stimulating its pro-inflammatory signalling receptors. Additionally, 
the nature of tenascin-C’s induction in inflammation might also help it act as a 
persistence driver as it has been shown to be able to self-induce its own expression 
(Kanayama et al., 2009, Goh et al., 2010). This could be either directly, through its 
own pro-inflammatory signalling, or indirectly, by inducing mediators such as 
cytokines which themselves induce tenascin-C production. In either case this positive 
feedback loop thus creates a mechanism whereby autocrine or paracrine tenascin-C 
signalling could promote persistent tenascin-C expression at the chronically inflamed 
site.  
In summary this model, diagrammatical illustrated in figure 1.7, proposes that the 
microenvironment created by tenascin-C at sites of chronic inflammation helps 
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propagate the local inflammatory response by forming a persistent pro-inflammatory 
positive feedback loop.  
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1.5.3 Tenascin-C as a biomarker of disease 
With the above highlighted body of literature supporting the notion that tenascin-C is 
inextricably associated with inflammatory disease it is of no surprise that tenascin-C 
has been investigated for potential clinical utility. These investigations have included 
studies into its value as a biomarker. 
Biomarker, a portmanteau of biological and marker, is the term used to describe a 
characteristic that can be objectively measured as an indicator of normal or 
pathological biological processes, or responsiveness to a therapeutic intervention 
(Group, 2001). Biomarkers are measured in clinical practice as tools for identifying 
and classifying diseases in patients at diagnosis, as well as for informing predictions 
of disease course when considering prognosis. In recent years these processes have all 
become more critical with the development of the precision medicine approach to 
patient management where treatment is aimed to be tailored more closely to a patient’s 
specific presentation of disease (Committee, 2011). Biomarkers have a clear role in 
this approach in aiding in the better subclassification of disease, in terms of specific 
disease mechanisms and prognosis, to which tailoring of treatment can be applied.  
Tenascin-C presents a potentially attractive biomarker of inflammatory disease based 
on its characteristics described previously. This includes its limited expression in the 
adult outside of the context of inflammation making it a specific marker of the process. 
Additionally, with its implicated roles in disease pathogenesis tenascin-C would be 
classified as a mechanistic biomarker which display superior utility over simple 
descriptive surrogate markers (Robinson et al., 2013). As such, it is not surprising that 
numerous studies have already been undertaken to investigate tenascin-C’s utility as 
an inflammatory disease biomarker in a range of contexts, which are summarised in 
table 1.2 below.  
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Table 1.2: Summary table of published data on tenascin-C as a biomarker of 
inflammatory disease. References and detail on the methodology employed to 
measure tenascin-C in the study are also provided. Disease and assay abbreviations 





Key findings Reference 
AAV 
ELISA of serum 
tenascin-C (FN III-
C splice specific) 
Tenascin-C was higher in active disease 
compared to healthy controls and patients in 
remission and correlated with disease 




ELISA of serum 
tenascin-C (FN III-
C splice specific) 
 
Tenascin-C was higher in severe asthma 
compared to mild asthma and was associated 






ELISA of serum 
tenascin-C (FN III-
C splice specific) 
 
Tenascin-C was elevated in patients 
compared to healthy controls and correlated 
with markers of disease activity. Levels also 
correlated with response to treatment 
(Gupta et al., 
2018) 
IBD 
ELISA of serum 
tenascin-C 
 
Tenascin-C was higher in IBD patients 
compared to healthy controls and correlated 
with measures of disease activity. A 
treatment responsive decrease was also 
observed. 
(Riedl et al., 
2001) 
 
IHC for tenascin-C 
in colon biopsies 
 
Thickened subepithelial tenascin-C staining 
shown to be an accurate marker for 




IHC of tenascin-C 
in muscle biopsies 
 
Tenascin-C staining pattern was shown to 
distinguish dermatomyositis from 
polymyositis 
(Muller-








Tenascin-C protein staining was associated 
with disease chronicity while mRNA 





ELISA of serum 
tenascin-C (FN III-
C splice specific) 
 
Tenascin-C was elevated in active disease 
compared to inactive disease and healthy 
controls. Levels correlated with markers of 





ELISA of serum 
tenascin-C (FN III-
C splice specific) 
 
Tenascin-C found elevated in the serum 
compared to healthy controls and recovering 
patients. Levels correlated with disease 





Table continued on next page 
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Key findings Reference 
Myocarditis 




Tenascin-C staining was elevated in cases 
with active myocarditis and discriminated 
from patients with non-inflammatory dilated 
cardiomyopathy. Staining correlated with 
severity of histological lesions. 
(Morimoto 




IHC of skin 
biopsies 
 
Tenascin-C was shown elevated in psoriatic 
skin lesions although it did not correlate 
with disease activity 
(Latijnhouw
ers et al., 
1998a) 
RA 
ELISA of serum 
tenascin-C (FN III-
C splice specific) 
 
Tenascin-C was elevated in patients 
compared to healthy controls and further 
increased with longer disease duration. 
Levels also correlated with joint erosion 
severity and decreased in response to 
therapy. Baseline tenascin-C was predictive 
of treatment responsiveness.  










Autoantibodies against citrullinated 
tenascin-C (cTNC) had high diagnostic 
specificity for RA and were found in ~50% 
of patients. cTNC autoantibodies were found 
to pre-date disease development and in 
undifferentiated disease were associated 
with the development of RA. cTNC 
autoantibodies also associated with a subset 
of patients with periodontitis. 
(Schwenzer 
et al., 2015, 
Raza et al., 
2016, 
Schwenzer 
et al., 2017) 
Scleroderma 
ELISA of serum 
tenascin-C (FN III-
C splice specific) 
 
Tenascin-C was higher in scleroderma 
patients compared to healthy controls. 
Patients with pulmonary fibrosis 





ELISA of serum 
tenascin-C (FN III-
B splice specific) 
 
Serum tenascin-C was higher in patients 
with active disease compared to those with 
inactive disease and healthy controls. 
Elevated levels predicted need to escalate 




AS, ankylosing spondylitis; SLE, systemic lupus erythematosus; RA, rheumatoid 
arthritis; IIM, idiopathic inflammatory myositis; AAV, antineutrophil cytoplasmic 
antibody (ANCA)-associated vasculitis; JIA, juvenile idiopathic arthritis; IHC, 
immunohistochemistry; ISPCR, in situ polymerase chain reaction; ELISA, Enzyme-
linked immunosorbent assay; SPECT, single-photon emission computed tomography 
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These publications highlight the broad range of conditions which have been studied in 
the context of tenascin-C. Additionally, they also highlight the range of methodologies 
employed to detect tenascin-C. This includes direct observation of tenascin-C in situ 
as in the case of immunohistochemical detection of the protein in biopsy samples as in 
the case of Muller and colleagues’ study of tenascin-C in collagenous colitis diagnosis 
(Muller et al., 2001). Enzyme-linked immunosorbent assay (ELISA) for the detection 
of tenascin-C in solution was by far the most commonly used methodology with 
tenascin-C having been detected in a variety of bodily fluids. This has included 
synovial fluid (Hasegawa et al., 2004), lung epithelial lining fluid (Kaarteenaho-Wiik 
et al., 1998), cerebrospinal fluid (Yoshida et al., 1994), as well as in the serum of the 
circulatory system.  
Tenascin-C was first reported to be found in human serum in 1991 in a study by Herlyn 
and colleagues (Herlyn et al., 1991). Shortly after this discovery Schenk and 
colleagues demonstrated the link between systemic tenascin-C and inflammation by 
showing its correlation with other circulating inflammatory markers (Schenk et al., 
1995). Since these early observations unsurprisingly, due it’s to more ubiquitous 
availability for testing in the clinical setting, it is this systemic tenascin-C on which 
the majority of inflammatory biomarker work has focused. Of note are the number of 
studies which demonstrate a link between systemic tenascin-C and disease activity as 
well as other specific aspects of disease pathology. Additionally, the studies of Závada 
and Page and their respective colleagues are of particular interest due to their 
demonstration that measurement of systemic tenascin-C has prognostic value. In the 
case of the Závada study this was shown in SLE, a disease characterised by periods of 
flare and remission, which showed that elevated tenascin-C levels were predictive of 
initiation of a flare (Zavada et al., 2015). The Page study conversely focused on the 
inflammatory joint disease rheumatoid arthritis and showed that high tenascin-C levels 
were predictive of poor response to the biologic anti-TNF therapy infliximab (Page et 
al., 2012). As such, both of these studies suggest that tenascin-C could have utility as 
part of a companion diagnostic, a diagnostic tool which accompanies a specific 
treatment and allows tailoring of its application for maximum clinical benefit to 
patients (Jorgensen, 2015).  
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In summary these studies collectively demonstrate that measurement of tenascin-C by 
a variety of methodologies presents a variety of potential uses as diagnostic tool in a 
range of inflammatory diseases. In particular measurement of systemic tenascin-C, 
while not specific enough to be of use in diagnosis, could yet find utility in clinical 
practice for monitoring disease activity and assessing disease prognosis. 
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1.6 Aims and strategy 
This introduction has summarised the previous work which has established tenascin-
C as a pathological driver of inflammation implicated in many different IMIDs, 
including IBD.  
In regard to this the first arm of this project aimed to further the understanding of the 
role of tenascin-C in IBD in vivo, building on this previous work which has been 
primarily of a descriptive rather than mechanistic nature. To do this the murine dextran 
sulphate sodium (DSS) model of colitis was identified as a valid model in which to 
study IBD in a controlled setting (Wirtz et al., 2017). In addition, the Tnc-/- mouse was 
also identified as a useful tool which in combination with this model would allow the 
dissection of tenascin-Cs contribution to colitis pathology.  
The second arm of this project has focused upon a more immediate clinical application 
of tenascin-C as a potential systemic biomarker of inflammatory disease. As well as in 
IBD, tenascin-C is also found elevated in many other IMIDs. However, further 
investigations of the nature of this circulating tenascin-C have been limited by the tools 
available, with no sensitive, robust, and reliable commercially ELISA able to detect 
all forms of the protein in biological samples. As such, in partnership with the company 
Axis Shield Diagnostic Ltd, it was determined that the development of assays to 
measure tenascin-C in human serum would be undertaken. These assays were then 
aimed to be characterised and used to determine the nature of tenascin-C in a healthy 
control and IMID patient serum samples. 
Towards both these goals the following aims have been achieved: 
I. Characterise the expression of tenascin-C in a murine colitis model 
II. Examine the effect of tenascin-Cs genetic ablation in a murine colitis model 
III. Design novel tenascin-C based assays and assess their use as inflammatory 
disease diagnostics. 
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Chapter 2 Materials and Methods 
2.1 Reagents and solutions 
All chemicals and buffers were purchased from Sigma-Aldrich (Dorset, UK) unless 
otherwise stated. Commercial buffer recipes are shown in Appendix I. All primers and 
antibodies used are shown in Appendices II, III, and IV. 
2.2 Bioinformatics 
Tenascin-C expression data was obtained from the online gene expression databases 
Bio-GPS (http://biogps.org) (Wu et al., 2009) and SAGE-genie 
(http://cgap.nci.nih.gov/SAGE) (Boon et al., 2002). The bio-GPS data obtained was 
from the MOE430 Gene Atlas Data set (Lattin et al., 2008) which subjected a variety 
of tissue samples from 8-10 week old male C57BL/6 mice to MOE430_2 to microarray 
analysis. The SAGE-genie data comprised serial analysis of gene expression (SAGE) 
libraries of tissues taken from 84 day old mice of unspecified sex and strain. This was 
with the exception of the lung library which was obtained from a 109d old mouse and 
the MEF library which was of embryonic origin. 
2.3 In vivo studies  
2.3.1 Animal welfare 
Mice were maintained under conventional specific pathogen free (SPF) conditions in 
the Biological Resource Facility (BRF; Roslin Institute, University of Edinburgh, 
Midlothian, UK) with a 12 hour light/dark cycle. All animal experiments were 
approved by the Roslin Institute’s Animal Users Committee and the animals were 
maintained in accordance with Home Office guidelines for the care and use of 
laboratory animals.  
2.3.2 Maintenance of tenascin-C knockout mice 
All mice used in this thesis were on a 129sv genetic background strain from established 
colonies. Tenascin-C knockout (Tnc-/-) mice were generated as previously described 
(Saga et al., 1992) whereby the second exon of the Tnc gene, containing the translation 
start site, was replaced using homologous recombination with a LacZ gene, thus 
deleting the tenascin-C protein. The colony was established with mice provided by my 
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Oxford based supervisor Prof. Kim Midwood, with knockout (KO) and wild-type 
(WT) mice maintained through homozygous pair matings. To distinguish WT mice 
from this Tnc-/- Oxford derived colony from WT mice obtained from a separate Roslin 
Institute colony the Tnc-/- colony WT mice will be referred to as WT(Ox) mice. 
2.3.3 Genotyping 
For DNA extraction, ear clip samples were taken from new born mice and digested in 
200µl genotyping lysis buffer (1% SDS, 20mM EDTA, 0.1M NaCl, 50mM Tris-HCl 
pH8) supplemented with 1mg/ml proteinase K (recombinant PCR Grade; Roche, 
Mannheim, Germany) overnight at 55°C. The following day the tubes were cooled to 
room temperature and a 100µl of 3.75M NH4OAc added. Tubes were vortexed and 
then centrifuged at 14,000 rpm for five minutes at 4°C. Following centrifugation, 
100µl of chloroform was added before centrifugation at 14,000 rpm for five minutes 
at room temperature. The supernatant was then transferred to a new tube containing 
500µl of 100% ethanol which was subsequently mixed by inverting. The tube was then 
centrifuged at 14,000 rpm for five minutes at room temperature after which the 
supernatant was removed and the DNA pellet left to air dry. Once dry the pellet was 
resuspended in 30µl TE buffer and left overnight at 4°C to fully dissolve. DNA 
concentration and purity was measured using a NanoDrop 1000 spectrophotometer 
(Thermo Fisher Scientific, Waltham, USA) ensuring that the A260/280 ratio was in 
the expected 1.8 to 2 range for pure DNA.   
Two primer pairs were previously designed to amplify either the WT or the Tnc-/- 
(LacZ) alleles (Saga et al., 1992) and both were used in separate reactions to determine 
genotypes (for primer sequences see Appendix IV). Reactions were set up using 
components from a Taq DNA polymerase kit (Thermo Fisher Scientific). Reactions 
consisted of 100-200ng of template DNA in 1x PCR buffer, 5mM MgCl2, 0.2mM 
dNTPs, 1% DMSO, 0.5µM forward primer, 0.5µM reverse primer, and 1.5 units Taq 
DNA polymerase made up to a 20µl final reaction volume with nuclease free water. 
No template control (NTC) reactions were prepared and ran alongside every PCR run 
for both primer sets. PCR was carried out on a DNA Engine DYAD (Peltier Thermal 
Cycler; Bio-Rad Laboratories, Hertfordshire, UK) using the following protocol: 95°C 
for five minutes, followed by 35 cycles of 94°C for one minute, 63°C for two minutes, 
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and 72°C for two minutes, with a final step to finish the reaction of 72°C for ten 
minutes.  
After the reaction was completed, 5µl of 5X DNA loading buffer red (Bioline, London, 
UK) was added to each reaction and 20µl loaded onto a 1.5% agarose/TAE gel 
supplemented with 1x SYBR Safe DNA gel stain (Thermo Fisher Scientific). A 1Kb 
Hyperladder (Bioline) was loaded alongside samples as a molecular weight marker. 
Gels were electrophoresed at 140V for 60 minutes in a gel tank containing 1x TAE. 
Gels were imaged on a Gel Doc XR system with Quantity One 1-D Analysis Software 
(Bio-Rad Laboratories). An example genotyping result is shown in figure 2.1. 
 
2.3.4 Dextran Sulphate Sodium (DSS) murine model of colitis 
Male mice of 7 - 9 weeks of age were used for all experiments. To induce colitis, 
Colitis Grade 36,000-50,000 MW DSS (MP Biomedicals, Santa Ana, USA) was 
administered in the drinking water ad libitum at a concentration of 2-3% (w/v) for five 
days. DSS was then withdrawn and the mice returned to regular drinking water for the 
remaining days before cull. In the acute model the mice were left for 3 days following 
DSS withdrawal and in the recovery model the mice were left for 17 days (Wirtz et 
al., 2007, Wirtz et al., 2017). Control age and sex matched mice received normal 
drinking water for the duration of the experiment. To control for potential genotypic 
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differences in water consumption between Tnc-/- and WT mice, water intake was 
monitored during the DSS dosing period as well by daily weighing of water bottles.  
Throughout the protocol, general welfare monitoring was carried out daily and 
included weighing the mice as well as scoring for general health parameters and 
disease activity. General health scoring included monitoring for changes in appearance 
such as coat staring, hunching, and change in gait; and behavioural changes such as 
reluctance to move, and restlessness. Additionally, the colitis specific changes in stool 
consistency and presence of faecal blood were also scored for. A daily disease activity 
index (DAI) score for each mouse was produced by summing these scoring 
parameters. The study scoring sheet is included in Appendix V.  Mice that exhibited 
severe adverse reactions, met DAI scoring severity thresholds, and/or lost more than 
20% body weight before the study end point were euthanized on humanitarian grounds 
in compliance with home office regulations and were not included for analysis. For 
presentation of body weight loss data, percentage body weight loss relative to the day 
zero time point at the start of the experiment were calculated, with data presented as 
the mean of this percentage ± standard deviation. For presentation of DAI scoring data, 
a DAI sum score was calculated as the sum of all parameters scored for which is then 
presented in this thesis as median score ± interquartile range. 
At the endpoint of all experiments the mice were culled by exsanguination by cardiac 
puncture while under terminal isoflurane induced anaesthesia to provide a terminal 
blood sample. 
2.3.5 Tissue harvesting 
Immediately following cull as detailed in section 2.3.4, blood samples and cadavers 
were collected. Blood samples were left to clot at room temperature for 30 minutes 
before centrifugation for 10 minutes, at 1000g, at 4°C. The serum supernatant was then 
transferred to another tube and flash frozen in LN2 before storage at -70°C until use.  
Colons were transected at the colorectal and colonocecal margins and resected with as 
much mesenteric tissue removed as possible. Colons were then inspected for gross 
pathology such as luminal blood, stool consistency, and enlarged lymph tissue before 
forceps were used to remove colonic contents. The colon was then flushed with PBS 
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to help remove any remaining faeces. Following flushing the colon length was 
measured and based on this it was transected into 3 equal segments corresponding to 
the proximal, middle, and distal portions of colon. These segments were further 
subdivided and processed for RNA extraction (see section 2.5.1), histology (see 
sections 2.4.1 to 2.4.2), protein extraction (see section 2.6.1), or myeloperoxidase 
assay (see section 2.7). 
2.4 Histology 
2.4.1 Paraffin embedded tissue processing and sectioning 
Colon segments obtained in section 2.3.5 were flushed with 10% neutral buffered 
formalin (NBF; CellPath, Powys, UK) and then placed in histology cassettes (Simport, 
Beloeil, Canada) and incubated in 10% NBF for a minimum of 48hrs with agitation at 
4°C. Cassettes were then transferred and stored in 70% ethanol before there transfer to 
the Easter Bush Pathology Department (Midlothian, UK) who carried out the wax 
embedding, sectioning, and staining (see section 2.4.3). Tissue processing used the 
following protocol: one wash in 95% ethanol for 1 hour, 5 washes in absolute ethanol 
for 1 hour each, 3 washes in xylene for 1 hour each, and embedding in paraffin wax 
for 4 hours with a wax change every 1 hour 20 minutes. Colon segments were 
embedded transversely and then sectioned at 5µm using a RM2155 microtome (Leica 
Biosystems, Milton Keynes, UK) before mounting on Superfrost slides (Thermo 
Fisher Scientific).  
2.4.2 Cryo-embedded tissue processing and sectioning 
Colon segments obtained in section 2.3.5 were placed in Surgipath embedding moulds 
(Leica Biosystems) in a transverse orientation and covered with Optimal Cutting 
Temperature (OCT) embedding compound (Cellpath). Blocks were then snap frozen 
in an ethanol-dry ice slurry cooled hexane bath for approximately one minute. Blocks 
were placed on dry ice for the hexane to evaporate before storage at -70°C until use. 
Cryosections were cut at 7µm on an OTF5000 cryostat (Bright Instruments, 
Bedfordshire, UK) and mounted on Superfrost slides (Thermo Fisher Scientific). 
Slides were allowed to air dry at room temperature for 30 minutes before storage at -
70°C until use. 
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2.4.3 Haematoxylin and eosin (H&E) staining 
The staining of paraffin embedded tissue sections (section 2.4.1) was performed by the 
Easter Bush Pathology Department (Midlothian, UK). Slides were dewaxed with 
xylene before rehydration through graded alcohol solutions. Slides were stained with 
Harris haematoxylin, washed, and further stained in 1% eosin. Stained slides were then 
dehydrated through graded alcohol solutions and cleared with xylene before mounting 
with coverslips using DePeX mountant (VWR, Radnor, USA). 
H&E staining was performed on cryo-embedded tissue sections (section 2.4.2).  
Briefly, slides were removed from the -70°C and allowed to equilibrate to room 
temperature for approximately ten minutes. Sections were then fixed in ice cold 
methanol for two minutes before a brief wash in tap water. Staining was then 
performed on an Autostainer XL (Leica) with the following steps. Firstly, sections 
were stained with Harris haematoxylin, washed, and then blued in Scott’s Tap Water. 
Slides were then washed and further stained with 1% eosin before dehydration through 
graded alcohol solutions and clearing with xylene. Finally slides were mounted with 
coverslips using Clearvue mountant Xyl (Thermo Fisher Scientific).  
2.4.4 Light microscopy imaging 
H&E stained sections stained as described in section 2.4.3 were visualised using an 
Eclipse E600 upright brightfield microscope (Nikon Instruments, Melville, USA) and 
images captured using an Axiocam 105 colour camera (Zeiss, Oberkochen, Germany) 
with Zen 2 software (Zeiss). Image processing, including adding scale bars and 
adjusting brightness, was performed using Zen lite software (Zeiss). 
2.4.5 Colitis histopathology grading 
H&E stained paraffin embedded and cryo-embedded sections which had been stained 
as described in section 2.4.3 were used for colon histopathology grading. Grading was 
performed blind by Professor Elspeth Milne (The Royal (Dick) School of Veterinary 
Studies, Midlothian, UK) using a published colitis grading system (Dieleman et al., 
1998), which had been used previously in our lab (Dobie et al., 2018) (table 2.1). 
Pathology was scored for at least one section of proximal, middle, and distal colon per 
mouse. The scoring system assessed inflammation severity, inflammatory extent 
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through the tissue, tissue regeneration, and crypt damage. Additionally, a grade was 
also given for each of these parameters based on the percentage of the tissue which 
was affected by it. Final scores for the individual scoring parameters, inflammation 
severity, inflammation extent, crypt damage, and regeneration, were calculated as the 
parameters score multiplied by its percentage involvement grade. Sum histopathology 
scores were then calculated as the sum of each of these individual scoring parameters. 
Data for individual parameters as well as the sum score are presented as median score 
± interquartile range throughout this thesis.  
Table 2.1: Scheme used for colitis histopathology grading. 
Feature Graded Grade Description 
Inflammation 0 None 
 1 Slight 
 2 Moderate 
 3 Severe 
Extent 0 None 
 1 Mucosa 
 2 Mucosa and submucosa 
 3 Transmural 
Regeneration 4 No tissue repair 
 3 Surface epithelium not intact 
 2 Regeneration with crypt depletion 
 1 Almost complete regeneration 
 0 Complete regeneration or normal tissue 
Crypt Damage 0 None  
 1 Basal 1/3 damaged 
 2 Basal 2/3 damaged 
 3 Only surface epithelium intact 
 4 Entire crypt and epithelium lost 
Percentage Involvement 1 1-25% 
 2 26-50% 
 3 51-75% 
 4 76-100% 
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2.4.6 Immunohistochemistry 
Cryo-embedded tissue sections which had been processed as described in section 2.4.2 
were removed from -70°C and allowed to equilibrate to room temperature for 
approximately ten minutes. Slides were washed with phosphate buffered saline-tween 
20 (PBST; 0.05%) for 5 minutes before blocking with blocking solution constituting: 
10% secondary antibody matched normal serum, 1% BSA, 0.1% Triton X-100 in 
PBST for one hour at room temperature. For CD11c staining, blocking solution was 
not used and PBST was used in its place for all steps. For CD3 staining, where a 
biotinylated secondary antibody was used, post blocking using an avidin biotin block 
was also performed (Vector Laboratories, Peterborough, UK). This was performed by 
first washing the slides in PBST briefly for one minute before applying Avidin D 
solution for 15 minutes. Another brief PBST wash was performed and the slides were 
then incubated with biotin solution for 15 minutes. Another brief PBST wash was 
performed before proceeding with primary antibody incubation. Sections were 
incubated with primary antibodies (see Appendix II) at appropriate concentrations 
diluted in blocking solution overnight at 4°C in a humidity chamber. The following 
day slides were washed with PBST 3 x 5 minutes, before application of appropriate 
fluorescent or biotin conjugated secondary antibodies at 2µg/ml diluted in PBST (see 
Appendix III). Slides were incubated for one hour at room temperature shielded from 
light. Slides which were incubated with biotinylated secondary antibodies were 
washed with PBST 3 x 5 minutes and followed with a 1 hour incubation with 
streptavidin conjugated to AF594 at 2µg/ml in PBST, followed by another 3 x 5 
minutes PBST wash. All slides were then counterstained by incubation with DAPI 
(Thermo Fisher Scientific) nuclear stain at 0.1µg/ml in PBS for five minutes. 
Following a final 3 x 5 minutes PBS wash slides were mounted with coverslips using 
ProLong Gold Antifade Mountant (Thermo Fisher Scientific) and left to cure overnight 
at room temperature before imaging.  
2.4.7 Fluorescent microscopy imaging 
Fluorescently stained sections generated as described in section 2.4.6 were visualised 
using a DMLB upright fluorescent microscope (Leica) with a quad pass filter 
excitation wheel (Zaber, Vancouver, Canada), and SOLA source (Lumencor, 
Beaverton, USA). Images were captured with a Coolsnap MYO low light monochrome 
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CCD camera (Teledyne Photometrics, Tuscon, USA) using ImageJ2 software (Rueden 
et al., 2017) with the µManager plugin (Edelstein et al., 2014). Image processing, 
including standardisation of colour balance and addition of scale bars, was performed 
using the Fiji distribution of ImageJ 1.52e software (Schindelin et al., 2012).  
2.5 RNA methods 
2.5.1 Tissue RNA extraction 
Tissue was extracted as described in section 2.3.5 and flash frozen in LN2 before 
storage at -70°C until use. RNA was extracted using the acid guanidinium thiocyanate-
phenol-chloroform method (Chomczynski and Sacchi, 1987). All surfaces and 
instruments coming into contact with the tissue was cleaned with RNAse Zap (Thermo 
Fisher Scientific) to remove any contaminating RNAses. Tissue was thawed on ice 
and at least 20mg added to 1ml of QIAzol Lysis Reagent (Qiagen, Hilden, Germany) 
in an Eppendorf. For RNA extraction from OCT embedded tissue processed as 
described in section 2.4.2 cryosections were cut at 10µm thickness and 5 sections per 
block were pooled and added to 1ml of QIAzol Lysis Reagent in an Eppendorf. 
Tissue was homogenised in QIAzol with 3 x 10 second bursts of a T10 basic ultra-
turrax handheld tissue homogeniser with an S10N 5G dispersing tool (IKA England, 
Oxford, UK). Following warming to room temperature 200µl of chloroform was added 
to the homogenate before 15 seconds vigorous mixing. Phases were then separated by 
centrifugation at 12,000 rpm for 15 minutes at 4°C after which the upper aqueous 
phase was taken off and transferred to a separate tube.  
RNA was then purified using an RNeasy spin column kit (Qiagen) following the 
manufacturer’s instructions. Briefly, an equal volume of ethanol was added to the 
aqueous phase before transfer to the RNeasy column. The column was then centrifuged 
to run samples through its silica membrane which selectively bound the sample RNA 
with contaminants discarded in the run through. An on column DNase treatment using 
an RNase-free DNase kit (Qiagen) was carried out to remove residual contaminating 
DNA before washing with wash buffers (provided with kit) to remove any remaining 
contaminants. Finally, RNase free water was passed through the column to elute the 
purified RNA.  
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RNA concentration and purity was assessed using a NanoDrop 1000 
spectrophotometer (Thermo Fisher Scientific) checking that the A260/A280 and the 
A260/230 ratios were both approximately 2.0 indicating low protein and organic 
compound contamination respectively. Samples below 100ng/ml were left undiluted 
while those with a higher RNA concentration were diluted to 100ng/ml with RNAse 
free water.  
2.5.2 Reverse Transcription 
Complementary DNA (cDNA) was generated from extracted RNA as described in 
section 2.5.1. Superscript II reverse transcriptase (RT) kit (Thermo Fisher Scientific) 
was used following the manufacturer’s instructions. Firstly, 10µl of RNA at or below 
100ng/ml was incubated with 100ng of random primers (mostly hexamers; Thermo 
Fisher Scientific) for ten minutes at 70°C in a DNA Engine DYAD thermalcycler (Bio-
Rad Laboratories). Following primer annealing, tubes were cooled on ice and 8µl of 
RT master mix was added to each for a 20µl total reaction volume containing 1x first 
strand buffer, 10mM Dithiothreitol (DTT), 0.5mM dNTPs, and 200U Superscript II 
RNase H. Tubes were returned to the DNA Engine DYAD thermalcycler and the 
following program ran: 25°C for 10 minutes, 42ºC for 50 minutes, 70°C for 15 
minutes, and finally held at 4°C. cDNA samples were stored at -20°C until used.  
2.5.3 Quantitative polymerase chain reaction (qPCR) 
qPCR was carried out using cDNA generated as described in section 2.5.2 in a 96 well 
plate (Thermo Fisher Scientific) format using the SYBR green method (Ponchel et al., 
2003). All qPCR reactions were run in technical duplicates with a NTC, where cDNA 
was replaced with RNase free water, also run alongside as a negative control. All 
cDNA was diluted to 5ng/µl with RNAse free water. For reactions using primers 
supplied by Sigma-Aldrich, the master mix (PrecisionPLUS mastermix, Primerdesign, 
Southampton, UK), was prepared in RNase free water and 20µl was added per well 
together with 5µl (25ng) diluted cDNA for a final reaction concentration of 1x SYBR 
green mastermix, 200nM forward primer, and 200nM reverse primer. For Tnc primers 
supplied by Primerdesign, 15µl of mastermix was added per well along with 5µl 
(25ng) diluted cDNA for a final reaction concentration of 1x SYBR green mastermix, 
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300nM forward primer, and 300nM reverse primer. All primer sequences used are 
listed in Appendix IV.  
qPCR reactions were carried out on a MX3000P qPCR system (Stratagene, San Diego, 
USA) using the following program: 95°C for 2 minutes, followed by 40 cycles of 95ºC 
for 15 seconds, 60°C for 1 minutes, before a final melt curve of all PCR products from 
55°C to 95ºC was generated.  
2.5.4 qPCR Data Analysis 
MxPro Mx3000P software (Stratagene) was used to calculate an arbitrary 
amplification-based threshold which was then used to assign each reaction a Ct (cycle 
threshold) value denoting the cycle number it reached this fluorescence threshold 
value. For further processing the Ct data was extracted and transferred to Microsoft 
Excel 2016 (Microsoft, Redmond, USA). For assessment of raw expression of genes 
in samples 2-ΔCT values were calculated where ΔCT relates to the gene’s relative 
expression to the housekeeping 18s rRNA, calculated by subtracting the samples 18s 
rRNA CT value from the gene of interests CT value. For calculation of relative gene 
expression between test conditions the ΔΔCt method was used (Livak and Schmittgen, 
2001). This method similarly initially calculated a ΔCT value relative to the 18s 
housekeeping gene to normalise the samples account for any slight variations in cDNA 
concentration. The ΔΔCt was then subsequently calculated with normalisation carried 
out to a selected control condition, which was set to 1, so that all other test condition 
values are presented as fold change relative to this value.   
2.5.5 Primer quality control assessment 
All primer sequences used were inputted into the NCBI Primer-BLAST webtool (Ye 
et al., 2012) initially to determine that the predicted specificity, GC% content, and self-
complementarity were all acceptable. Tests for specificity and efficiency were also 
performed. To do this serial dilutions of cDNA from a sample known to express the 
transcript of interest were prepared and used to carry out qPCR, as detailed in section 
2.5.3, to generate a standard curve. Firstly, to determine that the reactions had been 
successful the amplification plots for each primer were assessed to check amplification 
had taken place producing regular sigmoid curves. Additionally, Ct values were 
 Tenascin-C: A marker and driver of inflammation 
Chapter 2 – Materials and Methods 63 
checked to ensure they fell in the range for reliable detection below 35 cycles. Next 
specificity was assessed by checking the melt dissociation curve to ensure only one 
distinct peak and thus one distinct product had been produced. Specificity was further 
confirmed by running the qPCR product on an agarose gel as in section 2.3.3 to check 
the singular product detected was of the predicted length for that produced by the 
primer pair. Efficiency was assessed by checking the R2 value produced by the 
standard curve, which if >0.9 indicates a near perfect linear correlation and at least 
>90% primer efficiency. An example primer optimisation result is shown in figure 2.2. 
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2.6 Protein methods 
2.6.1 Protein extraction 
Tissue was extracted as described in section 2.3.5 and flash frozen in LN2 before 
storage at -70°C until use. Tissue was thawed on ice and a minimum of 35mg added 
to 300µl of RIPA buffer (Thermo Fisher Scientific) supplemented with 1x cOmplete 
mini EDTA-free protease inhibitor cocktail (Roche). Tissue was homogenised by 3 x 
10 second bursts of a T10 basic ultra-turrax handheld tissue homogeniser with an S10N 
5G dispersing tool (IKA England). Samples were then clarified by centrifugation at 
13,000 rpm for ten minutes at 4°C. The supernatant was then taken off and stored at -
20°C before use.  
2.6.2 Quantification of protein 
Protein concentration was determined using a DC Protein Assay kit (Bio-Rad 
Laboratories) using a 96 well plate format. Initially, Reagent A’ was prepared by 
adding 20µl of reagent S per 1ml of Reagent A and 25µl of Reagent A’ added per plate 
well. A 1/10 dilution of the sample prepared as described in section 2.6.1 was then 
made up in RIPA buffer and 5µl added per plate well with two technical replicate wells 
prepared for each sample. A standard curve of known protein concentrations was also 
prepared on the plate utilising bovine plasma gamma globulin diluted in RIPA buffer. 
Reagent B was then added to the plate with 200µl dispensed per well. The plate was 
mixed and then left to develop at room temperature for at least 15 minutes, during 
which time the alkaline copper tartrate and Folin reagent in the kit reagents reacted 
with the protein in solution to produce a blue product proportional to the protein 
concentration. The colour change was then quantified by measuring the plate’s 
absorbance at 750nm on a Synergy HT Multi-Mode Microplate Reader (BioTek 
Instruments, Winooski, USA). The Gen5 microplate reader software (BioTek) was 
then used to fit a standard curve, using a four parameters logistic regression, to the 
gamma globulin standards. The protein concentration of the samples was then 
interpolated from this standard curve. 
2.6.3 Polyacrylamide Gel Electrophoresis (PAGE)  
Samples were electrophoresed using a NuPAGE Novex PAGE system under 
denaturing conditions with buffers and equipment all provided by Thermo Fisher 
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Scientific unless otherwise specified. Sample loading mixes were prepared containing 
1x NuPAGE LDS (lithium dodecyl sulphate) sample buffer, 1x NuPAGE reducing 
agent, and 1mg/ml protein sample (from section 2.6.1 and using concentrations 
calculated in section 2.6.2) diluted with  distilled water (dH2O) if required. Loading 
mixes were then denatured by incubation at 70°C for 10 minutes before cooling at 
room temperature. Samples were then loaded onto NuPAGE pre-cast 10% Bis-Tris, 4-
12% Bis-Tris, or 3-8% Tris-Acetate protein gels in a Novex XCell SureLock Mini-
Cell gel tank. A pre-stained molecular weight marker (Precision Plus Protein All Blue 
Prestained Protein Standards; Bio-Rad Laboratories) was also loaded onto all gels 
alongside the samples. Bis-Tris gels were run with 1x NuPAGE MOPS SDS running 
buffer at constant 200V until desired protein separation was achieved. Tris-acetate gels 
were run with 1x NuPAGE Tris-acetate SDS running buffer at constant 150V until 
desired protein separation was achieved. 
2.6.4 Western blotting 
Following gel electrophoresis as described in section 2.6.3 proteins were wet 
transferred onto Amersham Protran nitrocellulose membranes (GE Healthcare Life 
Sciences, Buckinghamshire, UK). Transfer was carried out in a Novex XCell II Blot 
Module (Thermo Fisher Scientific) filled with 1x transfer buffer (20% methanol, 
0.04% SDS, 39mM glycine, 50mM Tris) with the gel and membrane sandwiched 
together between filter paper and sponges. Transfer was carried out with the tank on 
ice at 30V for 90 minutes. Immediately after transfer the membrane was briefly washed 
in dH2O before staining with Ponceau S solution to confirm transfer success and 
uniform sample loading. Membranes were then washed in PBST (0.05%) to de-stain 
before blocking in Odyssey PBS Blocking Buffer (LI-COR Biotechnology, 
Cambridge, UK) for one hour at room temperature with agitation. Following blocking 
the blocking buffer was discarded and primary antibodies applied to the membrane at 
the indicated concentrations (see Appendix II) in Odyssey PBS Blocking Buffer. 
Membranes were incubated with primary antibody overnight at 4°C with agitation. 
The following day primary antibody solution was tipped off and the membrane washed 
3 x 5 minutes in PBST (0.1%) at room temperature with agitation. Appropriate 
secondary antibodies were then applied to the membrane at the indicated 
concentrations (see Appendix III) in Odyssey PBS Blocking Buffer and incubated for 
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one hour at room temperature with agitation. As secondary antibodies were conjugated 
to near infrared dyes the membrane was protected from light exposure for all 
subsequent steps. Secondary antibody solution was then discarded and the membrane 
washed for 3 x 5 minutes in PBST (0.1%) at room temperature with agitation. Blots 
were then visualised using an Odyssey imaging system (LI-COR Biotechnology) and 
captured scans analysed using Image Studio Lite Ver 5.2 software (LI-COR 
Biotechnology). Blots were stored in PBS at 4°C after scanning until re-probing, if 
necessary.  
2.6.5 Protein gel silver staining 
Samples were run on an SDS-PAGE gel as detailed in section 2.6.3 and immediately 
after running transferred to a gel dish containing gel fixer solution (40% ethanol, 10% 
acetic acid in dH2O) and incubated with agitation for one hour. The gel was then 
washed with dH2O overnight with multiple changes of the dH2O. The gel was then 
sensitised to staining by incubating with 0.02% sodium thiosulphate solution for one 
minute followed by three quick washes with dH2O. The gel was then stained with 
cooled (4°C) silver nitrate solution (0.1% silver nitrate, 0.02% formaldehyde) for 20 
minutes with agitation followed by washing four times briefly with dH2O to ensure 
any residual silver nitrate was removed. Stain was then developed by incubating the 
gel with sodium carbonate solution (3% sodium carbonate, 0.05% formaldehyde). 
Once protein was sufficiently stained the staining was terminated by first washing the 
gel briefly in dH2O before incubating it with 5% acetic acid solution for five minutes. 
The gel was then stored in 1% acetic acid solution at 4°C until use. 
2.7 Myeloperoxidase (MPO) Assay 
MPO enzymatic activity, a surrogate marker of neutrophil infiltration (Krawisz et al., 
1984), was assessed according to a published protocol (Kim et al., 2012). Tissue was 
extracted as described in section 2.3.5 and flash frozen in LN2 before storage at -70°C 
until use. Tissue was thawed on ice, weighed, and at least 25mg placed in an Eppendorf 
tube. Hexadecyltrimethylammonium bromide (HTAB) buffer (0.5% HTAB, 50mM 
potassium phosphate pH 6.0) was then added to the tissue at a ratio of 25mg tissue per 
ml of HTAB buffer. The tissue was then homogenised by 3 x 10 second bursts of a 
T10 basic ultra-turrax handheld tissue homogeniser with an S10N 5G dispersing tool 
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(IKA England). Homogenate was then clarified by centrifugation for 6 minutes at 
13400g at 4°C. The supernatant was then taken off and stored at -70°C before use. 
The assay was carried out in a 96 well plate format with all samples tested in triplicate 
as technical replicates. To begin, 7µl of HTAB tissue homogenate was added per test 
well followed by 200µl of o-dianisidine buffer (0.5mM o-dianisidine dihydrochloride, 
0.0006% H2O2, 5mM potassium phosphate buffer pH 6.0). O-dianisidine is catalysed 
to produce a yellow-orange substrate by the MPO in the homogenate. This colour 
change was quantified by measuring the plate’s absorbance at 450nm on a Synergy 
HT Multi-Mode Microplate Reader (BioTek) using Gen5 microplate reader software 
(BioTek). Three measurements were taken over a one minute period at 0 seconds, 30 
seconds, and 60 seconds. The MPO activity in units (U; the amount of MPO needed 
to degrade 1μmol of H2O2 per minute at room temperature) per mg of tissue was then 
determined using the following equation: 
𝑈 𝑚𝑔⁄  𝑜𝑓 𝑡𝑖𝑠𝑠𝑢𝑒 = (
∆𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
∆min 𝑥 1.13𝑥10−2
) 0.175⁄ 𝑚𝑔 
ΔAbsorbance: The change in 450nm absorbance which was calculated by subtracting 
the starting absorbance read from the end absorbance read. 
Δmin: The change in minutes between each absorbance reading used to calculate the 
ΔAbsorbance. 
1.13x10-2: The change in absorbance that 1µmol of H2O2 gives per minute. 
0.175mg: The amount of tissue homogenate added per well.  
U/mg was calculated using the average ΔAbsorbance of the technical replicates for 
both the 0 to 30 seconds time point and the 30 to 60 seconds time point. The MPO 
activity for each sample was then taken as the average of both of these time points 
activity. 
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2.8 Human cTNC autoantibody enzyme-linked 
immunosorbent assay (ELISA) 
2.8.1 Plate washing and coating 
Streptavidin Immobilizer 96 well plates (Nunc, Thermo Fisher Scientific) were used 
for all experiments. All washes were carried out using a Stat-Matic II plate washer 
(Sigma-Aldrich). Wells were filled with cTNC wash buffer (PBS-T (0.05%)) followed 
by inverting to remove wash buffer. Washes were repeated as indicated. After the final 
wash the plates were dried by blotting onto paper towels to remove residual buffer.  
Biotinylated peptides used for coating the plates were cyclic citrullinated peptide 
(CCP; second generation; Axis-Shield Diagnostics Ltd, Dundee, UK), non-
citrullinated TNC5 (rTNC5), and citrullinated TNC5 (cTNC5) (both peptides 
produced by Pepceuticals Ltd (Leicester, UK)). The CCP2 peptide is a component of 
Axis Shield’s commercial anti-CCP assays and its amino acid sequence is confidential. 
The rTNC5 and cTNC5 peptides, have the amino acid sequences 
EHSIQFAEMKLRPSNFRNLEGRRKR and EHSIQFAEMKL-cit-PSNF-cit-NLEG-
cit-cit-KR respectively and were derived from the human tenascin-C protein as 
previously described (Schwenzer et al., 2015). For plate coating, peptides were 
prepared at 0.3µg/ml in cTNC peptide buffer (PBST (0.05%), 0.1% BSA). Plates were 
washed three times before the addition of 100µl/well of the peptide coat solutions. For 
the no peptide control wells, 100µl/well of cTNC peptide buffer alone was added. The 
plates were incubated for one hour at room temperature on an orbital plate shaker at 
200 rpm. Peptide coating solution was then decanted, and the plates washed three times 
before sample loading.  
2.8.2 Sample preparation  
Human serum or plasma samples were diluted 1/100 in cTNC sample buffer (1M 
NaCl, 4.9mM disodium phosphate, 0.5% Tween 20, 2% BSA, pH 7.2) for all assays. 
Every plate included three control samples diluted in the same manner as the test 
samples. These included a negative control individual normal serum sample (Access 
Biologicals, Vista, USA), as well as the intermediate (QC2) and high (QC5) positive 
control samples from a commercial Architect CCP assay (Axis-Shield Diagnostics 
Ltd).  
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Plates prepared as described in section 2.8.1 were loaded with 100µl/well of each 
control and test sample in duplicate. Plates were incubated for one hour at room 
temperature on an orbital plate shaker at 200 rpm after which the sample solutions 
were decanted and plates washed three times prior to autoantibody detection. 
2.8.3 Autoantibody detection  
Detection antibodies were conjugated to horseradish peroxidase (HRP) for enzymatic 
colourimetric detection and were diluted in cTNC conjugate buffer (PBS, 0.05% 
Tween 20, 1% BSA) to a working concentration of 0.1µg/ml. For detection of IgG 
class autoantibodies a goat anti-human IgG (γ-chain)-HRP detection antibody 
(catalogue number: 074-1002) was used and for detection of IgA a goat anti-human 
IgA (α-chain)-HRP detection antibody (catalogue number: 14-10-01) was used, both 
from Kirkegaard & Perry Laboratories (KPL; Gaithersburg, USA).  
Plates from section 2.8.2 were incubated with 100µl/well of detection antibody for one 
hour at room temperature on an orbital plate shaker at 200 rpm after which the 
detection antibody solutions were decanted and plates washed three times. For 
colourimetric detection 3,3',5,5'-tetramethylbenzidine (TMB) HRP substrate (Moss 
Inc, Pasadena, USA), a clear solution which produces a blue product upon incubation 
with HRP, was added to the plate at 100µl/well. The plate was incubated at room 
temperature for five minutes and then colour change was quantified by measuring 
absorbance at 650nm using a Varioskan Flash Multimode Reader with SkanIt 
Microplate Reader software (both Thermo Fisher Scientific). Raw absorbance data 
was exported to Microsoft Excel 2016 (Microsoft) for analysis.  
2.9 Human tenascin-C sandwich ELISA  
The below protocol detailed in sections 2.10.1 to 2.10.3 is the final assay protocol 
developed. However, while this basic scheme of work was followed during assay 
development some steps or materials were later amended during optimisation. This 
includes during initial antibody screening in which 1% BSA PBST was used as the 
block, sample, and antibody dilution buffer instead of the respective buffers detailed 
below. Additionally, during screening differing antibody concentrations were 
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investigated with detection antibodies used in a range from 5 to 0.001µg/ml while all 
capture antibodies were kept constant and coated at 1µg/ml.  
2.9.1 Plate coating and washing 
High binding capacity 96 well plates (Biomat, Trento, Italy) were used for all 
experiments. All washes were carried out as specified in section 2.8.1. 
Mouse anti-tenascin-C monoclonal antibody, clone 9F8 (MAB1911; Merck, 
Darmstadt, Germany) was used as capture antibody. For coating, antibody was 
prepared at 2µg/ml in carbonate buffer (15mM sodium carbonate, 35mM sodium 
bicarbonate, pH 9.6) and then 100µl/well was added to the plate. Plates were coated 
overnight at 2-8°C. The following day the coating solution was decanted, and plates 
washed three times before proceeding with blocking.  
2.9.2 Plate blocking and sample preparation 
Coated plates from section 2.9.1 were blocked by adding 200µl/well of blocking buffer 
(PBS, 0.05% Tween 20, 2% BSA) and incubating for one hour at room temperature 
on an orbital plate shaker at 200 rpm. 
Human serum and plasma samples were diluted 1/200 in cTNC sample buffer. A 
standard curve (0 to 50 ng/ml tenascin-C) was prepared using human tenascin-C 
purified from a glioma cell line (Merck) diluted in cTNC sample buffer. The 0ng/ml 
standard was cTNC sample buffer alone. A standard curve was included on all plates. 
After blocking, the plate was washed four times before samples and standards were 
added to the plate at 100µl/well in duplicate. The plates were then incubated for one 
hour at room temperature on an orbital plate shaker at 200 rpm. Following incubation, 
the sample solutions were decanted and the plates washed four times before proceeding 
with detection. 
2.9.3 Tenascin-C detection  
Tenascin-C specific detection antibody, NSCT-121 (kindly provided by Nascient Ltd, 
Cambridge, UK), was conjugated to biotin (kindly carried out by Dr Mel Lewis, see 
section 2.12.1) and diluted in cTNC conjugate buffer to a working concentration of 
5ng/ml. Plates from section 2.9.2 were incubated with 100µl/well of detection 
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antibody for one hour at room temperature on an orbital plate shaker at 200 rpm. 
Following incubation, the detection antibody was decanted and plates washed four 
times.  High sensitivity streptavidin-HRP conjugate (Thermo Fisher Scientific) was 
used as a secondary detection reagent. This was diluted to a working concentration of 
0.2µg/ml in cTNC conjugate buffer before use. Plates were incubated with 100µl/well 
of streptavidin-HRP for one hour at room temperature on an orbital plate shaker at 200 
rpm. Following incubation streptavidin-HRP was decanted and the plates washed three 
times. Colourimetric detection was carried out using TMB solution as described in 
section 2.8.3. Raw absorbance data was exported to Microsoft Excel 2016 (Microsoft) 
and sample tenascin-C concentrations interpolated from the standard curves as detailed 
in section 2.14.3. 
2.10 Human tenascin-C competition assay 
2.10.1 Plate coating 
Nunc Immuno-Module F8 MaxiSorp plates (Thermo Fisher Scientific) were used for 
all experiments. All washes were carried out as specified in section 2.8.1. 
Plates were coated with 100µl/well 0.5µg/ml of his-tagged recombinant human 
tenascin-C fibrinogen-like globe domain (his-FBG; kindly provided by Nascient Ltd) 
in carbonate buffer overnight at 2-8°C. The following day coating solution was 
decanted, and plates washed three times before proceeding with blocking. 
2.10.2 Sample and antibody competitor preparation 
Coated plates from section 2.10.1 were blocked as described in section 2.9.2 and after 
blocking, washed three times before addition of samples.  
Human serum and plasma samples were diluted 1/100 in blocking buffer. A standard 
curve (0 to 100 ng/ml tenascin-C) prepared as described in section 2.9.2 was included 
on all plates. Biotinylated detection antibody, NSCT-121 (kindly provided by Nascient 
Ltd) was prepared to 1.25ng/ml in blocking buffer.  
Samples and standards were mixed with the detection antibody solution in a 1:1 (v/v) 
ratio (100µl:100µl) and then incubated for one hour at room temperature on an orbital 
plate shaker at 200 rpm. Following the co-incubation, 150µl /well of each standard and 
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sample in triplicate was transferred to his-FBG coated plates. The plate was then 
incubated for one hour at room temperature on an orbital plate shaker at 200 rpm.  
2.10.3 Detection 
Secondary detection and colourimetric development were carried out with a 
streptavidin-HRP conjugate and TMB substrate solution as described in section 2.9.3 
except that streptavidin-HRP was used at 0.1µg/ml. Raw absorbance data was exported 
to Microsoft Excel 2016 (Microsoft) and sample tenascin-C and sample tenascin-C 
concentrations interpolated from the standard curves as detailed in section 2.14.3. 
2.11 Tenascin-C Large FnIII-B and FnIII-C ELISAs 
The tenascin-C large FnIII-B and FnIII-C ELISA kits (IBL International, Hamburg, 
Germany) were used to quantify tenascin-C FnIII-B or FnIII-C splice variants 
respectively. Both ELISAs were performed according to the manufacturer’s 
instructions with samples and standards run in duplicate. Sample dilutions for human 
serum and plasma samples was determined by titration with samples diluted 1/400 for 
the FnIII-B assay and 1/10 for the FnIII-C assay using the EIA sample dilution buffer 
provided by the kits. For chromogenic development plates were left at room 
temperature in the dark for 30 minutes before addition of stop solution. Absorbance 
was then measured at 450nm using a Varioskan plate reader as described in section 
2.8.3. Raw absorbance data was exported to Microsoft Excel 2016 (Microsoft) and 
sample tenascin-C FnIII-B and FnIII-C concentrations interpolated from the standard 
curves as detailed in section 2.14.3. 
2.12 Tenascin-C immunoprecipitation (IP) 
2.12.1 Antibody biotinylation and bead coupling 
Prior to biotintylation, antibody was buffer exchanged into PBS using a Zeba Spin 
Desalting Column with a 7000Da molecular weight cut off (MWCO) (Thermo Fisher 
Scientific) according to the manufacturer’s instructions. In brief, the column’s storage 
buffer was removed and then PBS was passed through the column resin three times. 
This consisted of applying 300µl of PBS to the top of the column and then centrifuging 
the column at 1500g for one minute. After the final PBS wash, the antibody was 
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applied to the column followed by centrifugation at 1500g for two minutes with the 
antibody in PBS obtained in the run through. 
Antibody was biotinylated using EZ-Link NHS-PEG4-biotin (Thermo Fisher 
Scientific) according to the manufacturer’s instructions. In brief, the NHS-PEG4-biotin 
was rehydrated in dH2O and then added to the antibody at a 12mmol excess. The 
biotinylation reaction was then left to occur for 30 minutes at room temperature. 
Biotinylated antibody was dialysed into PBS overnight at 4°C to remove non-reacted 
biotin using a 7000Da MWCO Slide-A-Lyzer MINI Dialysis Unit (Thermo Fisher 
Scientific) Using the IgG extinction coefficient of 1.35 and the antibody solutions 
absorbance at 280nm, measured against a PBS blank using a Varian Cary 50 UV-Vis 
Spectrophotometer (Agilent Technologies, Santa Clara, USA), the final concentration 
of the dialysed antibody was determined.  
Biotinylated antibodies were coupled to magnetic M-270 streptavidin Dynabeads 
(Thermo Fisher Scientific). Raw microparticles were first resuspended by mixing on a 
roller mixer. The appropriate volume of resuspended raw microparticles were 
transferred to a centrifuge tube and PBS-10% Tween 20 was added to a final 
concentration of 0.05% Tween 20.  Microparticles were washed by rotating for ten 
minutes using an end over end mixer. After washing particles were immobilised to a 
magnet and the supernatant removed.  This wash protocol was repeated, and the 
particles were finally resuspended in PBST (0.05%). Biotinylated antibody was added 
to the microparticles at a ratio of 1 mg antibody per 40 mg of microparticles. 
Microparticles were incubated with antibody using an end over end mixer for one hour 
to allow binding of biotinylated antibody to the streptavidin on the surface of the 
microparticle. Following coupling the microparticles were washed in PBST (1%) 
using a magnet and end over end mixer as described above.  This wash was carried out 
with rotation for ten minutes and was repeated twice. Following the final wash 
microparticles were finally resuspended in microparticle storage solution (100mM 
Tris, 150mM NaCl, 20mM EDTA, 0.1% Tween 20, 0.1% Proclin) at 20mg/ml and 
stored at 4°C.  
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2.12.2 Human serum and plasma tenascin-C IP 
To immunoprecipitate tenascin-C, Dynabeads coupled to the tenascin-C specific 
NSCT-121 antibody (Nascient Ltd) were used. For all samples a matched control IP 
was also carried out using Dynabeads coated with an antibody to an irrelevant target. 
Uncoupled dynabeads were also used for pre-clearing the samples. All dynabead 
preparations were made up as described in section 2.12.1 with antibody omitted for 
uncoupled dynabeads. 
The Dynabead preparations were initially washed three times with an excess volume 
of PBS using an end over end mixer and magnet before resuspension in their original 
volume with PBS. Serum and plasma samples were diluted 1/5 in PBS (200µl sample 
+ 800µl PBS) before addition of 2mg of uncoupled beads which were then left to roll 
for at least one hour to pre-clear. Following pre-clearing, the particles were brought to 
a magnet and the supernatant equally split between two tubes, one for tenascin-C IP 
and one for the control IP. For both the control and tenascin-C IP 1mg of Dynabeads, 
prepared in PBS as above, were added to the IP tubes and left on a roller mixer at 4°C 
overnight. The following day the dynabeads were washed three times with an excess 
volume of PBS using a tube rotator and magnet. After the final wash, the dynabeads 
were brought to the magnet and as much fluid drained as possible before immediate 
elution or storage at -20°C for later use.  
To elute tenascin-C from the beads for measurement in the tenascin-C sandwich 
ELISA beads were incubated with 20µl of 50mM Glycine pH 2.5 (elution solution) 
for approximately one minute. The tube was then placed to the magnet to remove the 
beads from solution and the eluent transferred to another tube. The eluent was then 
neutralised with the addition of 1M Tris-HCl pH 7 till a neutral pH was achieved as 
determined using litmus paper (Sigma-Aldrich). Eluents were then diluted 1/25 and 
supernatants 1/100 in cTNC sample buffer, while IP waste wash buffer was left 
undiluted, prior to analysis in the sandwich ELISA as detailed in section 2.9.  
For western blot and gel band mass spectrometry analysis proteins were eluted from 
dynabeads beads in 20µl 1x NuPAGE sample buffer supplemented with 1x NuPAGE 
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reducing agent and then processed for gel electrophoresis as described in section 2.6.3. 
For on bead digestion for mass spectrometry analysis see section 2.13.1. 
2.13 Mass spectrometry (MS) 
Mass spectrometry was carried out with the assistance of Dr Dominic Kurian of the 
Roslin Proteomics and Metabolomics Facility (PMF) at the Roslin Institute unless 
otherwise stated. 
2.13.1 On bead protein digestion 
IP Dynabeads prepared as described in section 2.12.2 were resuspended in 70µl of MS 
buffer 1 (2M Urea, 50mM ammonium bicarbonate, 1mM DTT) supplemented with 
5µg/ml sequencing grade modified trypsin (Promega, Madison, USA). Tubes were 
then left to digest on a thermomixer at 29°C for 30 minutes at 1200 rpm. After 
digestion a magnet was used to separate the beads and the supernatant was taken off 
and transferred to another tube. The IP Dynabeads were then resuspended in 60µl of 
MS buffer 2 (2M urea, 50mM ammonium bicarbonate, 5mM iodoacetamide), mixed, 
separated using a magnet, and the supernatant taken off. This second supernatant was 
pooled with the first supernatant and was then left to digest overnight protected from 
light on a thermomixer at 37°C and at 800 rpm. To stop the reaction the next day the 
sample was acidified by addition of trifluoroacetic acid (TFA) for final sample 
concentration of 0.5%. 
2.13.2 In gel protein digestion 
Gels silver stained as detailed in section 2.6.5 were washed three times for ten minutes 
in dH2O to remove any residual acetic acid. Bands were then cut out with sterile scalpel 
blade and diced into 1mm cubes which were placed in Protein Low bind tubes 
(Eppendorf, Hamburg, Germany). In gel protein digestion was then carried out by the 
Roslin PMF staff. In brief, the gel bands were dehydrated with acetonitrile to shrink 
them and enhance solution penetration. The proteins in the gel were then reduced and 
alkylated with incubations in 10mM DTT and 55mM iodoacetamide respectively, 
before overnight digestion with trypsin. Formic acid was then added the next day to 
stop digestion and peptide extraction buffer (50% Acetonitrile, 0.001% formic acid) 
was added to fully extract peptides from the gel.  
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2.13.3 Peptide purification 
Before mass spectrometric analysis peptides from protein digests as detailed in 
sections 2.13.1 and 2.13.2 were first purified using C18 HyperSep SpinTip Microscale 
SPE Extraction Tips (Thermo Fisher Scientific). The column was washed by passing 
70µl of acetonitrile buffer (80% Acetonitrile, 0.05% TFA) through the column, by 
spinning it at 2000 rpm for one minute, three times. The column was then equilibrated 
by washing three times in a similar manner with 0.05% TFA. The peptide samples 
were then loaded onto the column and passed through with the run through, collected 
and passed through a second time. The column was then washed twice with 100µl of 
0.05% TFA before elution by passing 60µl of acetonitrile buffer through. This elution 
step was repeated and the eluents pooled before sample drying in a Savant SPD 2010P1 
speedvac (Thermo Fisher Scientific). Once dried the sample was dissolved in formic 
acid and stored at -20°C until use. 
2.13.4 Liquid chromatography- tandem mass 
spectrometry (LC-MS/MS) analysis 
Peptides obtained as in section 2.13.3 were analysed by mass spectrometry by Roslin 
PMF staff. Analysis was carried out using an UltiMate HPLC system (Thermo Fisher 
Scientific) coupled to a micrOTOF-Q II ESI-Qq-TOF mass spectrometer (Bruker, 
Billerica, USA). Spectra were analysed using ProteinScape software (Bruker) in 
combination with the Mascot database search engine (Matrix Science, London, UK) 
for protein identification.   
2.14 Statistical analysis 
2.14.1 Significance tests and data presentation 
Statistical analysis was carried out using Prism 8 statistical software (Graphpad 
Software, San Diego, USA). Data was checked for normal distribution, to inform 
statistical test choice, using the Shapiro–Wilk test. For normally distributed continuous 
data direct comparisons were carried out using the Student’s t-test or a one-way 
analysis of variance (ANOVA). For multiple comparisons a two-way ANOVA with 
Sidak’s multiple comparisons test was used. For direct comparisons of non-parametric 
data the Mann-Whitney U test was used. For multiple comparisons the Kruskal-Wallis 
test with Dunn’s multiple comparisons test was used. P<0.05 was considered to be 
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significant for all tests carried out. All continuous data are presented as the mean ± the 
standard deviation (StdDev) and ordinal data as the median ± the interquartile range. 
2.14.2 Assessment of correlation and prevalence 
Both correlation and prevalence were graphed and statistically assessed utilising Prism 
8 statistical software (Graphpad Software). 
Correlation between two variables was assessed using the non-parametric Spearman's 
rank correlation test providing a correlation coefficient (ρ) describing the relationship 
between the variables with 1 indicating a perfect positive and -1 a perfect negative 
correlation. A p value was also computed testing the null hypothesis that the two 
variables were not correlated, with significance (p<0.05) indicating that they do 
display some correlation. 
Prevalence of a variable was calculated and graphed as the percentage of total animals 
exhibiting the variable over time. Statistical significance of differences in prevalence 
between groups was then assessed for each time point using Fisher's exact test. 
2.14.3 ELISA standard curve interpolation and signal to 
noise ratio calculations 
Standard curves were fitted using a quadratic polynomial regression for the IBL and 
sandwich ELISAs (described in sections 2.9 and 2.11) while a cubic polynomial 
regression was used for the competition assay (described in section 2.10). A new 
standard curve was calculated based on the on-plate standards for every plate from 
which interpolation of that plates unknown sample concentrations was then carried out 
either manually in Microsoft Excel 2016 (Microsoft) or using the Prism 8 statistical 
software (Graphpad Software). 
To calculate a signal to noise ratio the absorbance of the highest standard concentration 
was divided by the lowest standard concentration on the assay plate. This was done for 
at least three plates with the mean signal to noise ratio calculated across the plates 
given.   
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2.14.4 Receiver operating characteristic (ROC) curve 
calculation and assessment of diagnostic ability 
ROC curves, calculated using the Prism 8 statistical software (Graphpad Software), 
were used to assess test diagnostic ability by plotting sensitivity (percentage of true 
positives identified) against test specificity (percentage of false positives identified) 
across a range of assay cut offs. Area under the curve (AUC) values calculated from 
the ROC curve reflect the ability of the test to discriminate between controls and 
patients. A p value was also calculated alongside the curve generation based on the 
AUC value testing the null hypothesis that the diagnoses are made no better than 
random chance. This was done by assessing if the AUC value calculated was 
significantly different from 0.5, the AUC value expected if a test is not able to 
discriminate true positives from true negatives. Likelihood ratios were also computed 
during curve generation which indicate how much more likely a patient with a positive 
test result is to be a true positive compared to a patient with a negative result.  
2.14.5 Survival analysis 
Survival was analysed using Prism 8 statistical software (Graphpad Software) and was 
first assessed by using the product limit method of Kaplan and Meier to generate 
Kaplan-Meier survival curves. Significant difference in survival between groups was 
then assessed using the logrank test which tests whether the median survival between 
the groups differed significantly. 
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Chapter 3 Profiling tenascin-C in murine 
dextran sulphate sodium colitis 
3.1 Introduction 
Tenascin-C is expressed dynamically at numerous sites during embryonic 
development, including during epithelial morphogenesis (Chiquet, 1992), 
neurogenesis (Faissner, 1997), and developing connective tissues (Tucker and 
Chiquet-Ehrismann, 2009). In the adult this expression becomes more sparse and 
restricted, narrowing to a few tissues under tensile stress, such as muscle (Fluck et al., 
2000), underlying some epithelia, such as blood vessels (Hedin et al., 1991), and within 
a number of stem cell niches (Chiquet-Ehrismann et al., 2014).  
In the response to tissue injury however, tenascin-C has been shown to become 
markedly upregulated as part of the inflammatory response. This has been 
demonstrated in in a variety of  different tissues, and in response to a wide range of 
insults (Midwood and Orend, 2009). In these scenarios tenascin-C acts as a damage 
associated molecular pattern (DAMP), a class of endogenous molecules which 
promote and drive inflammation through their interactions with immune and stromal 
cells (Schaefer, 2014). In the case of tenascin-C this interaction has been shown to be 
mediated by the pattern recognition receptor (PRR) Toll-Like Receptor 4 (TLR4) 
(Zuliani-Alvarez et al., 2017) as well as the integrins α9β1 (Asano et al., 2014) and 
αVβ3 (Shimojo et al., 2015), whose engagement by tenascin-C promotes cell 
activation and often the production of a variety of pro-inflammatory mediators. While 
this pro-inflammatory action may be beneficial in the normal physiological response 
to injury it has become increasingly appreciated in recent years that DAMPs also play 
a role in the pathogenesis of inflammatory disease (Piccinini and Midwood, 2010). In 
this context tenascin-C itself has already been implicated in a diverse range of chronic 
inflammatory conditions such as rheumatoid arthritis (Midwood et al., 2009), systemic 
lupus erythematosus (Zavada et al., 2015), as well as Inflammatory Bowel Disease 
(IBD).  
IBD encompasses a group of conditions in which an aberrant chronic inflammatory 
response of unknown aetiology targets the intestinal tract which results in its 
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progressive dysfunction and destruction. It presents clinically as two main subtypes 
which are ulcerative colitis (UC) and Crohn’s disease (CD). UC is characterised by 
continuous mucosal inflammatory lesions affecting only the colon whereas CD 
presents as patchy transmural inflammation potentially affecting any region along the 
alimentary tract, although most commonly found in the distal small intestine (Neurath, 
2019). Both of these conditions are chronic with no medically curative therapies 
available except for major surgical intervention, with its own potentially serious 
complications, in extreme cases of UC (Mowat et al., 2011). This is particularly 
problematic when considering disease burden has been increasing globally in recent 
decades with prevalence now surpassing 0.3% in most of Europe and North America 
(Ng et al., 2018). It is thus apparent that further work on understanding the 
pathogenesis and drivers of the disease is needed to aid in the development of effective 
tools for its clinical management and treatment.  
In terms of tenascin-C’s involvement in IBD a genome wide association study has 
previously identified a SNP linked to the tenascin-C gene as being associated with 
IBD. This was found within an intronic region of the gene between the alternative 
spliced FNIII repeats A4 and B with the impact on tenascin-C expression or function 
as yet unknown (Brant et al., 2017). At the protein level it has been demonstrated that 
systemic levels of circulating tenascin-C are increased in IBD patients compared to 
healthy controls (Riedl et al., 2001). Furthermore, these levels were shown to correlate 
with disease activity and showed responsiveness to therapy with proctocolectomy 
surgery and successful biologic therapy resulting in a significant decrease in tenascin-
C levels (Magnusson et al., 2015). This systemic increase is also reflected at the local 
level with a number of histological studies showing high levels of tenascin-C staining 
in the inflamed gut tissue of patients with UC (Geboes et al., 2001), CD (Ambort et 
al., 2010), and microscopic colitis (Salas et al., 2003). Collectively these largely 
descriptive studies indicate that tenascin-C is potentially an inflammatory driver of 
interest in IBD. However, additional work is needed to further validate and 
characterise the functional role tenascin-C may be playing. 
With a myriad of confounding factors to consider in IBD, including variations in 
genetics and gut microflora, murine models of colitis provide a useful controlled 
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setting for studying the underlying mechanisms of disease (Kolios, 2016). A number 
of models of colitis exist which can be broadly broken down into chemically induced 
models, cell transfer models, spontaneous models, and genetically engineered models. 
Out of these, owing to their relative simplicity and adaptability, the chemically induced 
models, including Dextran Sulphate Sodium (DSS) induced colitis, are the most 
commonly used. The DSS model involves the dosing of mice with commonly between 
1-5% DSS in their drinking water for four to eight days to induce acute colitis. 
Alternatively, repeated cycles of DSS dosing to induce colitis followed by brief 
recovery periods can be used to induce a self-perpetuating chronic colitis (Wirtz et al., 
2017). The exact mode of action by which DSS induces colitis is not fully clear 
although it has been suggested that DSS forms lipocomplexes with fatty acids in the 
colon. These lipocomplexes are believed to be partially toxic to the colonic epithelial 
cells inducing inflammatory signalling and cell death which compromises epithelial 
barrier integrity. The resulting injury and exposure of sub-epithelial immune cells to 
luminal antigens is thus believed to trigger the acute inflammatory response observed 
(Laroui et al., 2012). With this proposed mechanism the genetic background of the 
host would be expected to influence the colitic response and this is seen with 
susceptibility as well as the area of colon affected varying among inbred mouse strains. 
Additionally, the microbiota is another variable that must be taken into account with 
the type of luminal antigens and pathogens of obvious importance to disease 
development (Perse and Cerar, 2012). As such, local optimisation of colitis induction 
protocols is required to account for each of these factors which will vary by facility.  
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3.2 Hypothesis  
Tenascin-C will have restricted expression in adult mice but will become upregulated 
with the induction of an inflammatory state such as in the DSS model of colitis.   
3.3 Aims 
I. Profile tenascin-C’s expression in the mouse under basal conditions with a 
focus on the colon. 
II. Establish and optimise the DSS model of colitis for use with the 129sv 
mouse strain. 
III. Profile the gross and histopathological features of DSS colitis in this strain 
of mice. 
IV. Study tenascin-C’s spatiotemporal expression in control and colitic mice 
relating this back to the gross and histopathology observed.  
V. Further map tenascin-C’s expression in relation to a range of inflammatory 
mediators and cell types. 
3.4 Materials and methods 
3.4.1 Tissue culture 
All tissue culture reagents were acquired from Thermo Fisher Scientific unless 
otherwise indicated. Passage one mouse embryonic fibroblasts (MEFs) isolated from 
E13.5 CD1 mouse embryos were acquired frozen from Elisabeth Thornton 
(McLachlan group, Roslin Institute).  
MEFs were thawed in a 37°C water bath before drop wise addition of 5mls culture 
medium (high glucose Dulbecco's modified Eagle medium (Sigma Aldrich) 
supplemented with 10% heat inactivated foetal bovine serum, 1% GlutaMAX and 
50µg/ml gentamicin). The cells were then transferred to a 30ml universal tube and 
centrifuged at 1000g for five minutes to pellet the cells. The supernatant was then taken 
off and the cells resuspended in fresh culture medium before transfer to tissue culture 
flasks. MEFs were cultured in a humidified atmosphere (37°C, 5% CO2) with media 
changed every two to three days. MEFs were passaged when they reached ~80% 
confluency.  
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To passage cells they were initially rinsed in sterile Dulbecco’s PBS before addition 
of trypsin-EDTA (0.25%) cell dissociation reagent. After a five minute incubation at 
37°C the flasks were gently tapped to aid the detachment of cells from the culture 
flask. Culture medium was then added to the dissociated cells which were then 
transferred to a universal tube and pelleted by centrifugation at 1000g for five minutes. 
The supernatant was then removed, and the pellet resuspended in fresh culture 
medium. Cells were counted using a haemocytometer and then either transferred to 
fresh flasks at the desired cell number for continued culture or seeded at 1x104 
cells/cm2 in multi-well plates for use in experiments. Cells were rested for a minimum 
of 24 hours after seeding before use in experiments and were not used past passage 5.  
3.4.2 Tissue and cell gene expression analysis 
Bio-GPS and SAGE-genie gene expression data, expressed as arbitrary units and tags 
per 200,000 tags respectively, were obtained as detailed in section 2.2. 
RNA extraction from tissue and RT-qPCR analysis carried out as detailed in section 
2.5. For profiling Tnc expression a range of tissues were harvested and snap frozen 
from three 8 week old male 129sv WT mice for later RNA extraction. Data for this 
analysis is presented as 2-ΔCT values relative to the housekeeping 18s rRNA. For initial 
colon region gene expression analysis in the DSS model RNA was similarly extracted 
from snap frozen colon tissue segments. For gene expression analysis for DSS time 
course samples the RNA was extracted from cryosections containing multiple 
segments across the full length of the colon.  In both cases analysis of DSS colon data 
is presented as fold change compared to control non-colitic samples calculated using 
the ΔΔCt method as detailed in section 2.5.4. 
For extraction of RNA from MEF cells seeded in 6 well plates the culture media was 
first aspirated and the cells lysed with the addition of 350µl RLT lysis buffer (Qiagen) 
supplemented with 10µl per millilitre β-mercaptoethanol. Wells were then scraped, 
and the lysate transferred to an Eppendorf tube which was vigorously vortexed to aid 
complete cell lysis. RNA was then extracted as detailed in section 2.5.1, starting from 
the addition of an equal volume of 70% ethanol step, utilising an RNeasy spin column 
kit (Qiagen).  
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3.4.3 Western blotting 
Colon tissue from 7-9 week old male WT and Tnc-/- mice was dissected as detailed in 
section 2.3.5 and flash frozen in LN2. Neonate lungs were dissected from five day old 
WT mice. Protein was extracted from approximately 40mg of tissue. Following 
quantitation, 20µg of each tissue homogenate was run on a 10% Bis-Tris SDS-PAGE 
gel and western blotted using the MTn-12 anti-tenascin-C and 13E5 anti-β-actin (Cell 
Signalling Technology) antibodies, the former of which was a kind gift from Dr. 
Gertraud Orend (INSERM, Strasbourg, France). All western blotting procedures were 
carried out as detailed in section 2.6. 
3.4.4 Immunohistochemistry (IHC) 
Cryosections of tenascin-C rich murine tumour tissue, cut at 7µm, were a kind gift 
from Dr. Gertraud Orend (INSERM, Strasbourg, France). Colon tissue was harvested 
for IHC analysis as detailed in section 2.3.5. Proximal, middle, and distal sections from 
one mouse were embedded together in the same OCT block for cryosectioning, 
immunostaining, and imaging together. All IHC staining procedures were carried out 
as detailed in sections 2.4.2, 2.4.6, and 2.4.7. Negative controls were performed where 
the primary antibody was either omitted (no primary) or replaced with non-specific 
IgG from the animal the primary antibody was raised in (Sigma Aldrich). 
3.4.5 DSS murine model of colitis  
DSS colitis was induced, as detailed in section 2.3.4, in 7-9 week old male 129sv mice, 
provided as a kind gift from a colony belonging to Prof. Bernadette Dutia (Roslin 
Institute). Initial DSS titration experiments were carried out utilising a more simplistic 
disease activity index (DAI) scoring scheme where only faecal blood and stool 
consistency were scored for. The final scoring sheet, as shown in Appendix V, was 
subsequently developed and was used for all other experiments. Body weight data are 
presented as mean percentage body weight loss ± standard deviation and DAI sum 
score data is presented as median score ± interquartile range, as specified in section 
2.3.4. Mice that exhibited severe adverse reactions or exceeded study severity limits, 
as described in section 2.3.4, were immediately euthanized and were not included for 
analysis. 
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3.4.6 Colitis histopathology grading 
H&E staining of paraffin and cryo-embedded colon tissue sections was carried out as 
detailed in section 2.4.3 and colons graded for histopathology as described in section 
2.4.3. For the DSS titration experiments histopathology was graded using paraffin 
embedded sections and for the DSS time course experiment cryo-embedded sections 
were scored.  
3.4.7 Statistical Analysis 
Statistical analysis was carried out as detailed in section 2.14. Continuous data, 
including body weight loss, colon length, and qPCR results, were analysed using 
Student’s t-test, a one-way ANOVA, or a two-way ANOVA with Sidak’s multiple 
comparisons test unless found to be not normally distributed. Non-normally distributed 
continuous data or ordinal data, such as DAI and histopathology scoring, were 
analysed using the appropriate non-parametric Mann-Whitney U or Kruskal-Wallis 
with Dunn’s multiple comparisons tests.  
3.5 Results 
3.5.1 Tenascin-C’s gene expression profile in adult mice 
Tenascin-C is reported not to be expressed, or to be expressed at low levels, in the 
majority of adult tissues (Midwood et al., 2016). However, no single systematic study 
of tenascin-C expression covering multiple tissues has been carried out.  To confirm 
this observation a review of published expression data as well in-house profiling was 
carried out. The BioGPS database of microarray data was the first resource to be 
interrogated with the data extracted presented in figure 3.1a. The SAGE-genie 
database of SAGE library data was the next source of expression data utilised, with 
the data extracted shown in figure 3.1b. Finally, to confirm the data generated by these 
high-throughput screening methods tenascin-C expression was analysed by RT-qPCR 
in a similar array of tissues extracted from adult 129sv mice, shown in figure 3.1c. 
Alongside the major tissues investigated MEF cells, an embryonic stromal cell type 
known to produce high levels of tenascin-C (Brellier et al., 2011), were also analysed 
as a benchmark for high tenascin-C expression.  
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Each of the approaches utilised, while showing some differences, broadly confirmed 
that tenascin-C is comparatively lowly expressed at the mRNA level in most murine 
adult tissues. This included no expression found in spleen, liver, and heart, while only 
low levels of mRNA were detected in brain, bone, and the intestines, including the 
colon. This was particularly clear when comparing tissue expression levels with the 
MEF cells, which displayed by far the highest tenascin-C expression across all 
methods.  
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3.5.2 Expression of tenascin-C at the protein level in the colon 
of adult mice 
With the identification of the adult colon as an expression site of tenascin-C it was 
next decided to validate this mRNA data at the protein level. To do this protein lysates 
of colon samples were prepared and western blotted for tenascin-C with the result 
shown in figure 3.2. Supporting the gene expression data tenascin-C was found to be 
expressed in the colon with a major band seen at approximately 200kDa as well as a 
minor band at 280kDa. The positive control of a known expression site, five day old 
neonate lung (Saga et al., 1992), showed the presence of the same bands although at 
higher levels. Also conversely compared to the colon, a predominance of the higher 
molecular weight form of tenascin-C was observed in lung lysate suggestive of 
differential splicing and/or of differential glycosylation of tenascin-C between the 
tissues. The negative control of colon tissue from a Tnc-/- mouse produced no bands as 
expected. 
Having demonstrated protein expression in the colon its localisation within the tissue 
was next investigated. To do this an immunohistochemistry protocol using the MTn-
12 antibody against tenascin-C was optimised with cryosections of murine tumour 
tissue which express high levels of tenascin-C. Strong staining with MTn-12, shown 
in figure 3.3, was observed in the matrix of the tumour and this was demonstrated to 
be specific with no staining observed in the matched negative controls. 
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Having optimised tenascin-C IHC staining, cryosections were generated covering the 
length of the colon of eight-week-old male mice which were then immunostained for 
tenascin-C, shown in figure 3.4a. This further confirmed the basal expression of 
tenascin-C protein in the colon with staining observed along the length of the colon. 
Additionally, despite morphological differences in different regions of the colon, the 
staining followed broadly the same staining pattern in each region. This included 
tenascin-C staining in the outer muscle layer of the colon, the muscularis externa, as 
well as a subepithelial band in the lamina propria directly underlying the surface 
epithelium. Specific to the middle colon, some additional tenascin-C staining appeared 
to be present in the lamina propria extending further down the crypts from this 
subepithelial band. Higher magnification images also revealed tenascin-C 
immunoreactivity present in the muscularis mucosa, although this was less apparent in 
the proximal colon compared to the middle and distal segments. To further confirm 
this was the result of specific tenascin-C staining a second tenascin-C specific 
antibody, NSCT-121, recognising a different epitope of tenascin-C was also used for 
colon IHC staining, shown in figure 3.4b. The same pattern of staining was again 
observed with this antibody as was seen by MTn-12, confirming its specificity. 
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3.5.3 129sv mice develop acute colitis upon dosing with DSS 
Following the profiling of tenascin-C under basal conditions in the colon the next aim 
of the project was to profile tenascin-C under inflammatory conditions. To do this the 
DSS chemically induced colitis model was established in the lab for 129sv strain mice. 
This mouse strain was chosen as it is the background strain for the Tnc-/- mouse colony 
which was utilised in future experiments. As well as DSS dosing concentration and 
duration the genetic background and local gut microflora are known to impact colitis 
induction and severity (Perse and Cerar, 2012). As such, a titration experiment was 
required to optimise DSS dosing for this 129sv colony to ensure robust induction of 
colitis which remained within animal welfare severity limits as mandated by home 
office regulations.  
The most common doses used in the literature range between one to five percent DSS 
(Perse and Cerar, 2012). As such, for the titration experiment groups of mice were 
dosed with between one to five percent DSS in their drinking water for five days. They 
were then returned to normal drinking water before cull on day seven. As expected, a 
dose response was seen with presentation of gross pathology, with increasing doses of 
DSS inducing more severe colitis.  This was first demonstrated using body weight loss 
and DAI readouts of animal health, the data for which is shown in figure 3.5a and 
figure 3.5b respectively. Control animals, which were not dosed with DSS, showed no 
DAI scoring or weight loss over the duration of the experiment. Mice dosed with the 
lowest DSS concentration of 1% also displayed no significant bodyweight loss 
although they showed a significant increase in DAI scoring on day 6 of the protocol. 
All of the dosages tested above 1% conversely did show significant body weight loss 
for at least one time point with the trend in body weight loss beginning at around day 
5-6. For the higher doses of 4-5% this weight loss became significant from day five 
itself whereas for the lower doses of 2-3% while a trend down was apparent this only 
achieved significance on the final day 7. These changes were likewise reflected in the 
DAI which also showed scoring for all these doses from day five onwards. It was 
apparent however that the basic scoring sheet used for these initial experiments didn’t 
capture the full picture of observable animal health however as it only recorded stool-
based symptoms. This prompted the development of the final more holistic health 
monitoring which was used for all future experiments. 
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Overall based on these gross health parameters the two higher doses were judged to be 
too severe, with mice culled on humane grounds on day five and six, resulting in no 
mice from these groups reaching the experimental end point. The 3% dosage, while 
reaching the study end point, was also judged by the facility named veterinary surgeon 
to be too severe. Thus, the 2% DSS dosage appeared to be the most appropriate and 
this was confirmed by the final gross parameter examined, the colon length at cull 
which is shown in figure 3.5c. One of the hallmarks of DSS induced colitis is a 
shortening of the colon due to tissue wastage associated with the pathology (Chassaing 
et al., 2014). As such, the observation that the colon length in the 2% group showed a 
significant shortening compared to control mice provided further evidence that colitis 
had been successfully induced. Additional observations at cull, including that 2% DSS 
treated mice had loose stool and in some cases faecal blood present, further supported 
the conclusion that colitis had been successfully induced. In comparison and in line 
with the other parameters examined no difference in colon length or other gross 
features at cull was observed between the control and 1% DSS groups.  
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Based on the gross pathology it was thus decided to go forward with the 2% DSS dose 
and confirm the induction of colitis at the histopathological level. Histological analysis 
of H&E stained colon sections showed normal colonic architecture and little 
inflammation in control mice. In comparison DSS treated mice showed significant 
inflammatory pathology which was predominantly localised to the middle and distal 
colon. As reported by trained histopathologist Elspeth Milne; Professor of Veterinary 
Clinical Pathology, University of Edinburgh; this included significant mixed 
infiltration of macrophages and neutrophils into the submucosa and which 
occasionally extended transmurally across the entire colonic wall. Additionally, 
moderate to severe oedema, another marker of inflammation, was also commonly 
observed in the submucosa. Tissue damage was also apparent with ulceration and crypt 
loss present alongside hyperplastic epithelial tissue, indicative of atypical tissue 
regeneration in response to damage.  
These changes were quantified by blinded histopathology scoring, which was also 
carried out by Prof. Elspeth Milne, with the results presented in figure 3.6a. This 
confirmed the above observations with the proximal colon appearing unaffected by 
DSS treatment while a significant increase in pathology score was observed for the 
distal colon. The middle colon in comparison exhibited a more variable intermediate 
pathology score which was still significant increased compared to control samples. 
Scoring breakdown for the distal portion of colon, shown in figure 3.6b, demonstrated 
a significant increase compared to the control for all the parameters scored for. This 
included showing a marked increase in inflammation with the inflammatory severity 
and extent measures, representing the severity of the inflammatory pathology, such as 
degree of immune cell infiltration, and the extent of its penetration into the gut wall 
respectively, both showing significant increases. Additionally, the crypt damage and 
regeneration parameters, measuring damage to the mucosa and the presence of tissue 
repair processes, such as epithelial hyperplasia, respectively, likewise also showed 
significant increases.  
To confirm the greater degree of inflammatory pathology in the distal colon 
myeloperoxidase (MPO) activity was assayed in each of the colonic regions. 
Myeloperoxidase is expressed in neutrophils and is often used as a surrogate marker 
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for their infiltration into the intestines in inflammatory models (Krawisz et al., 1984). 
The results of this assay, presented in figure 3.6c, again supported the histological 
observations that DSS pathology was worse in the distal colon with significant increase 
in MPO activity only observed in the distal segments. Conversely, just a non-
significant trend towards increase was seen in the mid colon while no significant 
difference was observed in the proximal colon. This matches with previously reported 
data that the distal portion of the colon is often the most affected by DSS treatment 
(Perse and Cerar, 2012). 
3.5.4 Upregulation of tenascin-C in the distal colons of DSS 
treated colitic mice 
Having established the DSS colitis model in 129sv mice, work began to characterise 
tenascin-C’s expression in this murine inflammatory model. This was initially done at 
the gene expression level by carrying out RT-qPCR on RNA extracted from colon 
tissue from the control or 2% DSS treated mice. The results of this analysis, shown in 
figure 3.7a, demonstrated a significant upregulation in tenascin-C mRNA expression 
in the distal colon of DSS treated mice compared to controls. No significant difference 
in tenascin-C mRNA expression between the groups was observed in either the 
proximal or middle colon. 
To confirm this increase at the protein level IHC was carried out on distal colon 
samples from control and 2% DSS treated mice, with representative images shown in 
figure 3.7b. Control mice exhibited the same tenascin-C staining pattern in the mucosa 
and muscularis externa as shown previously, with mucosal expression restricted to a 
distinct subepithelial band. As the histopathology scoring suggested tissue architecture 
in the DSS treated mice appeared perturbed with oedema and immune cell infiltration 
evident in the submucosa, alongside significant mucosal damage including crypt loss. 
In terms of tenascin-C expression compared to the controls an increase in staining was 
observed in the mucosa of DSS treated mice. This presented as expression which was 
no longer restricted to a distinct subepithelial band but was now found as diffuse 
staining throughout the entire width of the damaged mucosa. Additionally, a 
thickening of the muscularis mucosa was observed in some areas with a matching 
increase in the tenascin-C staining for this structure.   
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3.5.5 Temporal profiling of acute DSS coltis pathology 
Having demonstrated tenascin-C’s upregulation at the acute stage of inflammation it 
was next decided to interrogate the temporal nature of this increase. To do this a DSS 
time course experiment, outlined in figure 3.8a, was carried out in which mice were 
culled at two-day intervals throughout the now established DSS colitis protocol. To 
accommodate this chosen time point interval it was decided to increase the study end 
point from day seven to day eight at which acute colitis should still be firmly 
maintained. The same gross and histological pathological readouts were chosen to be 
monitored as well as collecting colon tissue for further gene expression and IHC 
analysis at each cull time point. 
Initial assessment of gross pathological readouts confirmed successful colitis 
induction. This included body weight loss, presented in figure 3.8b, mimicking the 
titration experiment with a significant decrease compared to controls observed from 
day seven onwards. The improved DAI scoring scheme, better capturing observable 
mouse health, likewise showed a significant increase in pathology, with the results 
shown in figure 3.8c.  This showed the development of symptoms, such as the presence 
of pasty stools and faecal blood, preceding the weight loss starting from as early as 
day four and become significantly established at day five. Finally, at cull the last gross 
parameter presented in figure 3.8d, colon length, also demonstrated colitis induction 
at the roughly the same time point with a trend towards decreasing length which 
became significant from day six.  
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To definitively determine induction of colitis histological analysis of H&E stained 
colon sections, shown in figure 3.9, was again carried out. Control mice (plotted as 
day zero indicating zero days DSS treatment) displayed normal colonic architecture 
and little evidence of any inflammation present along the length of the colon. Likewise, 
day two time point DSS mice also showed no signs of any pathology along the length 
of the colon, which appeared indistinguishable from control mice. From day four of 
DSS treatment some evidence of pathological changes began to become apparent with 
minor immune infiltration seen in some sections for the middle and distal colon. Tissue 
damage was not apparent at this stage however, with tissue architecture appearing 
largely normal. This dramatically changed when moving on to the day six time point 
tissues where significant pathological changes were now readily apparent in the middle 
and distal colon of all mice assessed. This included inflammatory changes such as 
marked submucosal oedema and now significant immune cell infiltration by mainly 
neutrophils as well as occasionally mononuclear cells. Additionally, tissue damage, 
including disrupted mucosal architecture with extensive ulceration, loss of crypts, and 
hyperplasia, was now also readily apparent in all mice assessed. From this time point 
till the final time point on day eight this pathology was maintained and presented 
similarly in all in the day eight mice assessed. 
These changes were additionally quantified and confirmed using the blinded 
histopathology scoring scheme. Sum scores, presented in figure 3.10a, again 
demonstrated the focus of pathology towards the distal end. This also confirmed the 
time point for colitis initiation with scores beginning to raise above background levels 
at around day four. It also confirmed the establishment of acute colitis at day six at 
which point both middle and distal scores appeared elevated, although this was only 
significant for the former colonic region. From day six to eight only a moderate 
increase was observed at which point both the middle and distal colons showed 
significant scoring increases. Breakdown by scoring parameter, shown in figure 3.10b, 
for the distal colon further supported earlier observations that the early pathology seen 
at day four was due solely to inflammatory changes. Tissue damage conversely only 
began to appear at day six before achieving significance at day eight.  
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3.5.6 Pro-inflammatory mediators are increased from day six 
of the DSS colitis protocol 
Having shown establishment of pathology at day six gene expression analysis for 
tenascin-C as well as other key inflammatory regulators was carried out on RNA from 
cryosections containing colon segments covering the full length of the colon. This 
strategy of extracting RNA from cryosections rather than snap frozen individual 
colonic segments was required to accommodate for the lack of tissue due to shortening 
of the colon with colitis. The result of this for tenascin-C, presented in figure 3.11a, 
showed that unlike seen previously when colon RNA was isolated from separate 
colonic regions (figure 3.7a) a statistically significant increase in expression was not 
observed at any time point, although a upwards trend was seen from day six. In terms 
of other mediators, the classical pro-inflammatory cytokines interleukin (Il)-6, Il-1β, 
tumour necrosis factor (Tnf), and Il-12a were also analysed with the results shown in 
figures 3.11b, 3.11c, 3.11d, and 3.11e, respectively. Il-6, Il-1β, and Tnf all showed 
higher fold inductions compared with tenascin-C and conversely demonstrated 
significance in their upregulation from day six. Il-12a by comparison did not 
demonstrate significance at any time point with only a trend upwards seen on day 
eight. Additionally, the non-classical pro-inflammatory cytokine Il-17, related to the 
Th17 response implicated in IBD pathogenesis (Fujino et al., 2003), was also analysed 
and the result shown in figure 3.11f. Like the classical pro-inflammatory mediators 
high fold inductions were observed for Il-17a and differentially while a trend was 
evident at day six significance of this increase was only achieved at day eight. The 
final gene analysed, presented in figure 3.11g, was the immunomodulatory cytokine 
Il-10, which is associated with immune down regulation and anti-inflammatory 
processes. While a trend to increase was seen from day six, matching the pro-
inflammatory cytokines profile, this was not determined to be significant.  
  
 Tenascin-C: A marker and driver of inflammation 
Chapter 3 – Profiling tenascin-C in murine dextran sulphate sodium colitis  107 
  
 Tenascin-C: A marker and driver of inflammation 
Chapter 3 – Profiling tenascin-C in murine dextran sulphate sodium colitis  108 
3.5.7 Tenascin-C is elevated at the protein level in the colitic 
mucosa from day six 
With the gene expression analysis for tenascin-C conflicting with previous results 
(figure 3.7a), likely due to the methodological changes resulting in the mixing of tissue 
from proximal, middle and distal parts of the colon it was decided to profile tenascin-
C at the protein level by IHC as well. The results of this IHC analysis, shown in figure 
3.12, did corroborate previous results with an increase in tenascin-C staining in the 
middle and distal colonic mucosa evident with the induction of colitis. Additionally, 
matching the development of the tissue damage pathology this increase was seen from 
the day six time point, where it appeared tenascin-C stained more prominently in the 
areas with heightened damage.  
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3.5.8 Co-localisation of tenascin-C and α-smooth muscle actin 
(αSMA) under basal conditions 
To probe tenascin-C’s association with various histological features of the healthy and 
inflamed gut, dual IHC staining for a variety of other markers was performed alongside 
tenascin-C. Initially, based on the observation that tenascin-C appeared to localise to 
the muscularis externa and muscularis mucosa staining was carried out for αSMA, a 
marker of smooth muscle and myofibroblasts. This staining, presented in figure 3.13a, 
showed that under basal conditions αSMA stained the muscularis externa and 
muscularis mucosa predominantly as expected. Additionally, tenascin-C co-localised 
largely with these same areas showing a close association in the matrix around the 
αSMA positive cells. The exception for this appeared to be the subepithelial mucosal 
tenascin-C staining which did not show any αSMA positivity (see arrow heads in the 
proximal, middle and distal portions of the control tissue). 
Under colitic conditions αSMA localisation remained unchanged, staining to the same 
smooth muscle structures as under basal conditions. These structures likewise 
appeared largely similar to basal conditions with the exception of a slight thickening 
of the muscularis mucosa in the distal colon of the DSS treated mice from day six. Co-
staining with tenascin-C likewise remained similar to basal conditions with αSMA also 
absent from the colitis induced mucosal tenascin-C staining (see asterisk in the middle 
and distal portions of the colitic tissue).  
Additional chance observations were also made during staining with the identification 
of gut associated lymphoid tissue (GALT), including a colonic patch (CP) and a 
putative isolated lymphoid follicle (ILF). These were identified morphologically as 
aggregates embedded in the mucosa and submucosa of the gut wall with the ILFs 
distinguishable due to their solely mucosal localisation. The identity of these 
aggregates as CPs was confirmed by staining for B and T lymphocytes, as shown in 
figure 3.13b and c respectively, which confirmed their lymphoid tissue nature. 
Interestingly while the ILFs did not appear to show strong tenascin-C staining in their 
matrix colonic patches did.  This staining localised around the periphery of the patch 
with some matrix staining also extending into and sounding cells within the patch as 
well (see middle portion of the control tissue).  
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3.5.9 Tenascin-C associates with areas of ulceration in the 
colonic mucosa of DSS treated mice 
Having observed tenascin-C’s upregulation appearing to coincide with the onset of 
mucosal damage, the colonic epithelium was the next structural feature to be studied. 
To do this the tenascin-C staining was performed alongside the epithelial cell marker, 
CD326, which is also known as epithelial cell adhesion molecule (EpCAM). This dual 
IHC staining, shown in figure 3.14, demonstrated strong CD326 staining for the 
mucosal epithelium along the length of the colon in control tissue. This staining was 
maintained in the proximal colon throughout the induction of colitis corroborating the 
observed lack of tissue damage in this region. For the middle and distal colon however 
ulceration, evidenced by loss of CD326 mucosal staining, was observed which 
exposed the underlying connective tissue and subepithelial tenascin-C to the lumen. In 
some cases, the epithelial debris from the sloughed epithelium was also present in the 
colonic lumen overlying these areas. In terms of colitis induced tenascin-C staining 
this appeared to predominantly occur in these damaged ulcerated areas. In contrast, 
areas maintaining at least some CD326 expression showed reduced or absent mucosal 
tenascin-C staining suggesting tenascin-C was being deposited directly at the sites of 
mucosal injury.  
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3.5.10 Tenascin-C localisation in relation to the vascular 
system 
The vasculature is of obvious inflammatory importance with vasodilation and immune 
cell trafficking among the key events in any response. As tenascin-C has been reported 
to localise to blood vessels in other tissues (Mackie et al., 1992) these vessels were the 
first to be stained for using the endothelial cell marker CD31, shown in figure 3.15. 
Normal blood vessel architecture was observed in control tissue along the length of 
the colon with discrete vessels clearly present in the submucosa and extending into the 
lamina propria. In terms of tenascin-C staining this did not appear to co-localise with 
these vessels in the submucosa although the apical tips of the mucosal vessels did 
appear in some cases to co-localise with subepithelial tenascin-C staining. From day 
six of DSS treatment, alongside the inflammatory disruption of the mucosal 
architecture, the vascular network likewise became distorted. In hyperplastic epithelial 
regions the mucosal blood vessels expanded matching the increased thickness of the 
mucosa. In damaged areas of the mucosa, rich in tenascin-C, endothelial staining was 
also still observed although now as a disrupted microvascular network in the 
granulation tissue.  
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Besides the cardiovascular system the other component of the body’s vasculature is 
the lymphatic system. To investigate the spatial relationship between the lymphatic 
system and tenascin-C IHC was performed for the lymphatic endothelium specific 
marker lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), as shown in 
figure 3.16. In control tissue, lymphatic vessels were observed in the mucosa along the 
length of the colon. In the proximal colon, staining was localised to a band of vessels 
just overlying the muscularis mucosa as well as vessels extending into the lamina 
propria of the mucosal folds. A similar pattern was seen with the middle and distal 
colon although here the vessels extending into the lamina propria were far less 
prominent. This localisation positioned LYVE-1 in close association with tenascin-C 
which stained the underlying muscularis mucosa. Also, in contrast to the CD31 
staining the lymphatics in the lamina propria did not extend as far apically and thus 
did not appear to contact the subepithelial tenascin-C staining.  
From day six of DSS treatment the apically extending vessels appeared to be lost with 
the breakdown of mucosal architecture with some staining only appearing to remain 
in hyperplastic regions. Vessels overlying the now thickened tenascin-C staining 
muscularis mucosa remained however and appeared dilated with enlarged lumens, 
presumptively as a result of the marked oedema observed.  
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3.5.11 Tissue resident macrophages underlie the band of 
subepithelial tenascin-C staining  
Having examined several structural features of the colon it was next decided to 
interrogate the immune compartment in more detail. To begin the lamina propria 
resident macrophage population was investigate by IHC using the integrin CD11c as 
a marker, the results of this shown in figure 3.17. In control mice resident macrophages 
were found throughout the lamina propria, tending to localise more towards the upper 
apical regions closer to the lumen. The macrophages occupying these apical locations 
were thus found to closely associate with the band of subepithelial tenascin-C staining 
also found in this region.  
With the onset of obvious colitic damage at day six of DSS treatment numbers of 
resident macrophages did not appear to change from the basal state. The cells remained 
within the damaged mucosa and were found in both tenascin-C rich ulcerated regions 
as well as and non-staining areas, such as less damaged hyperplastic regions.  
3.5.12 Mucosal tenascin-C upregulation is concurrent 
with immune infiltration by T-cells 
Following from the investigation of the innate tissue resident macrophages the final 
cell type to be examined was the T cells of the adaptive arm of the immune system. 
Staining for the T cell marker CD3, a component of the T cell receptor, was carried 
out along with staining for tenascin-C with representative images of staining shown in 
figure 3.18. In control tissue, T cells were found to sparsely distributed along the length 
of the colon within the lamina propria. This was similar to the resident macrophages 
albeit in lower numbers and with no apical preference in location observed. Despite 
this however, some T cells were still observed to localise to the same apical locations 
underlying tenascin-C staining which the resident macrophages were shown to occupy.  
Unlike the resident macrophages however, upon establishment of colitis on day six of 
the time course a significant increase in T cell numbers was observed. This increase 
was largely seen as infiltrating cells within the mucosa in damaged ulcerated and 
hyperplastic regions. A small number of T cells were additionally observed among the 
cells infiltrating within the oedematous submucosa.   
 Tenascin-C: A marker and driver of inflammation 
Chapter 3 – Profiling tenascin-C in murine dextran sulphate sodium colitis  124 
  
 Tenascin-C: A marker and driver of inflammation 
Chapter 3 – Profiling tenascin-C in murine dextran sulphate sodium colitis  125 
 Tenascin-C: A marker and driver of inflammation 
Chapter 3 – Profiling tenascin-C in murine dextran sulphate sodium colitis  126 
  
 Tenascin-C: A marker and driver of inflammation 
Chapter 3 – Profiling tenascin-C in murine dextran sulphate sodium colitis  127 
  
 Tenascin-C: A marker and driver of inflammation 
Chapter 3 – Profiling tenascin-C in murine dextran sulphate sodium colitis  128 
3.6 Discussion 
In summary in this chapter I have systematically profiled the basal expression of 
tenascin-C in the healthy murine colon and then followed its induction and localisation 
at this site during DSS induced colitis. The significance of these findings and the 
hypothetical roles and mechanism by which tenascin-C may be acting, in both health 
and disease, will now be discussed. 
3.6.1 Expression pattern of tenascin-C in the adult mouse 
All the methods investigated, including microarray, SAGE, and qPCR, broadly 
confirmed tenascin-C’s restricted adult expression with the majority of tissues 
showing low to negligible expression, especially in relation to embryonic MEF cells. 
The less sensitive high throughput microarray and SAGE screening data largely 
corroborated with each other. This included the identification of bone as an expression 
site although this was more variable in the BioGPS data owing to the pooling of data 
for bone and bone marrow samples. The majority of the remaining common tissues 
analysed were also in agreement with comparatively low levels of mRNA expression 
observed. The one exception observed was brain tissue which showed some expression 
in the SAGE-genie dataset but little expression in the BioGPS dataset.  This could be 
explained by the fact that the expression for brain was calculated in both datasets by 
pooling data from a number of microdissected regions. This included the cerebellum, 
cerebral cortex, prefrontal cerebral cortex, amygdala, hippocampus, hypothalamus, 
nucleus accumbens, olfactory bulb, and pituitary gland in the BioGPS dataset. 
Conversely, the data available in the SAGE-genie set was much more limited and only 
included the hippocampus, amygdala, and thalamus, with the thalamus, which was not 
included in the BioGPS dataset, accounting for the majority of the tags identified. 
Indeed, even within the regions pooled in the BioGPS dataset variation was observed 
with cerebellum for example appearing to express far more tenascin-C than the other 
brain areas sample. This thus supports the notion that tenascin-C’s expression is tightly 
restricted down to the level of sub-localisation within tissues.  
In comparison, the RT-qPCR data showed a generally similar pattern of low 
expression for most tissues. This included the brain, like for the SAGE genie dataset, 
being identified as the highest tissue expressing tenascin-C alongside bone and colon 
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which were also picked up as expressers in the BioGPS dataset. Unlike, the above 
methods however the testis, kidney, and muscle were also identified as expressers. 
This could potentially be a sensitivity issue however as some expression within the 
testis (Paranko et al., 1995), kidney (Aufderheide et al., 1987) and muscle tissue (Fluck 
et al., 2000) has been reported previously. Additionally, differences in the 
methodology of RNA extraction used as well as mouse strains and age may also 
explain some of the observed discrepancies.  
3.6.2 Basal expression of tenascin-C in the murine colon  
Focusing in on the colon it was clear by all the gene expression methods utilised that 
it was one of the more prominent tenascin-C expressing tissues. Additionally, it was 
apparent that the expression varied along its length, with the highest expression seen 
in the mid colon, followed by the distal, and then the proximal segments respectively.  
This basal gene expression in the adult colon was further found to have relevance at 
the protein level. Initially, western blotting of adult colon tissue extracts revealed two 
molecular weight variants present with a predominance of the small form. This 
corroborated with published data reporting RNA splice variants of tenascin-C in the 
developing and adult colon.  Early in development both variants were found but in the 
adult the small variant predominated (Saga et al., 1991). This contrasts with what was 
observed in neonate lung samples in which higher levels of tenascin-C were seen with 
a predominance for the large variant, as has been previously reported (Young et al., 
1994). As such, it appears the colon seems to follow a similar expression pattern as 
has been observed in a variety of other tissues, including in the brain (Dorries and 
Schachner, 1994) and kidney (Weller et al., 1991), whereby expression of large 
tenascin-C variants decreases with age (Giblin and Midwood, 2015). This potentially 
contrasts with what has been reported for the small intestine in which equal expression 
between the small and large variants as well as an increase in expression of the large 
variant with age has been reported (Aufderheide and Ekblom, 1988, Weller et al., 
1991). However, other reports appear to contradict this observation and instead, like 
in the colon, have reported a predominance of the small tenascin-C variant 
(Probstmeier et al., 1990b) and a reduction of expression with age (Saga et al., 1991). 
This observed tissue specific variation in molecular weights could have a number of 
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explanations including alternative splicing or post translational modification such as 
glycosylation, both of which have been shown to vary by cell or tissue source (Giblin 
and Midwood, 2015, Mangan et al., 2019).  
In terms of localisation within the colon tenascin-C was found in the lamina propria as 
well as the muscularis mucosa and externa along the length of the colon. Supporting 
the gene expression data, the mid colon was also found to contain the highest amount 
of tenascin-C staining where in the lamina propria it expanded beyond the tight 
subepithelial staining seen in the proximal and distal colon.  This expression pattern is 
similar to what has been observed in the murine small intestine (Aufderheide and 
Ekblom, 1988, Probstmeier et al., 1990a) and stomach (Scherberich et al., 2004) where 
tenascin-C has been shown in the smooth muscle tissue as well as in the mucosal 
lamina propria. More similarly to the mid colon the mucosal staining is more 
prominent along the length of the villus co-localising with its core and subepithelial 
sheath with, as in the colon, increasing expression towards the apical surface. This 
difference is potentially developmentally rooted as tenascin-C staining of the 
embryonic small intestine likewise showed strong mucosal villus core staining while 
the colonic mucosa showed none (Desloges et al., 1994). Additionally, this same 
expression pattern in the small intestine and colon has also been reported in adult 
human samples, suggesting this is a conserved aspect of tenascin-C biology not unique 
to the mouse (Sakai et al., 1993, Beaulieu, 1997).  
Having demonstrated tenascin-C’s presence in the colon under basal conditions the 
identification of the tenascin-C producing cells from which it originates is of obvious 
interest. For the muscularis mucosa and externa tenascin-C this appears to be of 
smooth muscle cell origin as demonstrated by the clear overlap with αSMA staining 
at these sites. This is similar to what has been observed in other tissues with basal 
expression of tenascin-C also observed surrounding vascular smooth muscle cells of 
the aorta (Kimura et al., 2014) and pulmonary smooth muscles cells of the bronchi 
(Kaarteenaho-Wiik et al., 2002). While IHC staining does not confirm the smooth 
muscle cells as the source of the tenascin-C its close association by co-staining with 
this cell type across a number of tissues does lend credence to this theory. Future 
studies should aim to confirm these findings by micro-dissection or isolation of the 
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smooth muscle cell population specifically to examine their expression of tenascin-C 
by qPCR. The subepithelial tenascin-C by contrast had a number of potential origins 
the first of which was postulated as production by resident macrophages, whose 
marker staining was shown in close proximity to these subepithelial sites. 
Macrophages are known to be able to produce tenascin-C, being among some of the 
significant sources in pathological conditions such as in the inflamed synovium of 
rheumatoid arthritis patients (Goh et al., 2010). Another potential candidate were 
epithelial cells potentially laying down tenascin-C within their basement membrane. 
However, studies in the developing small intestine have shown the tenascin-C appears 
to be produced by cells of mesenchymal rather than epithelial origin (Perreault et al., 
1998). Additionally, studies utilising immuno-electron microscopy in the murine small 
intestine have also showed that subepithelial tenascin-C was not found within the 
basement membrane but was located below it associated with fibroblast like cells 
(Probstmeier et al., 1990a).   
The identity of these fibroblast like cell was not confirmed in this publication however 
and so the exact type of stromal cell remains to be determined.  Myofibroblasts were 
a potential candidate as their differentiation and activation has been closely linked to 
tenascin-C in other settings (Bhattacharyya et al., 2016), and in the cases of colonic 
adenomas they have already been proposed as producers of tumour related tenascin-C 
(Hanamura et al., 1997). However, the observed lack of αSMA staining, a marker of 
myofibroblasts, at the apical epithelium would appear to discount this cell type as a 
potential source. A similar lack of overlap has also been observed in human samples 
where myofibroblasts were found to be more prevalent towards the base of the crypts 
away from apical tenascin-C staining (Salas et al., 2003). Further stromal cell subtype 
information has been gleaned from a single cell RNA sequencing study of ileal tissue 
from Crohn’s disease patients which identified fibroblasts, smooth muscles cells, and 
pericytes as the main tenascin-C producing cells present (Martin et al., 2019). 
Following from this, the fibroblasts of the colon have recently been further broken 
down into a number of subtypes based on gene expression analysis. Reviewing the 
data in this study it was found that tenascin-C was expressed in the stromal 2 subtype 
which was characterised as colonic crypt niche mesenchymal cells with functions 
implicated in epithelial support and maintenance. In this role the stromal 2 population 
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was found to localise to the subepithelial space thus adding strength to its claim to be 
the source of the subepithelial tenascin-C also found in this location (Kinchen et al., 
2018). Why these cells produce tenascin-C preferentially at the apical surface remains 
to be determined although one potential mechanism hypothesised would be induction 
of tenascin-C expression by indian hedgehog (IHH) signalling. In regards to this, IHH 
has been found to be preferentially expressed by apically located mature colonic 
epithelial cells (van den Brink et al., 2004) and has additionally been shown to induce 
tenascin-C expression in some cell types (Liu et al., 2013, Foley et al., 2017).  
3.6.3 Potential functional roles of basal tenascin-C  
The exact role of tenascin-C in the gut under basal conditions remains to fully be 
determined although the apparent normality of Tnc-/- mice would suggest it is not 
essential for normal gut development (Saga et al., 1992). In terms of the muscularis 
related tenascin-C in other tissues it has been implicated as a smooth muscle cell 
survival factor. This has been shown predominantly for vascular smooth muscle cells 
which show enhanced proliferation in response to growth factors in the presence of 
tenascin-C (Jones et al., 1997). Work in the developing small intestine likewise 
supports this potential role in the gut context where tenascin-C is seen to localise to 
areas of smooth muscle generation (Beaulieu et al., 1993) suggesting it may be playing 
a supportive proliferative role here too. 
For the role of the subepithelial tenascin-C two main potential functions could be 
suggested. The first of these is that tenascin-C may be playing a role at sites of lumen 
immune surveillance, as suggested by its close proximity to the immune cells 
highlighted in this study.  In regard to this, the fibroblasts suggested above as the 
primary source of this tenascin-C are known to have immunological roles. This 
includes expression of innate immune receptors, such as TLR4 (Kurahashi et al., 
2013), and limited antigen presentation abilities (Saada et al., 2006, Owens et al., 
2013). As such, tenascin-C might form a part of these cells immunomodulatory niche 
influencing their own as well as accompanying immune cell interactions at the 
epithelial-lumen interface.  
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The second role postulated was tenascin-C may be playing a role in the support and 
maintenance of the colonic epithelium. Indeed, in the case of the dermal epithelium 
under wounding conditions a number of studies have implicated tenascin-C in 
epithelial differentiation, proliferation, and migration (Midwood and Orend, 2009). In 
the small intestine it has also been suggested that tenascin-C may aid in maintenance 
of the epithelial by promoting terminal epithelial cell shedding (Probstmeier et al., 
1990a). Tenascin-C could also influence the epithelium in an indirect manner by 
binding soluble factors for sequestration or presentation. A potential example would 
be hepatocyte growth factor (HGF), which can bind the FNIII 1-5 repeats of tenascin-
C (De Laporte et al., 2013), and has been suggested as a key epithelial repair promoting 
factor secreted by colonic macrophages (D'Angelo et al., 2013). This immune and 
barrier maintenance cross talk additionally demonstrates the potentially non-mutually 
exclusive role tenascin-C may be playing at this location. 
3.6.4 Evaluation of the DSS model of colitis  
To study tenascin-C under inflammatory conditions the DSS model of colitis was 
established and shown to behave in a similar manner as has previously been reported 
in the literature. This included the predominantly distal nature of the colitis induced as 
well as its gross and histopathological features (Perse and Cerar, 2012).  
A number of chemically induced as well as genetic models of IBD have been 
developed over the years. Of these the DSS model has proved popular as it provides a 
relatively rapid and reproducible platform for studying colonic inflammation in 
immunocompetent wild-type mice (Wirtz et al., 2017). The model additionally 
successfully recapitulates a number of pathological changes observed in ulcerative 
colitis patients. This includes gross parameters such as weight loss, diarrhoea and 
colonic bleeding as well as histological features such as, epithelial ulceration, crypt 
abscesses, and mucosal immune cell infiltration. (Okayasu et al., 1990). The epithelial 
barrier integrity disruption induced by DSS also likewise mimics the defective barrier 
function which is seen in both ulcerative colitis and Crohn’s disease (Antoni et al., 
2014). Further bolstering the translational credentials of the model DSS has 
additionally been shown to recapitulate the therapeutic responses seen with some drugs 
in use clinically for the treatment of IBD (Melgar et al., 2008).  
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Despite these advantages however the limitations of the model should also be taken 
into account. In particular, the disease mechanism of acute mass barrier disruption, 
while mimicking some features of IBD, is unlikely to be the main disease mechanism 
present in IBD patients (Kiesler et al., 2015). Additionally, due to this mechanism of 
action and the acute nature of the protocol DSS colitis is primarily a model of innate 
immune driven pathology. The innate cell types macrophages and granulocytes in this 
case are the key inflammatory pathology drivers constituting the primary cell type 
detecting the initial barrier disruption and then infiltrating the tissue in response 
respectively. This is evidenced by the fact that the adaptive immune system has been 
previously found to not be required for colitis induction (Dieleman et al., 1994). As 
such it’s mechanism of action may underestimate the contributions of the adaptive 
system to IBD pathology. 
3.6.5 Tenascin-C expression in DSS induced colitis 
Tenascin-C has been shown in this study to be upregulated in the colitic colon at the 
mRNA and protein level. This increase is in line with previously reported omic studies 
of DSS colitis which have also showed tenascin-C upregulation in the colitic colon by 
gene expression microarray (Fang et al., 2011) and mass spectrometry (Zhang et al., 
2019). Additionally, tenascin-C has also been shown to be elevated at the protein level 
in the colitic colons of Il-10-/- mice, a genetic model of IBD, suggesting this 
upregulation is not simply a quirk of the DSS colitis model (Shimshoni et al., 2019). 
This increase of tenascin-C in animal models likewise matches what has been observed 
in human samples, with increased tenascin-C detected in inflamed UC colon tissue 
compared to uninflamed and control samples (Moriggi et al., 2017). Likewise, the 
distribution of tenascin-C within the colon of the DSS colitic mice also matched what 
has been reported in human samples. This includes an observed general increases in 
disorganised tenascin-C deposition within the lamina propria outside of its normal 
apical localisation in both UC and Crohn’s disease samples (Riedl et al., 1992, Ambort 
et al., 2010). Additionally, as in the DSS model, this increase has been reported to be 
particularly prominent within the granulation tissue stroma of ulcerations (Geboes et 
al., 2001).  
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Besides inflammatory pathology the IBDs are also associated with fibrosis such as 
thickening of muscularis mucosa which is observed in both CD (Lee et al., 1991) and 
UC (Gordon et al., 2018). As shown in this study, as well previously in the literature 
(Forbes et al., 2004), DSS colitis likewise replicates this muscularis mucosal 
thickening pathology. With tenascin-C’s strong localisation to the muscularis mucosa 
and its known pro-fibrotic properties (Bhattacharyya et al., 2016) this potentially 
implicates tenascin-C in another aspect of IBD pathology. Indeed, findings from 
patients with the less common microscopic collagenous colitis may provide additional 
evidence for this pro-fibrotic hypothesis. Collagenous colitis is characterised by an 
absence of gross colonic pathology, such as ulceration, with only the presence of 
histological inflammation alongside deposition of a thick subepithelial collagen band 
(Miehlke et al., 2019). This subepithelial collagen band coincides with the localisation 
of the basal apical mucosal tenascin-C staining which is shown to be significantly 
increased in collagenous colitis patients (Aigner et al., 1997). As such, this again 
places tenascin-C at a site of colonic inflammatory associated fibrosis suggesting 
further its involvement.   
Together these observations suggest that tenascin-C’s upregulation in colitis is 
conserved across disease models and types as well as species, implicating it in a 
common colitis promoting role. Additionally, this indicates that the DSS model is 
appropriate for studying tenascin-C in IBD and that the conclusions gained will be 
potentially translationally relevant.  
3.6.6 Kinetics of tenascin-C upregulation in colitis 
In terms of the kinetics of the Tnc mRNA upregulation in colitis a trend towards an 
increase was observed from day six alongside a variety of other pro-inflammatory 
mediators. This analysis was likely abrogated however due to sampling constraints 
which resulted in the full length colon being analysed rather than just solely the colitic 
distal colon. Inclusion of the uninflamed sites potentially introduced additional 
variation into the mRNA samples resulting in the modest approximately four fold 
increase seen in earlier experiments being diluted out. This explanation is supported 
by the observation that other genes which have previously been shown to be 
upregulated in acute DSS colitis, such as Il-10 and Il-12a (Egger et al., 2000, Yan et 
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al., 2009), also only displayed a non-significant trend to increase in this analysis. Other 
pro-inflammatory mediators, including Tnf, Il-6, and Il-1β, did show robust increases 
from day six however, although their significance was likely preserved due to their 
many fold higher induction compared to Tnc, Il-10, and Il-12a. These genes were 
likely many fold higher induced due to the fact that, unlike tenascin-C, as potently pro-
inflammatory cytokines they are likely very lowly expressed under basal conditions 
resulting in higher induction from the resting state. Indeed, this could be observed at 
the level of the CT values which for Tnc in control samples was approximately 23 
cycles, contrasting with for example Il-6 which in the same samples was only present 
at the much lower 29 cycles. This difference in upregulation likewise might be 
expected as higher amounts of cytokines, which are more readily cleared locally by 
diffusion, degradation, and internalisation, are likely needed to be produced compared 
to a large ECM molecule which likely persists more readily. 
Considering the protein level, the trend in upregulation seen at the mRNA level was 
found to be likewise present with tenascin-C staining increased from day six. This 
mimicked the development of significant histological pathology in the mice which, as 
reported by others (Nunes et al., 2018), developed by day six of initial DSS dosing. As 
such, this would suggest that as expected tenascin-C is not an early inducer of the 
inflammatory response but instead only becomes increased at sites of established 
inflammation and tissue damage.  
One potential mechanism of induction may involve the microbiome, which has been 
shown to be essential in the establishment of DSS colitis (Hudcovic et al., 2001). Early 
in DSS dosing, colonic permeability has been shown to increase significantly by as 
early as day three and increase further by day five (Yan et al., 2009). This would thus 
result in luminal bacterial content leaking into the underlying lamina propria and 
activate PRRs on the resident stromal and immune cell populations. A variety of 
bacterial components acting via various different PRRs, including the TLRs 1, 2, 4, 
and 5, have previously been shown to drive tenascin-C production in human dendritic 
cells (Goh et al., 2010).  
An endogenous mechanism may also potentially be responsible with the observation 
that the earliest observed pathological sign was limited immune cell infiltration seen 
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on day four. These cells were likely neutrophils as they have previously been identified 
in the literature as the earliest immune cell type recruited to the colon in DSS colitis 
(Hall et al., 2011). Neutrophils display limited ability to produce tenascin-C and thus 
are unlikely the source of the tenascin-C subsequently found at day six (Giblin, 2018). 
However, neutrophils can produce significant amounts of the pro-inflammatory 
cytokine TNF (Tecchio et al., 2014) which in turn has been shown to induce the 
expression of tenascin-C in a number of cells types (Latijnhouwers et al., 1998b, 
Nakoshi et al., 2008).  
These two pathways thus both present themselves as potential mechanisms of tenascin-
C induction in DSS colitis. 
3.6.7 Identity of the tenascin-C producing cells of the inflamed 
colon 
Having shown the upregulation of tenascin-C at sites of mucosal damage this raises 
the question of what cells are responsible for its deposition. In regard to this stromal 
cells, such as fibroblasts, with the capacity to produce large amounts of ECM culture 
have been implicated in the production of tenascin-C in other inflammatory contexts. 
This includes within the inflamed synovium in a murine model of rheumatoid arthritis 
in which the stromal synovial fibroblasts were shown to be the main cell type 
responsible for tenascin-C production (Goh et al., 2010). In the case of DSS colitis a 
previous publication suggested myofibroblasts as the tenascin-C producing cells 
(Islam et al., 2014) of the colitic colon. However, in this present study little expression 
of the myofibroblast marker αSMA was observed in the colitic mucosa and thus these 
findings do not corroborate this. Also, in contrast, single cell RNA sequencing of 
mesenchymal cells from DSS treated mice has also highlighted increased tenascin-C 
expression in a non-myofibroblast stromal cell subset. This subset, termed stromal 4, 
was significantly expanded in colitic mice and was characterised as having an 
expression profile associated with responses to bacteria and TNF (Kinchen et al., 
2018). As such, it is likely that this fibroblast subset is the primary source of tenascin-
C in colitis. 
As mentioned previously macrophages are also well known producers of tenascin-C 
at sites of inflammation (Goh et al., 2010) and thus could also potentially contribute to 
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the elevated levels seen in DSS colitis. In this current study only the colonic resident 
macrophage population was analysed by IHC. This population is known for its anergic 
anti-inflammatory phenotype (Bain and Schridde, 2018) and thus while retained 
throughout the induction of colitis, as seen in the present study, it is unlikely the source 
of the pro-inflammatory tenascin-C. Instead newly recruited infiltrating monocytes 
and their immediate progeny, previously shown to become the predominant 
macrophage subset in colitis (Jones et al., 2018) but not investigated in this current 
study, would likely be the myeloid source of some of the tenascin-C produced.  
3.6.8 Putative roles for tenascin-C in DSS colitis pathology 
A number of potential roles for tenascin-C in colitis can be postulated based on the 
findings in this study. One potential role could be, as seen in other inflammatory 
disease models (Midwood et al., 2009), as a local modulator of the inflammatory 
process. For example, it was observed that tenascin-C upregulation at the protein level 
appeared to occur prior to upregulation of the pro-inflammatory cytokine IL-17 at the 
mRNA level. Tenascin-C has previously been shown to promote the polarisation of T 
cells to the key IL-17 producing Th17 subtype and thus this is a potential role it may 
be playing in the colitic colon as well (Ruhmann et al., 2012).  
As well as directly activating immune cells tenascin-C may also impact the 
inflammatory response by regulating immune cell recruitment to the colon. T cells and 
neutrophils were both shown to be major infiltrating immune cell types in the DSS 
model, and the trafficking of both cell types has previously been shown to be impacted 
by tenascin-C. For T cells tenascin-C has been shown to promote lymphocyte tethering 
and rolling adhesion and thus is potentially promoting T cell migration into the colitic 
colon (Clark et al., 1997). In terms of neutrophils in a mouse model of hepatic injury 
tenascin-C was shown to upregulate the chemokine CXCL2 a chemoattractant for 
neutrophils. Additionally, tenascin-C was also shown to upregulate matrix 
metalloproteinase 9 (MMP9) which has been shown degrade the vascular ECM and 
thus aid leukocyte transmigration (Kuriyama et al., 2011).  
Besides these impacts on the infiltrating immune cells tenascin-C could also 
potentially shape the inflammatory response by influencing local stromal remodelling 
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such as in the case of the vasculature. Neovascularisation is important for the 
inflammatory response and has been shown to worsen pathology in DSS model 
presumably by aiding immune cell infiltration (Scaldaferri et al., 2009). Previous 
publications have highlighted a pro-angiogenic role for tenascin-C, including a 
promotion of endothelial cell migration and enhancement of proliferation in response 
to vascular growth factors (Chung et al., 1996). This pro-angiogenic role has been 
shown to be particularly important in the early stages vessel formation (Radwanska et 
al., 2017), which would be occurring within the newly deposited granulation tissue of 
the damaged colonic mucosa where tenascin-C is also expressed.  
These potential roles for tenascin-C in driving the inflammatory response, as well as 
its basal expression and mechanism for induction in colitis, are summarised in figure 
3.19.  
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Chapter 4 Tenascin-C knockout mice are 
protected from DSS colitis 
4.1 Introduction 
Upon the development of gene knockout technologies in the late 1980s tenascin-C was 
among some of the first genes to be targeted for ablation, with the first Tnc-/- mouse 
generated in 1992 (Saga et al., 1992). Its selection for targeting was due in part to its 
wide-ranging expression at sites of interest during embryonic development leading 
many to infer it to be performing key developmental roles. In contrast to these 
predictions however, the mice generated, harbouring a homozygous insertion of the 
lacZ reporter gene into the tenascin-C locus, were obtained according to Mendelian 
laws with no gross developmental defects (Saga et al., 1992). This lack of an obvious 
phenotype was so surprising that a second independent Tnc-/- mouse was generated 
which likewise confirmed that mice lacking tenascin-C undergo normal development 
(Forsberg et al., 1996).  
In light of these findings’ subsequent studies of Tnc-/- mice shifted emphasis from 
embryonic development to more subtle phenotypes which were found to occur 
postnatally (Mackie and Tucker, 1999). These have ranged from neurological 
behavioural phenotypes, such as hyperlocomotion linked to changes in 
neurotransmission (Fukamauchi et al., 1996), to abnormalities in the cellularity of 
whisker follicles resulting from dysregulated stem cell differentiation (Hendaoui et al., 
2014). The area of study which has garnered most interest however has stemmed from 
studies probing the sometimes stark phenotypes Tnc-/- mice have displayed in models 
of pathological stress, inflammation, and tissue injury.  
On the back of early observations that tenascin-C was significantly upregulated at sites 
of tissue injury it was postulated that tenascin-C played a role in the inflammatory 
response (Schenk et al., 1995). Tnc-/- mice provided a useful tool to interrogate this 
hypothesis further in vivo with the first study to this end carried out using a model of 
contact dermatitis which showed Tnc-/- mice exhibited an aberrant inflammatory 
response (Koyama et al., 1998). Subsequent studies utilising other disease models, 
employing a wide variety of different mechanisms and targeting numerous different 
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tissue types, have found similar phenotypes of altered responses (Marzeda and 
Midwood, 2018). In the majority of these models this alteration has shown that while 
an acute response can still be initiated the loss of tenascin-C proves protective of 
progression to more serious chronic disease.  Models of rheumatoid arthritis (RA) 
prove a good example of this paradigm with both acute zymosan induced and erosive 
antigen induced models demonstrating favourable outcomes in Tnc-/- mice. In both 
cases an initial immune response in the joint was found to have been mounted, 
suggesting no severe intrinsic immunological deficits in the mice. However, these 
initial responses failed to progress further in Tnc-/- mice with accelerated inflammatory 
resolution and thus reduced joint damage observed instead (Midwood et al., 2009). 
Likewise, similar findings were found with an experimental autoimmune encephalitis 
(EAE) model of multiple sclerosis in which Tnc-/- mice showed significantly reduced 
clinical scores and duration of symptoms than seen in wild-type (WT) mice 
(Momcilovic et al., 2017). As a final example, a model of autoimmune myocarditis 
has also shown the protective effects of tenascin-C deficiency with Tnc-/- mice showing 
reduced histopathology scoring and retained heart function in comparison to WT mice 
(Machino-Ohtsuka et al., 2014). In each of these systems this protection in the 
knockout mouse was attributed to tenascin-Cs ability to drive the production of pro-
inflammatory cytokines as well as the induction of pathological Th1 and Th17  T cell 
responses resulting in more severe disease in its presence (Ruhmann et al., 2012, 
Machino-Ohtsuka et al., 2014, Momcilovic et al., 2017).  
Besides these inflammatory autoimmune driven examples other diseases characterised 
by other aspects of immunological dysregulation have also shown protection in Tnc-/- 
mice. This includes pathological allergic type 2 immunity such as seen in the 
ovalbumin induced model of bronchial asthma. In this case Tnc-/- mice showed reduced 
lung inflammation, with decreased pathological Th2 cytokines and IgE antibodies 
observed, resulting in increased lung function compared to WT mice (Nakahara et al., 
2006). Aberrant tissue remodelling and fibrosis related to immune responses, such as 
seen in disease such as systemic sclerosis, is another area in which tenascin-C’s 
ablation has been shown to be protective. For example, in a bleomycin induced model 
of pulmonary fibrosis Tnc-/- mice showed reduced fibroblast activation and collagen 
deposition (Carey et al., 2010). Similarly, in a model of bleomycin induced skin 
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fibrosis Tnc-/- mice were also protected showing reduced immune cell infiltration and 
accelerated fibrotic resolution as measured by dermal thickness (Bhattacharyya et al., 
2016). 
Despite these examples however not all trauma and inflammation models have shown 
a protective phenotype in Tnc-/- mice. The first study mentioned investigating contact 
dermatitis found that the haptenizing agent dinitrofluorobenzene (DNFB) produced a 
more severe response in Tnc-/- mice. This manifested as increased and prolonged 
neutrophil infiltration alongside aberrant tissue remodelling (Koyama et al., 1998). 
Another early study of a model of acute kidney injury, habu snake venom induced 
glomerulonephritis, likewise showed a more severe non-resolving phenotype in Tnc-/- 
mice as measured by histological damage and assays of kidney function (Nakao et al., 
1998). More recently studies utilising both spontaneous and surgical osteoarthritis 
models have found more severe joint degeneration develops in Tnc-/- mice with 
cartilage regeneration appearing disrupted (Okamura et al., 2010). In all these cases it 
appeared that lack of tenascin-C perturbed tissue repair in response to the initial insult. 
What causes this perturbation to occur in some model systems while benefit is seen in 
others is unknown.  
The gastrointestinal system is one of the few remaining systems in which tenascin-C’s 
role in inflammatory pathology has yet to be investigated thoroughly utilising Tnc-/- 
mice. This is despite tenascin-Cs known association with IBD at the genetic (Brant et 
al., 2017) as well as the protein level (Geboes et al., 2001). As was demonstrated in 
the preceding chapter, mimicking to some extent these changes found in IBD patients, 
tenascin-C was likewise found to be upregulated in a chemically induced DSS colitis 
model. As such, this model would appear appropriate for further interrogation utilising 
Tnc-/- mice to assess the impact of tenascin-C deficiency on the colitis and thus infer 
to some degree tenascin-C’s role in the model.  
4.2 Hypothesis  
Genetic ablation of tenascin-C will impact the inflammatory response and prove 
protective in the murine DSS model of colitis.  
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4.3 Aims 
I. Assess the basal colonic phenotype of Tnc-/- mice. 
II. Optimise the DSS protocol and confirm its ability to induce colitis in mice 
from the Tnc-/- colony. 
III. Compare the gross and histopathological features of DSS colitis in WT and 
Tnc-/- mice. 
IV. Profile a range of cell types and structural markers in the colons of control 
and colitic WT and Tnc-/- mice. 
V. Compare the gross and histopathological features of a colitis recovery 
model in WT and Tnc-/- mice. 
4.4 Materials and methods 
4.4.1 DSS murine model of colitis  
Colitis was induced following the standard protocol, described in section 2.3.4, in 7-9 
week old male WT or Tnc-/- mice from the Tnc-/- colony, originally from the University 
of Oxford, maintained at the Roslin Institute, University of Edinburgh. To distinguish 
the WT mice from this colony from those from the RI colony used in Chapter 3 they 
will be referred to as WT(Ox) in this chapter. To study acute colitis the DSS protocol 
was followed with mice culled at day eight. To study recovery after the acute period 
the DSS protocol was again followed with the mice culled at the later time point of 
day twenty-two. During the DSS dosing period to control for potential genotypic 
differences in water consumption water intake was monitored by daily water bottle 
weighing. Body weight data are presented as mean percentage body weight loss ± 
standard deviation and DAI sum score data is presented as median score ± interquartile 
range, as specified in section 2.3.4. Mice that exhibited severe adverse reactions or 
exceeded study severity limits, as described in section 2.3.4, were immediately 
euthanized and were not included for analysis, except when calculating survival. 
4.4.2 Colon histology and colitis histopathology grading 
H&E staining of paraffin embedded colon tissue sections was carried out as detailed 
in section 2.4.3 and colons graded for histopathology using these paraffin stained 
sections as described in section 2.4.3.  
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4.4.3 Immunohistochemistry (IHC) 
The IHC work in this chapter was carried out with the assistance of University of 
Edinburgh undergraduate honours project student Brandon Shek. Colon tissue was 
harvested for IHC analysis as detailed in section 2.3.5. Proximal, middle, and distal 
sections from one mouse were embedded together in the same OCT block for 
cryosectioning, immunostaining, and imaging together. All IHC procedures were 
carried out as detailed in sections 2.4.2, 2.4.6, and 2.4.7. Negative controls were 
performed where the primary antibody was either omitted (no primary) or replaced 
with non-specific IgG from the animal the primary antibody was raised in (Sigma 
Aldrich). 
4.4.4 Statistical Analysis 
Statistical analysis was carried out as detailed in section 2.14. Continuous data, 
including body weight, body weight loss, colon length, and water consumption were 
analysed using Student’s t-test, a one-way ANOVA, or a two-way ANOVA with 
Sidak’s multiple comparisons test unless found to be not normally distributed. Non-
normally distributed continuous data or ordinal data, such as DAI and histopathology 
scoring, were analysed using the appropriate non-parametric Mann-Whitney U or 
Kruskal-Wallis with Dunn’s multiple comparisons tests.  
4.5 Results 
4.5.1 The Tnc-/- mouse colon is grossly and histologically 
indistinguishable from that of WT(Ox) mice 
To confirm the Tnc-/- mouse was appropriate for modelling colitis their colonic 
phenotype under basal conditions was first assessed. Tenascin-C has been reported to 
be present at high levels in the developing intestinal tract including in the colon 
(Beaulieu, 1997). As such, this profiling was necessary to ensure no developmental 
defects or other abnormalities in comparison to WT mice were present which may 
have confounded future analysis. 
To begin, Tnc-/- mice appeared to have normal gastrointestinal function with passage 
of firm faecal pellets of a similar size to those observed in age matched WT(Ox) mice. 
At cull, dissection of the colon revealed it to likewise be of similar gross appearance, 
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including in morphology and length, to WT(Ox) mice. To confirm these observations 
at the histological level paraffin-embedded sections covering the length of the colon 
from WT(Ox) and Tnc-/- mice were taken for H&E staining, representative images of 
which are shown in figure 4.1a. Additional supplementary representative images of 
both genotypes’ colon tissue are provided in Appendix VI. Examination of these 
sections revealed normal colonic architecture present in Tnc-/- mice which was the 
same as that in WT(Ox) mice. This included a morphologically normal mucosa, with 
an enterocyte lined epithelium facing the lumen interspersed with goblet cell lined 
crypts, with an underlying submucosa separating the mucosa from the outer muscularis 
externa smooth muscle tissue. Regional specific features of the colonic architecture 
were also preserved such as the prominent mucosal folds of the proximal colon which 
were absent in the middle and distal colon of both genotypes. To confirm these 
observations the slides were examined by a qualified pathologist, Elspeth Milne, 
Professor of Veterinary Clinical Pathology, University of Edinburgh, who likewise 
found no differences between Tnc-/- and WT(Ox) mouse tissue.  
Having confirmed the presence of normal colonic architecture the ablation of tenascin-
C expression in the Tnc-/- mice was confirmed by immunohistochemistry, the results 
of which are presented in figure 4.1b. As seen previously colon tissue from WT(Ox) 
mice exhibited tenascin-C staining present in the smooth muscle of the muscularis 
mucosae and the muscularis externa, as well as underlying the luminal epithelium of 
the mucosa. In contrast and as expected no staining, comparable to negative control, 
was observed in Tnc-/- mouse tissue along the length of the colon, indicating that 
tenascin-C protein expression was indeed ablated.  
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4.5.2 Optimisation of DSS colitis in the Tnc-/- mouse colony 
The DSS colitis model was established in 129sv mice in the previous chapter with a 
dosing regime of 2% DSS administered for five days. The Tnc-/- mouse colony while 
on the same genetic background was setup utilising animals imported from the 
Kennedy Institute of Rheumatology at the University of Oxford. It was initially 
apparent that these mice, including the WT(Ox)s, differed from the 129sv mice at the 
Roslin Institute with much heavier weights observed. This was postulated to likely be 
due to dietary differences, with the mice at the Kennedy Institute found to be on a diet 
with higher fat content, as well as possible genetic drift. Local environment (Tasnim 
et al., 2017) as well as diet (Tremaroli and Backhed, 2012) are known to affect the 
makeup of the gut microbiota, which is vertically transmitted to offspring during birth 
and weaning (Moeller et al., 2018). As such, this founding population of mice as well 
as potentially being genetically distinct from the Roslin 129sv would also likely impart 
a differential microbiota onto their offspring as well. Commercial health screening 
(Envigo, Huntingdon, UK) of these imported mice did however confirm their specific 
pathogen free status and thus no highly pathogenic gut microbes, such as rotavirus or 
Salmonella species, which could confound results were present.  
As both genetic and microbiota factors are known to influence the course of DSS 
induced colitis (Perse and Cerar, 2012) it was thus deemed necessary to trial the 2% 
DSS regime previously employed with this colony. This trial revealed the WT(Ox) 
and knockout mice of the Tnc-/- colony to be seemingly resistant to this dose of DSS. 
This was seen in the gross health parameter of body weight loss, data for which is 
presented in figure 4.2a, which showed that both genotypes displayed minimal to no 
weight loss over the eight days of dosing. Disease activity scoring, presented in figure 
4.2b, likewise showed minimal change over the eight days with most mice showing 
little to no colitis symptoms in contrast to previous experiments with the Roslin 129sv 
colony. In addition to these observations indicating lack of colitis induction no 
significant differences in gross parameters were observed between the genotypes. This 
included body weight at the start of DSS dosing, as shown in figure 4.2c, which 
showed that both WT(Ox) and Tnc-/- mice did not initially differ significantly in 
weight.  
 Tenascin-C: A marker and driver of inflammation 
Chapter 4 – Tenascin-C knockout mice are protected from DSS colitis 149 
To confirm the lack of colitis induction the gold standard of histopathology scoring 
was carried out, the results of which are displayed in figure 4.2d. This revealed some 
signs of colitis were present in the 2% DSS mice with significant increases in scores 
compared to controls seen in the middle and distal colon. Although the n numbers were 
low these also indicated that the colitis in the Tnc-/- mice was less severe in the distal 
colon as, in contrast to the WT(Ox)s, the increase in pathological scoring was not 
deemed to be significantly higher compared to the matched control. As expected, based 
on the gross parameters results however, these increases were all much reduced 
compared to those seen with the 129sv Roslin colony in which with distal colon sum 
scores ranged from 45 to 56 compared to the scores of 0 to 28 seen in this experiment. 
This scoring also highlighted that while inflammatory infiltration was present tissue 
damage appeared reduced and less severe of submucosal oedema present than 
observed in previous experiments. These all indicated that while the DSS did have 
some effect on the Tnc-/- colony mice it was not as significant at this dose as seen 
previously.  
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4.5.3 Tnc-/- mice develop acute DSS colitis with reduced 
severity as measured by gross pathological readouts 
With the optimisation experiment concluding the 2% DSS dose did not robustly induce 
colitis it was decided to increase the DSS dose to 3% in the Tnc-/- colony for future 
experiments. Thus, with this new regime, WT(Ox) and Tnc-/- mice were administered 
3% DSS for five days followed by three days of normal tap water before cull on day 
eight. Control mice of both genotypes were given normal tap water for the duration of 
the experiment before cull on day eight.  
Gross pathology was first assessed with survival initially considered for the six Tnc-/- 
and eight WT(Ox) mice which underwent DSS treatment. No Tnc-/- mice were lost due 
to adverse events or severity limit breaches. Likewise, no WT(Ox) were lost due to 
adverse events, although one mouse was lost from the group as it breached body 
weight loss and DAI severity limits. Based on these observations statistical analysis 
determined that both groups showed no significant difference in survival of DSS 
treatment.  
Body weight loss was the next parameter examined, the data for which is shown in 
figure 4.3a. This revealed that for both WT(Ox) and Tnc-/- mice the 3% DSS dose 
appeared sufficient to induce colitis with both showing significant weight loss 
compared to their genotype matched controls. This reached significance from day six 
in the Tnc-/- mice and from day seven in the WT(Ox). A significant difference was 
registered earlier at day one for the DSS treated Tnc-/- mice compared to their matched 
controls although this appeared mainly due to an aberrant increase in the control 
groups weight, potentially due to mis-weighing, rather than a decrease in the DSS 
treated groups weight. At the end point of the study on day eight a protective effect 
seemed apparent for the Tnc-/- mice which showed significantly less body weight at 
this time point compared to DSS treated WT(Ox) mice.  
Disease activity index scoring, presented in figure 4.3b, likewise showed that colitis 
appeared to be successful induced with the higher DSS dose with all the mice of both 
genotypes developing colitic symptoms. A protective effect of the loss of tenascin-C 
was not evident using this metric however with both genotypes displaying a similar 
degree of scoring, which in both cases was significantly different from matched 
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controls, by day eight. In fact, in contrast to the body weight data, it appeared by this 
measure that more Tnc-/- mice developed colitic symptoms before WT(Ox) mice, with 
a significant difference between the groups observed at day four.  
The final gross pathological feature measured was colon length at cull, shown in figure 
4.3c. Again, this measure suggested successful induction of colitis in both genotypes 
with a significant decrease in colon length seen for both. No difference in length was 
observed between the control groups of both genotypes. However, supporting the body 
weight loss data Tnc-/- mice appeared protected with DSS treatment resulting in 
significantly less colon shortening compared to DSS treated WT(Ox) mice.  
To ensure that these differences in gross pathology were not simply due to differential 
dosing resulting from genotype differences in water consumption during the five day 
treatment period water consumption was recorded. From these data average water 
consumption per mouse over this time period was calculated with the data presented 
in figure 4.3d. No significant difference was found between any of the groups with a 
rough average of around five millilitres of water, regardless of DSS supplementation, 
consumed per mouse per day for both genotypes.  
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4.5.4 Reduced inflammation and tissue damage are found in 
Tnc-/- mice with acute DSS induced colitis 
To confirm the reduction in colitis severity in Tnc-/- mice H&E stained paraffin-
embedded tissue sections of colon tissue, representative images of which are shown in 
figure 4.4, were generated for histological analysis. Control mice of both genotypes 
showed normal colonic architecture and minimal to no inflammation along the length 
of the colon. Likewise, the proximal tissues of the DSS treated mice of both genotypes 
appeared similarly unperturbed with minimal inflammation present.  Conversely, the 
middle and distal colon of these DSS treated mice showed marked colitic 
histopathology. This included inflammation such as mixed immune cell infiltration of 
the mucosa and submucosa. This infiltrate appeared in most cases to be composed 
predominantly of macrophages and lymphocytes as well as to a lesser extent 
neutrophils, although focal areas of neutrophilic infiltration were observed. 
Additionally, in contrast to the 2% DSS dosage submucosal oedema, another marker 
of inflammation, was observed in nearly all the slides examined. In terms of tissue 
damage again severe histopathology was noted with mucosal ulceration and crypt loss 
seen in both genotypes. Epithelial hyperplasia was also present in both groups resulting 
in crypt elongation and thus mucosal thickening. It did appear that tissue damage was 
reduced in the Tnc-/- mice with greater preservation of normal morphology such as 
areas of normal crypt architecture, absent in WT(Ox) tissue, observed. 
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To quantify these observations and confirm the apparent genotypic differences blinded 
histopathology scoring was undertaken by Elspeth Milne, Professor of Veterinary 
Clinical Pathology, University of Edinburgh. The sum scores of this scoring, presented 
in figure 4.5a, as expected confirmed the observation that treatment with DSS induced 
colitis in both genotypes. Additionally, the pathology was found to be regionally 
restricted with no increase observed in the proximal colon whereas a significant 
increase was observed in both the middle and distal colon for both genotypes. These 
middle and distal scores as expected were also elevated compared to the 2% dosing 
regime and thus more in line with those seen previously. Furthermore, as in the 2% 
dosing pilot, the DSS treated distal colon appeared to be protected in the Tnc-/- mice 
with a significantly lower score compared to the WT(Ox) mice found. Similarly, as in 
the 2% experiment the DSS treated middle colon conversely showed no differences in 
score between the genotypes, potentially due to, as seen previously, the pathology here 
being more variable.  
A breakdown of the distal score of the DSS treated mice by scoring parameter, 
presented in figure 4.5b, revealed the contribution of each of these parameters to this 
apparent overall reduction in Tnc-/- score. In terms of inflammatory pathology this 
showed that inflammatory severity was significantly reduced in Tnc-/- mice while 
inflammatory extent showed no difference. This shows that while the level of 
inflammation, such as the amount of immune infiltration, appears reduced in Tnc-/- 
mice it is still locally confined within the same areas of predominantly the mucosa and 
submucosa. In terms of tissue damage the crypt damage and regeneration parameters 
showed even greater decreases in Tnc-/- score compared to WT(Ox) mice which were 
likewise both significant. This confirmed the earlier observations that the Tnc-/- tissue 
appeared to have better preserved architecture and morphology compared to the 
WT(Ox)s. Indeed, confirming the focal nature of the damage and preservation a large 
contributing factor to the crypt damage score difference was the much lower scores 
recorded for percentage involvement for this parameter in the Tnc-/- samples. 
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4.5.5 Confirmation of tenascin-C upregulation in the colitic 
colon of WT(Ox) mice using the 3% DSS regime 
Having demonstrated a difference in pathology between the genotypes it was 
necessary to confirm the upregulation of tenascin-C in the colitic mucosa of the Tnc-/- 
colonies WT(Ox) mice. To do this IHC staining was carried out for tenascin-C with 
representative images displayed in figure 4.6. As seen previously under basal 
conditions the WT(Ox) mice showed normal smooth muscle and subepithelial 
tenascin-C staining while Tnc-/- mice showed only background staining similar to that 
present in the negative control. This same staining pattern for both genotypes was also 
found in the unaffected proximal colon of the DSS treated mice. However, confirming 
previous observations in the damaged mucosa of the middle and distal colon tenascin-
C was found to be upregulated in the WT(Ox) mice. As expected in the same regions 
from the DSS treated Tnc-/- mice no staining was again observed. 
4.5.6 Tnc-/- mice have normal colonic smooth muscle 
architecture 
To identify any histological or cellular differences between the WT(Ox) and Tnc-/- 
mice, which could potentially explain the differences in pathology observed, IHC 
staining for a variety of markers was carried out. To start with, sections from control 
and DSS treated WT(Ox) and Tnc-/- mice were stained for the smooth muscle marker 
α-smooth muscle actin (αSMA), the results of which are shown in figure 4.7. In control 
and DSS treated tissue from both genotypes this staining clearly labelled the 
muscularis mucosae and the muscularis externa. In the control tissue these structures 
appeared morphologically normal and comparable between the genotypes. As 
observed previously in WT mice (figure 3.13) αSMA staining changed minimally with 
DSS dosing with only a slight thickening of the muscularis mucosae observed in the 
colitic middle and distal colon. These same minimal changes were likewise also 
observed in the DSS treated Tnc-/- tissue. Negative control sections showed largely 
absent staining except for some diffuse staining at the mucosal surface, also observed 
in some αSMA stained sections, which was judged to be due to non-specific secondary 
antibody binding to luminal mucus. Overall, this staining appeared to confirm that the 
lack of tenascin-C did not appear to impact the smooth musculature of the colon under 
basal or colitic conditions.
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4.5.7 Vascular markers are the same in Tnc-/- and WT(Ox) mice  
The vasculature was the next feature of the colon to be examined this time utilising 
IHC dual staining for the blood vessel marker CD31 and the lymphatic vessel marker 
LYVE-1. Representative images of this staining are presented in figure 4.8 and show 
normal vascular architecture is present in along the length of the colon of control 
WT(Ox) and Tnc-/- mice. This includes evenly distributed vessel like staining of CD31 
showing diffuse blood vessel distribution throughout the mucosa and muscularis. 
LYVE-1 staining in contrast shows predominant staining present in a main lymphatic 
vessel running along the base of the mucosa just overlying the muscularis mucosae. 
This vessel co-stains albeit more weakly for CD31 which is known to also be expressed 
weakly on the lymphatic endothelium (Baluk and McDonald, 2008). As seen 
previously additional LYVE-1 staining lymphatics are also found extending up into 
the mucosa which seemed to stain less strongly for CD31.  
Similarly, with the induction of colitis with DSS treatment similar vascular changes 
were observed in both WT(Ox) and Tnc-/- mouse colons. No changes were observed 
in the unaffected proximal colon of either genotype. However, in the middle and distal 
colon colitic changes were apparent with marked oedema observed with 
accompanying dilation of the mucosal lymphatics. Severe mucosal damage was also 
seen, particularly in the distal colon, where granulation tissue was observed with 
accompanying microvascularisation of blood vessels.   
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4.5.8 Tenascin-C loss modulates epithelial & crypt 
architectural damage 
Following, from the observation that Tnc-/- mice suffered less tissue damage in 
response to DSS treatment the next markers chosen for investigation focused on the 
mucosal architecture. Colon sections from all groups were dual IHC stained for 
CD326, an epithelial cell marker, and type IV collagen (ColIV) a connective tissue 
marker to aid in delineating the structure of the mucosa. Representative images of this 
staining are shown in figure 4.9. In the control animals from both genotypes along the 
length of the colon the intact mucosal epithelium stained positive for CD326. 
Additionally, the ColIV staining allowed visualisation of the mucosa’s structure which 
showed it to have normal architectural appearance with clearly delineated crypts in 
both genotypes. 
With DSS treatment in both genotypes no changes were observed in the proximal 
colon. In contrast in the colitic distal colon of the WT(Ox) mice ulceration is apparent 
with loss of CD326 staining of the luminal surface of the mucosa. Furthermore, the 
damage to the mucosa has resulted in the loss of its normal structure with crypts no 
longer able to be delineated. In contrast, in the distal colon of the DSS treated Tnc-/- 
mice while these same changes are also still present areas of normal mucosal structure 
are also still present as well. These protected epithelial areas show preserved CD326 
staining showing that epithelial integrity has been maintained. Additionally, these 
areas also showed preserved structural architecture with normal crypts still clearly 
present.  
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4.5.9 Colitis induced immune cell changes appear the same in 
WT(Ox) and Tnc-/- mice 
To attempt to identify the cause of this increase in damage profiling of immune cell 
types was undertaken to determine the impact, if any, of tenascin-C’s deletion on this 
facet of the colitis pathology. This initially involved IHC staining for the resident 
macrophage population using the marker CD11c, the results of which are shown in 
figure 4.10. In control tissue samples from both genotypes this macrophage population 
was found liberally dispersed throughout the mucosal lamina lamina propria along the 
length of the colon. This included a population that was found localised in the 
subepithelial space below the luminal facing epithelium. Previous dual staining for 
tenascin-C identified this subepithelial populations as being in close contact with 
deposits of tenascin-C found in this same area. Similar numbers and localisation of 
CD11c positive cells in the Tnc-/- samples would suggest that tenascin-C in these 
locations does not appear to mediate macrophage recruitment or retention.  
With DSS treatment no major changes in proximal macrophage staining were observed 
with either genotype. In the damaged mucosa of the colitic distal colon macrophages 
were likewise still present within and around the granulation tissue. Again, no robust 
differences between the genotypes in macrophage number or localisation were 
observed here. 
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The final cell type to be interrogated by IHC were the T cells of the adaptive immune 
system which were detected by staining for CD3, representative images of which are 
shown in figure 4.11. In colon tissue from WT(Ox) control mice, T cells were found 
in low numbers scattered throughout the lamina propria and muscularis. Similar 
numbers and distribution of T cells were found in samples from Tnc-/- mice suggesting 
that lack of tenascin-C did not influence basal T cell recruitment and retention in the 
colon.  
Inducing colitis with DSS treatment in WT(Ox) mice resulted in a marked increase in 
the numbers of T cells observed in the colitic middle and distal colon. T cells while 
still seen within the muscularis were now found predominantly infiltrating the 
hyperplastic or damaged mucosa. Showing that in this instance T cell infiltration did 
not appear to be impacted by loss of tenascin-C similar numbers and distribution of 
CD3 staining were likewise observed in the colitic colon sections from Tnc-/- mice. As 
seen with other markers no changes from levels seen in control tissue were observed 
in the unaffected proximal colon in both genotypes.  
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4.5.10 No significant difference in gross pathology is seen 
between Tnc-/- and WT(Ox) mice during colitis recovery  
Having shown that Tnc-/- mice appeared partially protected at an acute time point in 
the DSS colitis model and considering tenascin-Cs known roles in wound repair it was 
next decided to study the colitis recovery phase in Tnc-/- mice. In this recovery version 
of the DSS protocol acute colitis was similarly induced by dosing for five days with 
3% DSS before transfer over to normal drinking water. In this case however instead of 
culling the mice three days later at day eight the mice were now left for a further 
seventeen days for cull on day twenty-two, at which point colitis symptoms should 
have resolved and recovery commenced.  
Following this revised protocol WT(Ox) and Tnc-/- mice were assigned to either the 
control or DSS treatment groups and gross pathology tracked as in previous 
experiments. As in the acute model survival was the first parameter assessed with 
increased loss of mice expected due to the potential of further decline after the acute 
time point resulting in mice breaching severity limits. This was observed in the Tnc-/- 
group which in this experiment lost three mice out a total of eleven administered DSS 
compared to no mice being lost in the earlier acute model. Two of these mice were lost 
to due to breaches of severity limit and thus were culled on humane grounds. The third 
was lost in an apparent adverse event as it was found dead in its cage after apparently 
suffering a severe colonic haemorrhage as evidenced by large amounts of fresh loose 
bloody stool present in the cage and on the fur near its anus. Necropsy supported this 
finding with large amounts of bloody stool found in the colon which appeared bloated 
suggesting it have potentially been suffering from a stool blockage as well. As for the 
WT(Ox) mice no change in survival was found compared to the acute model with 
again only one mouse out of seven lost due to breaching severity limits resulting in 
cull on humane grounds. Based on these low numbers of mice lost as in the acute 
model statistical analysis determined that both groups showed no significant difference 
in survival of DSS treatment. 
Body weight loss was the second parameter analysed with the data presented in figure 
4.12a. As expected, this showed both genotypes again suffered from significant body 
weight loss with DSS dosing compared to controls. As in the acute experiment this 
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began from day six for the DSS treated Tnc-/- group and in this experiment for the DSS 
treated WT(Ox) group as well. This significant difference between the Tnc-/- DSS and 
control groups was maintained consistently until the study end point on day twenty-
two. A similar trend was observed with the WT(Ox) mice although significance was 
lost briefly at day ten partially due to a sporadic decrease in the control groups weight. 
Significance was also lost at the later time points of day eighteen, twenty, and twenty-
one although this time seemingly more due to weight gain due to recovery in the DSS 
treated group. Unlike in the acute experiment the protective effect in the Tnc-/- mice 
was not apparent by this measure at day eight. Indeed, throughout the entire 
experiment no significant difference between the DSS treated WT(Ox) and Tnc-/- 
groups was noted for any time point. 
The DAI was the next gross pathological measure scrutinised with the scoring data 
shown in figure 4.12b.  In line with the body weight data again significant increases in 
sum score were observed for the DSS treated groups of both genotypes with a median 
score of two achieved at day eight for both genotypes.   
In a reversal of what was seen in the acute experiment a significant difference 
compared to the genotype matched control was first achieved by the DSS treated 
WT(Ox) group at day four. From this point onwards the WT(Ox) mice retained a 
median score of two or one until day thirteen after which median scoring began to fall 
back to zero. Significance of these scores was not retained completely throughout this 
period although this was potentially due to the low power provided by the comparative 
control group which only contained four mice. In contrast, although some Tnc-/- mice 
began scoring from day four as well this did not reach significance until day six. From 
this point like the WT(Ox) mice a median score of two or one was maintained with 
significance seen throughout until day twelve. Subsequence significant scoring was 
then also seen on day fourteen and sixteen as a median score of one was maintained 
until day seventeen after which scores began to fall back to zero. Examining the 
breakdown of the scoring parameters stool consistency scoring appeared to follow a 
similar trend in both genotypes with reductions in score and number of mice scoring 
seen at a similar rate. In contrast the faecal blood score appeared to differ between the 
genotypes with scoring for it completely stopping in all WT(Ox) mice from day 
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fourteen while it was still seen in some Tnc-/- mice up until day nineteen. Despite these 
apparent temporal differences in scoring overall no significant differences in sum DAI 
scores were found between the DSS treated WT(Ox) or Tnc-/- groups at any time point. 
Additionally, no significant difference in median max sum score, as determined by 
Kruskal-Wallis test, was found between the DSS treated groups with a median max of 
recorded 2 for the WT(Ox)s and 2.5 for the Tnc-/- mice. 
To assesses the apparent temporal difference in symptom presentation between the 
genotypes shown in the sum scoring data the prevalence of mice displaying symptoms 
in each group was also calculated. These data, presented in figure 4.12c, showed that 
from day five onwards all of the DSS treated WT(Ox) mice scored for at least one DAI 
parameter until day thirteen when symptoms began to subside. The majority of the 
WT(Ox) mice ceased scoring by day fifteen with all WT(Ox) mice no longer scoring 
for the remained of the experiment from day nineteen. In comparison it took until day 
seven until all of the Tnc-/- mice were displaying colitis symptoms although these 
continued for longer than seen with the WT(Ox) mice taking until day nineteen until 
the majority stopped displaying symptoms. From this point most Tnc-/- mice no longer 
displayed any symptoms aside for one which again registered soft stool consistency 
scoring on day twenty and twenty-one. Despite these trends being observable however, 
they were not found to be statistically significant as determined by Fisher’s exact test, 
with no significant difference in prevalence between the genotypes found at any time 
point. 
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4.5.11 Histopathology shows Tnc-/- mice retain their partial 
protective phenotype at the colitis recovery time point 
To interrogate the colons post-colitis recovery further histological analysis was carried 
out on H&E stained paraffin embedded tissue sections, representative images of which 
are shown in figure 4.13. As observed previously tissue from control mice of both 
genotypes showed normal colonic architecture and minimal inflammation along the 
length of the colon. In the DSS treated groups of both genotypes the proximal colon 
likewise showed the presence of normal colonic architecture and no pathology. The 
middle and distal colon from both these groups in comparison still had moderate 
histopathology detectable.  
In the mid colon for both genotypes this manifested as mainly the presence of residual 
immune cell infiltration in the lamina propria of the mucosa. This infiltrate now 
consisted, in contrast to the acute model, predominantly of just lymphocytes with less 
innate macrophages and neutrophils observed. Additionally, focal aggregates of 
immune cells were also observed in the mucosa which were potentially isolated 
lymphoid follicles (ILFs) produced in response to the earlier immunological challenge. 
This change would be expected as the immune response would be expected to be at a 
more advanced stage at which the adaptive immune system was playing a bigger role. 
The lack of submucosal infiltrate and oedema also contrasted strongly with what was 
observed at the acute time point indicating that the inflammatory response at this later 
time has subsided in this region of the colon. Finally, in terms of tissue damage this 
appeared to be largely resolved compared to what was seen at the acute time point with 
the epithelium appearing intact without ulceration and normal crypt architecture with 
goblet cells observed. 
In comparison to the mid colon the distal colon showed more severe histopathology, 
in line with it being worse affected by DSS treatment. Regeneration was still apparent 
with intact epithelium and crypt architecture with goblet cells present to a greater 
degree compared to the acute time point. However, compared to the mid colon this 
repair was less advanced with areas of aberrant architecture, epithelial hyperplasia, and 
occasional focal ulceration still present. The inflammatory pathology while reduced 
and now predominantly lymphocytic as in the mid colon was also likewise still more 
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severe in appearance. Mucosal infiltration was still present to a seemingly greater 
degree, particularly in or around areas of worse tissue damage such as areas of 
continued ulceration. In addition, putative ILF like immune cell aggregates, as 
observed in the mid colon, were also observed in this region. In contrast to the mid 
colon however submucosal immune infiltration with oedema was also still present.  
Comparing between the DSS treated genotypes the tissue appeared similar in the mid 
colon with no obvious difference observable. In the distal colon, as in the acute model, 
the tissue from the Tnc-/- mice appeared to display reduced pathology in comparison 
to that from WT(Ox) mice. This manifested as Tnc-/- mice appearing to have less 
aberrant mucosal architecture with more normal epithelium with goblet cell lined 
crypts present. Additionally, the inflammation in the Tnc-/- samples seemed somewhat 
reduced, particularly in terms of reduced submucosal oedema which appeared more 
common and severe in the WT(Ox) mice. 
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To quantify these observations in an objective manner blinded histopathology scoring 
was undertaken by Elspeth Milne, Professor of Veterinary Clinical Pathology, 
University of Edinburgh. The sum score results for the different regions of the colon, 
presented in figure 4.14a, largely confirmed the observations made above. Firstly, it 
was apparent that some degree of recovery had taken place by this time point with the 
sum histopathology scores for the middle and distal colon both appearing reduced 
compared to those seen at the acute time point. Additionally, as in the acute experiment 
and as noted above it confirmed that Tnc-/- mice retained their protective phenotype 
with significantly reduced scores observed in their distal colon in comparison to 
WT(Ox) mice. To further interrogate this difference further the distal colon scores 
were delved into in more detail by breaking them down by individual scoring 
parameter as presented in figure 4.14b. This revealed that while a trend in decrease 
was seen for the inflammatory severity and extent parameters for Tnc-/- mice compared 
to WT(Ox)s this was not statistically significant. The biggest contributor in score 
difference was thus found to be the tissue damage parameters of crypt damage and 
regeneration which were both significantly reduced in Tnc-/- mice compared to 
WT(Ox)s. The reduction in these scores appeared to be due to concomitant reductions 
in both the severity and percentage involvement components of the score. This 
contrasted with what was observed at the acute time point at which the major 
contributing factor to the score reduction in the Tnc-/- samples was the reduction in the 
percentage involvement component. This shows that at this time point Tnc-/- mice 
displayed less severe colitic damage compared to WT(Ox) mice rather than a similar 
degree of damage which affected a smaller area of the colon.  
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4.6 Discussion 
4.6.1 Loss of tenascin-C has no impact on colonic 
development and tissue maintenance 
In line with previous studies Tnc-/- mice were found to have undergone normal 
gastrointestinal development with no gross or histological abnormalities found in the 
adult colon (Saga et al., 1992, Forsberg et al., 1996). This is despite tenascin-Cs 
expression in the presumptive colon in the embryo (Beaulieu, 1997) as well as its 
continued expression postnatally through to adulthood. At these sites’ tenascin-C has 
been implicated, based mainly on in vitro experimental evidence, in a variety of 
processes. This has included in the developmental context mediating cell migrations 
(Aufderheide and Ekblom, 1988), smooth muscle cell survival (Jones et al., 1997), and 
epithelial-mesenchymal interactions (Belanger and Beaulieu, 2000). Despite these 
hypothesised roles, Tnc-/- mice showed no obvious changes from WT mice under basal 
conditions as shown by H&E staining as well as staining for a variety of specific 
features by IHC. In particular the colonic epithelium and enteric musculature appeared 
by all measures to be comparable to WT mice, both of which would have likely been 
significantly impacted if the above-mentioned developmental processes were affected.  
In the adult again due to its localisation and in vitro attributed functions a number of 
roles had been suggested for tenascin-C. One of the first to be attributed to tenascin-C 
was a potential role in epithelial homeostasis and in particular functioning in the 
important epithelial crypt migration and shedding cycle (Patterson and Watson, 2017). 
This was postulated due to its subepithelial expression pattern and apparent adhesion 
modulating properties which suggested it could either promote epithelial detachment 
during shedding (Probstmeier et al., 1990a) or allow for epithelial migration up the 
crypt (Hashimoto and Kusakabe, 1997).  The lack of any abrogation of the epithelium 
or the mucosal crypt architecture in Tnc-/- mice which would occur with disruption to 
these processes key to epithelial maintenance brings into question these theories.  
4.6.2 Immunological roles for tenascin-C under basal 
conditions in the colon 
The next intestinal compartment potentially impacted by tenascin-C would be the 
immune system and in particular the innate arm within the lamina propria. 
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Subepithelial macrophages within the colon are known to be a key barrier to invasion 
by the luminal microbiota that have breached the epithelium, acting to mount a rapid 
response which results in the infringing microorganisms containment and destruction 
(Rubio et al., 2018). With tenascin-C’s localisation at the subepithelial sites as well as 
it’s known ability to stimulate myeloid cells (Midwood et al., 2009) it is thus not 
unfeasible that tenascin-C may influence the innate immune system at these sites. 
Additionally, via its effects on innate immune cells or direct interactions, such as those 
suggested by in vitro experiments (Weismann et al., 1997), tenascin-C could also 
impact the adaptive immune system in the colon as well. In this study no apparent 
basal aberrations in either cell number or localisation were observed for the resident 
macrophage or T cell populations in any compartment found along or across the colon 
wall. This suggests that tenascin-C, despite its ability to influence both innate (Abbadi 
et al., 2017) and adaptive (Clark et al., 1997) immune cell migration, does not appear 
to do so under resting conditions in the colon. Likewise, these observations also 
support previous studies on immune cell development that found no abnormalities in 
blood immune cell development and number (Ohta et al., 1998) or myeloid cell 
differentiation (Ruhmann et al., 2012) in Tnc-/- mice.  
These analyses may prove too simplistic to rule out an immunological role of the gut 
tenascin-C however as it’s affects could likely be subtler influencing immune cell 
polarisation rather than absolute numbers and location. Indeed, it has already been 
shown that tenascin-C can aid in polarising innate cells such as in the case of 
macrophages driving them towards the M1 polarity at the expense of the M2 polarity 
(Kimura et al., 2019). Via its interactions with dendritic cells tenascin-C has also been 
shown to modulate polarisation of the adaptive immune system by for example 
promoting polarisation of T cells towards the Th17 subtype (Ruhmann et al., 2012). 
Studies of immune cell polarisation under basal conditions in Tnc-/- mice in lymph 
node and spleen, which also maintain tenascin-C expression in the adult (Ocklind et 
al., 1993), have demonstrated no difference in numbers of proportions of a variety of 
adaptive (Machino-Ohtsuka et al., 2014, Momcilovic et al., 2017) and innate (Kimura 
et al., 2019) subtypes. However, it cannot be assumed that the same is true for the 
gastrointestinal immune system where the continual immunological challenge of the 
microbiota results in its own distinct immune landscape (Mowat and Agace, 2014). As 
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such, further detailed analysis is needed of the colonic immune compartment in Tnc-/- 
mice to rule out any other more subtle changes.  
It could be argued that the health and seemingly normal immune status of Tnc-/- mice 
under homeostatic conditions would suggest that these differences do not exist or are 
functionally irrelevant. However, it should be stressed that, especially in terms of gut 
immunology, the Tnc-/- mice by nature of their specific pathogen free (SPF) housing 
are not kept under what should be considered normal conditions. It has been shown 
that the gut microbiota of laboratory mice differs significantly from their wild 
counterparts and this impacts upon host fitness (Rosshart et al., 2017). The 
evolutionary conservation of tenascin-C (Tucker et al., 2006) would suggest that it 
confers some evolutionary advantage and thus it might be these are only realised under 
the normal pressures exerted by the microbiota on the host.  
4.6.3 Potential for compensation of loss of tenascin-C in Tnc-/- 
mice 
Since the generation of the original Tnc-/- mouse, researchers have looked for 
mechanisms of compensation to account for the largely normal phenotype observed. 
These initially focused on the possibility of functional redundancy (Tautz, 1992) of 
tenascin-C, and in particular the potential of other members of the nascent tenascin 
family to compensate for tenascin-C’s loss (Chiquet-Ehrismann et al., 1994). This was 
found to be unlikely in the case for tenascin-R which has a very restricted expression 
pattern to the nervous system during both development and postnatal life (Brellier et 
al., 2009). Tenascin-W more similarly to tenascin-C shows more fluctuating and wide-
ranging expression where it has been implicated in smooth muscle development. In 
the colon however it was found to be absent in both development and in the adult 
(Scherberich et al., 2004). Tenascin-X conversely has shown to be expressed in the 
developing gastrointestinal tract including the colon (Geffrotin et al., 1995). While the 
colon has not been examined in the developing small intestine tenascin-X was found 
at similar sites of smooth muscle cell development, such as the presumptive muscularis 
mucosae, as tenascin-C (Matsumoto et al., 1994). Unlike tenascin-C this expression 
was not preserved in the adult however with tenascin-X found restricted to sensory 
and motor neurones of the enteric nervous system of the colon (Aktar et al., 2018). As 
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such, while tenascin-X may serve some compensatory role in development it does not 
appear to substitute for tenascin-C in the adult. With these spatiotemporal differences 
it was postulated that a compensatory upregulation of another tenascin may occur in 
Tnc-/- mice. Evidence for this hypothesis has been found lacking however with both 
tenascin-X (Saga et al., 1992) and tenascin-R (Steindler et al., 1995) found to maintain 
their same expression levels and patterns, while tenascin-W remains to be studied.  
Besides compensation by other members of the tenascin family other genetic 
mechanisms for compensatory modulation of gene expression exist by which loss of 
tenascin-C could be mitigated (El-Brolosy and Stainier, 2017). In particular, 
transcriptional adaptation whereby the mRNA degradatory machinery’s targeting of 
mutant mRNA transcripts results in compensatory upregulation of other genes could 
be of relevance (El-Brolosy et al., 2019). This is because the genetic knockout strategy 
employed in the generation of the in the Tnc-/- mouse (Saga et al., 1992) while 
abrogating protein expression still produces a mutant tenascin-C mRNA transcript. As 
such, this compensatory mechanism could be engaged, and gene expression modulated 
to broadly accommodate for tenascin-Cs loss resulting in more subtle phenotypes than 
expected. 
4.6.4 Acute colonic inflammation in Tnc-/- mice 
Despite no basal colonic differences observed the induction of acute colitis revealed 
genotypic differences with Tnc-/- mice showing reduced colitis severity. Due to 
tenascin-Cs known role in driving inflammatory pathology in other disease models 
this presents a clear mechanism by which DSS pathology might be mitigated in Tnc-/- 
mice (Marzeda and Midwood, 2018). These pro-inflammatory effects have been 
shown to be primarily mediated by tenascin-Cs activation of TLR4 (Midwood et al., 
2009) as well as the integrins α9β1 (Kanayama et al., 2011) and αVβ3 (Shimojo et al., 
2015). Activation of these receptors results in production of a wide variety of pro-
inflammatory mediators with relevance to colitis pathology. These include the 
classical pro-inflammatory cytokines IL-6 and TNF which have been shown to be 
upregulated at the transcriptional and post-transcriptional level via tenascin-C’s 
induction of histone deacetylase (HDAC) 1 (Haage et al., 2019) and the micro RNA 
miR-155(Piccinini and Midwood, 2012) respectively. The pro-inflammatory cytokine 
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IL-23 has also likewise been shown to be upregulated by tenascin-C although the exact 
mechanism has yet to be established (Kanayama et al., 2011). 
All of these cytokines are known to be upregulated and act as important drivers in 
colitis (Neurath, 2014). For example, TNF is upregulated in the colon of mice in the 
chronic DSS model and neutralising antibody treatment results in a reduction in 
inflammation (Kojouharoff et al., 1997). Similarly, IL-6 is likewise upregulated in the 
colon of DSS treated mice and mice with IL-6 genetically ablated show attenuated 
colonic injury and immune infiltration (Naito et al., 2004). IL-23 meanwhile has been 
shown to be instrumental in driving inflammation to chronicity in a separate model of 
colitis resulting from intestinal barrier impairment (Eftychi et al., 2019). IL-23 is 
known to be key for Th17 T cell polarisation (Toussirot, 2012) and indeed in this 
model a pathological Th17 response was implicated. Tnc-/- mice with reduced IL-23 
production are known to show deficiencies in Th17 responses (Ruhmann et al., 2012) 
and thus this presents another manner in which tenascin-C deficiency may confer 
protection in colitis. 
Further supporting the translational relevance of these studies these cytokines have or 
are currently being developed as the targets of IBD therapeutics. Therapies targeting 
TNF have proven strong clinical efficacy which demonstrates its mechanistic 
relevance with TNF neutralising antibody therapies in regular clinical use (Jarnerot et 
al., 2005). Therapies targeting IL-6 meanwhile are in an early stage of development 
although again have shown some benefit in patients confirming this cytokines role in 
disease (Danese et al., 2019). Likewise, therapies targeting IL-23 in IBD are also 
currently undergoing clinical trials for the treatment of Crohn’s disease (Ma et al., 
2018) with promising case reports of successful treatment already published 
(Grossberg, 2019).  
In terms of the cell types tenascin-C is likely mediating these pro-inflammatory signals 
through innate immune myeloid cells are a likely target as they have been identified 
as the primary cell types responsible for the production of these cytokines in IBD 
(Kamada et al., 2008). Indeed it is known that macrophages are key for the induction 
of DSS colitis as severe combined immunodeficient mice which lack adaptive immune 
cells still develop pathology and produce ample amounts of these pro-inflammatory 
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cytokines (Dieleman et al., 1994). These cells are unlikely the resident gut 
macrophages however as these are known to suppress their pro-inflammatory activity 
and display TLR hyporesponsiveness through co-receptor downregulation and 
chromatin remodelling  (Bain and Schridde, 2018). As such, it is likely recruited 
circulating pro-inflammatory myeloid cells interacting with the colonic tenascin-C to 
and adopting a pro-inflammatory M1 polarisation resulting in production of pro-
inflammatory mediators (Kimura et al., 2019).  
Aside from regulating the phenotype of cells in the colon tenascin-C deficiency could 
also affect immune cell recruitment and migration via regulation of chemokines. For 
example, it has been shown that the neutrophil attracting chemokines CXCL1 and 
CXCL2 are produced at reduced levels in Tnc-/- mice (Piccinini and Midwood, 2012, 
Matsumoto et al., 2017). Additionally, the myeloid attracting chemokine CCL2, has 
likewise shown to be decreased in Tnc-/- mice in a number of inflammatory models 
(Nakahara et al., 2006, Bhattacharyya et al., 2016). All of these chemokines have 
previously been shown to be increased in DSS colitis (te Velde et al., 2007) and are 
also increased in IBD patients (Banks et al., 2003, Alzoghaibi et al., 2008) suggesting 
they are relevant to IBD pathogenesis. In terms of functional outcomes while no 
differences in two broad immune cell populations were found in this study these 
investigations were far from extensive and thus warrants further investigation.  
Finally, tenascin-C deficiency may also potentially impact upon pathological 
remodelling of the colonic ECM. For example, unlike other TLR4 ligands tenascin-C 
has been shown to upregulate the membrane bound extracellular protease MMP14 
(Piccinini et al., 2016). MMPs are well known to be increased in IBD where through 
ECM degradation they mediate a variety of pathological processes (O'Sullivan et al., 
2015). In regards to MMP14 specifically it has been found at increased levels in the 
DSS model of colitis (te Velde et al., 2007)  as well as in the inflamed mucosa of IBD 
patients (von Lampe et al., 2000). Additionally, a SNP in the MMP14 gene has been 
shown to be associated with IBD in certain cohorts (Morgan et al., 2011). As such, 
MMP14 is clearly implicated in the pathogenesis of IBD and thus with tenascin-C’s 
known link to its expression shows another potential mechanism by which tenascin-C 
deficiency may be protective in colitis. 
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4.6.5 Tenascin-C in resolution of colonic inflammation  
Having shown reduced colitis severity during the acute phase of the DSS model in Tnc-
/- mice the observation period was extended by two weeks to study the impact of 
tenascin-C on colitis resolution. This was undertaken as tenascin-C as well as having 
known roles in supporting the initial inflammatory responses has also been shown to 
have roles in the later repair phases (Midwood and Orend, 2009). This study while not 
recapitulating the earlier acute findings entirely, including not showing the same 
protection from weight loss, did still find that Tnc-/- mice had reduced histopathology 
compared to WT mice. While it could be speculated that this may simply be a result 
of a reduction in initial inflammation and thus damage in the knockouts it cannot be 
ruled out that loss of tenascin-C is not positively impacting the wound healing response 
as well. These observations contrasted with a previous report in the literature which 
proposed tenascin-C as a protective factor in DSS colitis which mediated epithelial 
healing (Islam et al., 2014). This would appear to be supported in part by some work 
done on dermal wound healing models which have implicated tenascin-C in promoting 
keratinocyte proliferation and migration (Mackie et al., 1988). The findings in the 
current study of reduced tissue damage, including reduced ulceration, in Tnc-/- mice 
however would suggest that this is not the case in the gut.  
Besides impacting directly upon mucosal repair loss tenascin-C may also have 
promoted enhanced healing by leading to an upregulation of the pro-resolution 
immune response. For example, it has been shown that bone marrow derived 
macrophages from Tnc-/- mice show enhanced production of the anti-inflammatory 
cytokine IL-10 (Piccinini and Midwood, 2012). This bias has been shown to be 
preserved in vivo in murine models of Alzheimer’s disease (Xie et al., 2013) and 
cardiac injury (Kimura et al., 2019) which both showed increased levels of IL-10 in 
Tnc-/- mice. IL-10 is of particular importance in the gut where it is a key mediator for 
maintaining gut immune homeostasis as evidenced by the spontaneous development 
of chronic colitis in IL-10 deficient mice (Kuhn et al., 1993). To achieve this immune 
control IL-10 acts on a variety of immune cell types including T cells for which it is 
known to inhibit Th17 functions while supporting anti-inflammatory regulatory T cell 
functions (Murai et al., 2009, Chaudhry et al., 2011). It is probably best known for its  
action on myeloid cells however, with its ability to polarise macrophages towards an 
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anti-inflammatory reparative M2 phenotype (Mosser and Edwards, 2008). This action 
was apparent in the above mentioned disease models which alongside the increased 
levels of IL-10 also saw increases in the expression of the M2 macrophage marker 
MRC1 (Xie et al., 2013, Kimura et al., 2019).  
In addition to helping dampen the inflammatory response an increase in M2 
macrophages in Tnc-/- mice would likely also result in the promotion of mucosal tissue 
repair. This has been demonstrated in cell transfer experiments of M2 macrophages 
into DSS treated animals which show enhanced ulcer repair (Enderlin Vaz da Silva et 
al., 2014). This repair is likely mediated by several mechanisms which may include 
M2 macrophages enhanced ability to clear apoptotic cells debris (Zizzo et al., 2012) 
or ability to synthesise new ECM (Novak and Koh, 2013). M2 macrophages biggest 
impact on the repair process is likely in a trophic manner however by promoting repair 
by other stromal cell types. For example, M2 macrophages are known to produce 
growth factors such as TGFβ to promote fibroblast matrix synthesis and VEGF to 
promote angiogenesis by vascular endothelial cells (Brancato and Albina, 2011). In 
regard to colonic regeneration specifically M2 macrophages have been shown to 
secrete Wnt ligands which promote epithelial proliferation and differentiation as part 
of the reepithelialisation repair process (Cosin-Roger et al., 2016). Additionally, 
macrophage derived IL-10 was shown to promote epithelial secretion of CCN4 which 
acts in autocrine manner to promote epithelial wound healing in part by enhancing 
Wnt signalling (Quiros et al., 2017). As such, enhanced M2 macrophage activity in 
Tnc-/- mice presents another mechanism by which colonic damage is reduced in DSS 
colitis.  
A summary of all of the proposed protective mechanisms in DSS colitis is presented 
in figure 4.15 highlighting the anti-inflammatory and pro-repair affects that loss of 
tenascin-C mediates in Tnc-/- mice. 
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Chapter 5 Development of assays to assess 
the clinical utility of tenascin-C 
expression 
5.1 Introduction 
A large body of literature, including the preceding studies in this thesis, have shown 
tenascin-C is mechanistically associated with the inflammatory process (Marzeda and 
Midwood, 2018). Moreover, it is well described that tenascin-C expression in healthy 
adults is tissue restricted, with most tissues expressing low to negligible levels of the 
protein (Udalova et al., 2011). As such, tenascin-C may have utility as a potential 
biomarker of inflammation and more specifically of chronic inflammatory disease, a 
category of diseases where clinically useful markers are in great need.  
In regard to this it has been the systemic circulating form of tenascin-C which, due to 
its ease of sampling, has gained the most attention for potential use in a diagnostic tool. 
Indeed, systemic tenascin-C has been studied in a variety of inflammatory conditions 
with elevated levels having been demonstrated in conditions as diverse as IBD (Riedl 
et al., 2001), ankylosing spondylitis (Gupta et al., 2018), and systemic lupus 
erythematosus (Zavada et al., 2015). Furthermore, these studies have likewise shown 
clinical applicability with tenascin-C levels associated with disease activity in SLE 
(Zavada et al., 2015) and responsiveness to biologic therapy in IBD (Magnusson et al., 
2015). The studies of this thesis chapter will focus on adding to this body of work with 
the development of novel assays for the detection of tenascin-C in human serum 
samples. These assays it is envisaged could eventually be applied to a variety of 
inflammatory diseases with the above variety of conditions in which tenascin-C is 
implicated in indicating a potential common mechanism of action in disease.  
With this broad applicability in mind for the development and validation work of this 
chapter these assays were primarily applied to the inflammatory disease rheumatoid 
arthritis (RA). RA was chosen as a focus for three prime reasons the first of which was 
that it is this condition which has received the most characterisation in terms of 
tenascin-C’s role in disease in the literature, as will be outlined below. This has 
included some work on systemic tenascin-C and its potential clinical application, 
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which will also be described below. The second consideration was the current clinical 
diagnostic landscape with specific blood tests used regularly in the diagnosis of RA 
already (Allen et al., 2018). This contrasts with some other IMIDs, including IBD, in 
which diagnosis is currently carried out without specific serological tests with in the 
case of IBD a greater focus on symptoms, imaging, and histopathology (Magro et al., 
2017, Gomollon et al., 2017). As such, initial adoption of a serological test in the 
clinical setting might be more easily managed in the context of RA, in which they are 
already readily used, compared to these other conditions. The final consideration was 
a more practical one, relating to the availability of serum samples, with primarily those 
of RA patients initially identified at the commencement of the project.  
RA is a chronic inflammatory disease of the joints for which reliable diagnostic 
biomarkers, as well as markers of disease progression and treatment response, are few. 
Due to its heterogeneous nature, current diagnosis of RA is based on composite scoring 
systems, which, among other physical assessments, take into account four serological 
markers. These include testing for rheumatoid factor (RF) and anti-citrullinated protein 
autoantibodies (ACPA), as well as the more general inflammation markers of C-
reactive protein (CRP) and erythrocyte sedimentation rate (Aletaha et al., 2010). Both 
RF and ACPA are types of self-reacting antibodies, termed autoantibodies, which are 
produced due to loss of self-tolerance in autoimmune diseases. Autoantibodies are 
categorised by the specific self-antigens, termed autoantigens, which they recognise 
with RF for example constituting autoantibodies which target the Fc portion of IgG 
(Song and Kang, 2010). ACPA in particular are considered a highly specific 
serological marker of RA and consist of a heterogenous pool of autoantibodies which 
target autoantigens which have been post-translationally modified to include the non-
standard amino acid citrulline (Demoruelle and Deane, 2011). The current clinical gold 
standard test for ACPA is the cyclic citrullinated peptide (CCP)2 assay which utilises 
a pool of synthetic citrullinated peptides to capture citrulline specific autoantibodies 
in patient serum samples for detection (van Venrooij and Zendman, 2008).  
Overall, the CCP2 test in combination with the other available markers and diagnostic 
criteria has proven reasonably successful for the diagnosis of RA. However, the 
sensitivity and specificity of these measures is still only estimated at around 70% when 
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used in the diagnosis of patients presenting with synovitis suggesting that they still do 
not detect a significant proportion of patients (Alves et al., 2011, Cader et al., 2011). 
This is particularly problematic when considering the proposed existence of a ‘window 
of opportunity’ for treatment early in disease where intervention is associated with 
better long term patient outcomes (Espinoza et al., 2016). Any delay in diagnosis 
would thus result in delayed treatment and therefore worse patient outcomes. In 
addition, the absence of reliable prognostic and theranostic markers for RA presents a 
significant challenge for the clinical management of RA patients (Cuppen et al., 2016). 
For example, 30-40% of patients do not respond, or respond poorly, to the biologic 
therapies introduced in  recent years (Bansard et al., 2009). Reliable biomarkers for 
the stratification of patients prior to treatment would improve patient wellbeing and 
decrease cost by ensuring that patients receive treatment with the highest efficacy 
(Isaacs and Ferraccioli, 2011).   
Tenascin-C has a long association with RA, with early reports detailing its 
upregulation in the inflamed synovium of patients (Cutolo et al., 1992). More recent 
work has expanded on this association and demonstrated that tenascin-C is a driver of 
joint inflammation in murine models (Midwood et al., 2009) and may have potential 
as a target in therapeutic applications (Aungier et al., 2019). In addition to local 
upregulation of tenascin C, as with the other inflammatory conditions listed above, 
elevated levels of the tenascin-C have been shown in the serum of RA patients (Page 
et al., 2012). These preliminary studies have demonstrated that serum tenascin-C 
positively correlates with disease duration and degree of joint erosion, and was 
negatively correlated with response to anti-TNF biologic therapy (Page et al., 2012). 
This may reflect that tenascin-C is intrinsically involved in the disease process and as 
such is an example of a mechanistic biomarker, in contrast to the mainly descriptive 
biomarkers currently used for RA management (Robinson and Mao, 2016).  
Besides acting as a disease driver and biomarker, tenascin-C has been implicated in 
the ACPA response in RA. As mentioned earlier the ACPA in RA consist of a 
heterogenous population of autoantibodies which have been identified as targeting a 
range of citrullinated autoantigens which has included proteins such as fibrinogen 
(Masson-Bessiere et al., 2001) and vimentin (Vossenaar et al., 2004). Recently 
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tenascin-C was also identified in a subset of patients as an ACPA autoantigen by using 
citrullinated peptides derived from the protein to capture autoantibodies in patient 
serum. This approach identified a number of epitopes located in the FBG domain 
which were specifically recognised by RA patient autoantibodies when citrullinated. 
The most robust of the FBG domain derived peptides was called cTNC5 with an amino 
acid sequence of EHSIQFAEMKL-cit-PSNF-cit-NLEG-cit-cit-KR, with ‘cit’ 
indicating the citrulline residues in the peptide (Schwenzer et al., 2015). These 
autoantibodies were apparent in some cases many years before clinical disease 
manifested and were associated with the development of RA in patients presenting 
with early undifferentiated disease (Raza et al., 2016). This suggests that tenascin-C is 
involved in the very early stages of the disease and highlights that its measurement 
may be clinically informative.  
The full diversity of tenascin-C’s molecular forms has not been investigated in the 
studies of systemic tenascin-C owing to limitations of the assays used. Human 
tenascin-C contains 9 alternatively spliced fibronectin type III repeats, which produce 
a significant diversity in isoforms (Giblin and Midwood, 2015). The most commonly 
used assay in the literature for tenascin-C quantification is the tenascin-C large FNIII-
B ELISA kit produced by IBL, due in part to its high specificity and linear range 
(Giblin et al., 2018). However, the kit, as its name might suggest, detects only isoforms 
of tenascin-C containing the alternatively spliced FNIII type repeat B domain. The 
mechanism and impact of tenascin-C alternative splicing are still being investigated, 
although cell type and disease specific difference have been observed (Giblin and 
Midwood, 2015). Therefore, the impact of the measurement of one alternative splice 
variant rather than total tenascin-C levels is currently unknown. Some commercial 
assays do claim to detect all forms of tenascin-C but these are not well described in 
the literature and in some cases have shown poor assay performance (Giblin, 2018). 
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5.2 Hypothesis  
Tenascin-C, or autoantibodies against tenascin-C, are associated with inflammatory 
disease, particularly rheumatoid arthritis, and its measurement in the blood could be 
clinically informative. 
5.3 Aims 
I. Establish a commercially viable ELISA for measuring anti-citrullinated 
tenascin-C autoantibodies. 
II. Screen control, RA, and other inflammatory disease patient blood samples 
for citrullinated tenascin-C specific autoantibodies and compare to results 
obtained with the anti-CCP2 test.  
III. Develop and characterise an ELISA for measurement of total tenascin-C, 
including all splice variants, in human blood samples.  
IV. Screen control, RA, and other inflammatory disease patient blood samples 
to characterise the amount and molecular forms of tenascin-C in human 
blood under healthy and diseased conditions.  
V. Analysis of the diagnostic and prognostic potential of the ELISA tests 
developed and identify potential clinical utility.  
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5.4 Materials and methods 
Assay development and sample screening was carried out at Axis Shield Diagnostics 
Ltd alongside principal research scientist Dr Mel Lewis and with supervision from Dr 
David Pritchard and Dr Jeff Brady. 
5.4.1 Patient cohorts 
All human blood samples were provided by Axis Shield Diagnostics Ltd and consisted 
of four main cohorts. The main control sample cohort was lithium heparin plasma 
samples from 114 healthy Swiss donors. Donors ranged from 19 to 74 years old with 
a mean age of 49 years. In terms of sex it was composed 40% of males and 60% of 
females. Additional control samples were provided from Axis Shield’s own in-house 
plasma and serum sample stocks. 
For diseased samples the first cohort was of 40 RA patients from Mexico.  Patients 
ranged from 28 to 78 years old with a mean age of 55. In terms of sex it was composed 
15% of males and 85% of females. The second cohort was of 190 patients with 
inflammatory disease from Ipswich, UK. This included 103 RA patients of which 73 
were rheumatoid factor (RF) positive and 30 RF negative. Additional non-RA 
inflammatory disease patients included 9 scleroderma patients, 9 osteoarthritis (OA) 
patients, 24 psoriatic arthritis patients, 14 ankylosing spondylitis patients, 7 systemic 
lupus erythematosus (SLE) patients, 4 polymyalgia rheumatic, 6 vasculitis, and 8 
suffering from other miscellaneous rheumatic diseases. Patients in this cohort ranged 
from 12 to 87 years old with a mean age of 58. In terms of sex it was composed 32% 
of males and 68% of females. Additional RA samples were also provided from Axis 
Shield’s own in-house plasma and serum sample stocks. All samples were collected 
with informed consent in accordance with local ethical committee guidelines for the 
collection of research samples from human patients or donors.  
5.4.2 cTNC autoantibody ELISA  
The final ELISA format used for all sample screening was carried out as described in 
section 2.8. All cTNC5 screening was carried out with no peptide (streptavidin alone), 
CCP, and rTNC coating conditions run alongside on the same plate. Data for cTNC is 
presented as absorbance minus the absorbance value obtained for the rTNC coat. Data 
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for CCP are presented as absorbance minus the absorbance value obtained for the no 
peptide coat. 
5.4.3 Tenascin-C sandwich ELISA 
The final sandwich ELISA, used for all sample screening, was carried out as described 
in section 2.9 respectively. The final format of a tenascin-C competition ELISA, for 
which development and sample screening was carried out by Dr Mel Lewis at Axis 
Shield Diagnostics, is also included as results from this assay will be discussed in this 
chapter. The competition ELISA was carried out as described in section 2.10. Data are 
presented as ng/ml of tenascin-C as interpolated from the standard curve included on 
each plate and corrected for sample dilution factor.  
For ELISA assays detection antibodies were either biotinylated or conjugated to HRP. 
This was carried out by Dr Mel Lewis of Axis Shield Diagnostics, with biotinylation 
performed as detailed in section 2.12.1 and HRP conjugation carried out using a 
Lightning-Link HRP conjugation kit (Expedeon, San Diego, USA). 
5.4.4 Mass spectrometry 
With the assistance of Roslin Proteomics and Metabolomics Facility staff, mass 
spectrometry was carried out, as described in section 2.13, on tenascin-C IP samples 
produced as described in section 2.12.2. To account for protein hits produced due to 
non-specific bead binding a control non-specific IgG IP was analysed for each sample 
alongside the tenascin-C specific IP for the in solution digested samples. Protein lists 
between these two were compared and all hits of a similar or higher score in the non-
specific IP were filtered out of the tenascin-C IP results. Additional filtering of the 
lowest scoring protein hits was also carried out to remove low abundance potential 
contaminants.  
5.4.5 Statistical Analysis 
Statistical analysis was carried out as described in section 2.14. For the analysis of 
assay screen results involving multiple groups, significance was determined using the 
Kruskal-Wallis test with Dunn’s post-test for multiple comparisons. For comparisons 
between just two conditions significance was determined using a Student’s t-test for 
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normally distributed data or Mann-Whitney U test for not normally distributed data. 
Normal distribution was assessed using the Shapiro Wilk normality test.  
5.5 Results 
5.5.1 cTNC5 autoantibody ELISA detects IgG and IgA 
autoantibodies specifically in RA patients 
A cTNC5 autoantibody ELISA was developed and optimised wherein biotinylated 
cTNC5 peptides were immobilised onto streptavidin coated plates and used to capture 
autoantibodies within patient samples that recognized this epitope. Bound IgG or IgA 
autoantibodies were detected using HRP conjugated detection antibodies binding to 
the isotype specific γ heavy chain for IgG or α heavy chain for IgA. The same ELISA 
format was also optimised for detection of CCP2 autoantibodies for comparative 
purposes. Non-citrullinated TNC5 (rTNC5) peptide was used as a control for non-
specific binding. A schematic of the final ELISA design is shown in Figure 5.1a. The 
blue colour change of the TMB HRP substrate was measured at 650nm for 
autoantibody quantification.  
As a small pilot study, used to optimize conditions, I screened serum samples in this 
assay including commercial CCP2 assay standards as positive controls and a healthy 
donor sample as a negative control. Representative results for the IgG and the IgA 
assays are shown in Figure 5.1b and 5.1c respectively. For the IgG assay the healthy 
control sample gives the anticipated negative result with no signal observed in any 
condition. Both of the positive controls likewise gave their anticipated result for CCP 
with a strong high and weaker low signal observed. For the test serum samples both 
the RA samples were CCP positive and neither of the normal sera tested were. 
Additionally, RA serum sample 2 shows cTNC autoantibody positivity. The result is 
confirmed with the low background absorbance readings obtained for the no peptide 
and rTNC control conditions suggesting the binding to CCP and cTNC is specific. For 
the IgA assay just one positive control RA sera, identified in an earlier screening 
experiment, was used which again showed its expected strong signal for CCP 
autoantibodies. In this case the RA serum sample 2 was identified as CCP IgA positive 
while the RA serum sample 1 and both healthy control samples were negative. None 
of the samples were found to be cTNC IgA positive in this example.   
 Tenascin-C: A marker and driver of inflammation 
Chapter 5 – Development of assays to assess the clinical utility of tenascin-C 203 
  
 Tenascin-C: A marker and driver of inflammation 
Chapter 5 – Development of assays to assess the clinical utility of tenascin-C 204 
5.5.2 cTNC5 IgG autoantibodies are specifically detected in RA 
patients 
In total 318 human blood samples were screened in the cTNC5 ELISA including 82 
healthy donors, 150 confirmed RA patients, and 86 patients suffering from other 
rheumatic diseases. Patients with confirmed RA but not those with other rheumatic 
diseases showed a significant difference in both cTNC, see figure 5.2a, and CCP, see 
figure 5.2b, autoantibody response compared to the healthy control group. Using an 
arbitrary absorbance cut off of 0.2, estimated as a lower limit of positive detection for 
the assay, 14/318 samples were positive in the absence of peptide and 12/318 were 
rTNC positive. This indicated that the assay was not unduly hindered by non-specific 
plate or peptide binding and thus the majority of binding observed in the assay can be 
attributed to the specific recognition of the CCP or cTNC peptides.  
Attempts were made to stratify patients based on their cTNC or CCP levels, such as 
by RF positivity as is shown in figure 5.2c for cTNC and figure 5.2d for CCP. The 
majority of cTNC positive samples came from the RF+ group with no significant 
difference compared to healthy controls seen for the for the RF- samples. A similar 
trend was seen for CCP, although a significant difference was also observed between 
the RF- samples and the control albeit to a much lesser to degree than for RF+ samples. 
However, the number of RF- samples was far lower than the RF+ samples within the 
RA cohort, which may have reduced the power of the analysis.  
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5.5.3 cTNC5 IgG autoantibodies are less sensitive than CCP 
autoantibodies for diagnosis of RA 
With the established tests able to robustly detect cTNC autoantibodies, further analysis 
was carried out to test its diagnostic ability. To do this the cTNC and CCP assay results 
were subject to receiver operating characteristic (ROC) curve analysis to determine 
whether they could discriminate between the RA patient cohort and the healthy donor 
controls, the results of which are shown in figure 5.3a. Both the cTNC and CCP assays 
could significantly discriminate healthy samples from RA patients with area under the 
curve (AUC) values of 0.7933 (95% CI 0.7355 to 0.8510) for cTNC and 0.8851 (95% 
CI 0.8432 to 0.9270) for CCP which were both significantly different from the no 
discrimination value of 0.5. However, as the higher AUC value would suggest the CCP 
test was more sensitive than the cTNC assay, with the sensitivities of the assays using 
a 95% specificity cut off being 78.7% (95% CI 71.44% to 84.46%) and 52% (95% CI 
44.06% to 59.84%) for CCP and cTNC respectively. This translated into 77/150 
(51.3%) RA patients testing positive for cTNC specific IgG autoantibodies and 
110/150 (73.3%) for CCP IgG autoantibodies. This gave the cTNC assay a likelihood 
ratio of 10.66, indicating that a patient with a positive result was 10.66 times more 
likely to have RA than someone with a negative result. For the CCP assay the 
likelihood ratio was 16.13. 
In clinical practice, a diagnostic test for RA must identify patients with RA from those 
with other rheumatic diseases with similar clinical disease presentation. As such, these 
analyses of ideal conditions, comparing confirmed RA patients with healthy controls, 
is not truly reflective of clinical practice. To this end a further ROC analysis was 
carried out to compare the cTNC5 ELISAs ability to discriminate between the RA 
patient cohort and a non-RA group which combined the healthy control results with 
those obtained from patients suffering from a variety of rheumatic diseases. The results 
of this analysis are shown in figure 5.3b. Under these conditions both tests can still 
significantly discriminate the RA patients from the non-RA group. However, as might 
be expected a drop in diagnostic ability is observed with AUC values of 0.7927 (95% 
CI 0.7392 to 0.8461) and 0.8586 (95% CI 0.8146 to 0.9026) for cTNC and CCP 
respectively. Furthermore, the CCP test is still more sensitive than the cTNC assay 
with a sensitivity of 73.3% (95% CI 65.74% to 79.76%) as opposed to 51.33% (95% 
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CI 43.40% to 59.20%) when using a 95% specificity cut off. This gave the cTNC assay 
a likelihood ratio of 10.65 while the CCP assay had a likelihood ratio of 15.49. A 
summary of the results for all samples tested, broken down by disease type and cohort, 
along with the percentage testing positives using these cut offs is shown in table 5.1 
below. 
As multiple tests are usually employed to confirm an RA diagnosis it was next assessed 
whether the addition of cTNC alongside CCP for diagnosis had any additional benefit. 
Assigning cTNC and CCP positivity based on the 95% specificity cut off limit 
determined by the RA versus non-RA ROC curve analysis 110/150 (73.3%) of RA 
patients were correctly diagnosed by the CCP assay and 77/150 (51.3%) by the cTNC 
assay. No incremental benefit was seen with addition of the cTNC assay alongside the 
CCP assay with all cTNC positive RA patients in the cohorts also being CCP positive.  
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Table 5.1: Summary of CCP and cTNC assay screening results. Patients classified 
as positive for cTNC5 or CCP based on ROC curve analysis to obtain a cut off giving 
95% specificity of the assay. Early synovitis was not used for any of the non-RA 
grouped analysis due to the lack of definitive diagnosis. Significance was calculated 
compared to healthy donor controls using the Kruskal-Wallis test, ns = not 
significant. For groups with low n numbers significance was not determine (-).  
 










Healthy donors 82 3 (3.7)  0 (0)  
Rheumatoid arthritis 150 77 (51.3) <0.0001 110 (73.3) <0.0001 
Ipswich RF+ 73 44 (60.3) <0.0001 61 (83.6) <0.0001 
Ipswich RF- 30 5 (16.7) ns 9 (30.0) ns 
Mexico 40 28 (70.0) <0.0001 40 (100.0) <0.0001 
Other 7 0 (0.0) ns 0 (0.0) ns 
Scleroderma 9 0 (0.0) ns 0 (0.0) ns 
Osteoarthritis 8 0 (0.0) ns 0 (0.0) ns 
Psoriatic arthritis  23 0 (0.0) ns 3 (12.5) ns 
Ankylosing spondylitis  14 3 (21.4) ns 2 (14.3) ns 
SLE 7 0 (0.0) ns 0 (0.0) ns 
PR 4 1 (25.0) ns 0 (0.0) ns 
Vasculitis 6 0 (0.0) ns 0 (0.0) ns 
OID 11 2 (18.2) ns 2 (18.2) ns 
Sjögren’s syndrome 2 1 (50.0) - 1 (50.0) - 
Dermatomyositis 2 0 (0.0) - 0 (0.0) - 
Polymyositis 1 0 (0.0) - 0 (0.0) - 
Fibromyalgia 2 0 (0.0) - 0 (0.0) - 
JIA 2 0 (0.0) - 1 (50.0) - 
Reactive arthritis 1 0 (0.0) - 0 (0.0) - 
Sarcoidosis 1 0 (0.0) - 0 (0.0) - 
Early synovitis 3 1 (33.3) - 1 (33.3) - 
Non-RA diseased (all) 86 8 (9.3) ns 6 (7.0) ns 
Non-RA (all) 168 11 (6.6)  6 (3.6)  
AS, ankylosing spondylitis; SLE, systemic lupus erythematosus; PR, polymyalgia 
rheumatica; OID, other inflammatory disease; JIA, Juvenile idiopathic arthritis. 
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5.5.4 cTNC5 IgA autoantibodies are present in a fraction of RA 
patients 
IgG autoantibodies are the main isotype detected for most ACPA tests, although other 
isotypes have also been studied including IgA. In common with other citrillunated 
peptide autoantigens the cTNC5 ELISA was also able to detect cTNC5 specific IgA 
autoantibodies in RA serum samples. This is shown in figure 5.4a where a significant 
difference in cTNC5 IgA autoantibody levels is shown between the RA and healthy 
donor groups.  Similar to previous results in the literature (Verpoort et al., 2006), a 
subgroup of patients were also identified in the cohorts tested that had CCP specific 
IgA autoantibodies. This is shown in figure 5.4b where like for cTNC a significant 
difference between the RA and healthy donor group was found. 
Based on the average background reading of 0.06 (StdDev ± 0.02) an arbitrary cut off 
of 0.10 for CCP-streptavidin and cTNC-rTNC absorbance readings was set to 
determine autoantibody positivity. For the RA serums this resulted in 53/112 (47.3%) 
testing positive for CCP specific IgA autoantibodies and 5/112 (4.5%) for cTNC IgA 
autoantibodies. IgA anti-cTNC or CCP autoantibodies were not detected in any of the 
healthy controls tested (0/33). As for the IgG autoantibodies stratification was also 
attempted by RF status. For CCP most of the positive samples came from the RF+ 
patients with no significant difference observed between the RF- patients and controls.  
In total 49/53 of the CCP IgA autoantibody samples were RF positive whilst only 4/53 
were RF negative. No trends were observed with the cTNC assay which was 
unsurprising given the low number of positives detected overall. All 5 cTNC specific 
IgA positive samples were RF positive as well as positive for CCP specific IgA 
autoantibodies.  
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5.5.5 Antibody selection for total tenascin-C ELISAs  
In addition to the autoantibody ELISAs, development of an assay to measure tenascin-
C protein levels in human blood samples was also carried out. In aid of this, a review 
of a range of a range of commercially available anti-tenascin-C antibodies was carried 
out by Tara Kayser and Dr Mel Lewis of Axis Shield Diagnostics. Details of the 
antibodies identified are summarised in table 5.2. 
Table 5.2: Summary of the commercially available antibodies identified for the 
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After identifying available antibodies, a selection was screened for their compatibility 
to detect tenascin-C in a 96 well plate sandwich ELISA format. As part of this initial 
antibody screen two methods of detection, conjugation of detection antibody to HRP 
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or biotinylation of detection antibody with utilisation of HRP-conjugated streptavidin 
as a secondary detection reagent, were also evaluated. The results of this testing are 
summarised in table 5.3. Antibodies were ranked on an arbitrary scale on their ability 
to specifically detect purified tenascin-C. 
Table 5.3: Summary of antibody pair screening results. Antibody pairings were 
ranked on an arbitrary scale, indicated below, based on the specific absorbance 
signal they produced detecting purified tenascin-C. Some pairings were not tested 
and are marked as not determined. The results for the 4F10TT with 4C8MS and 
19C4MS pairings reflect those obtained using commercial kits by IBL. The 9F8 and 
EPR4219 antibody screens were carried out by myself while all other antibody pair 













































NSCT121 - - ++ ++++ - - +/- - 
9F8 ++ +++ - ++++ - - - - 
4F10TT + ++ - + - - - ND 
T2H5 ++ ND +/- ND - - - ND 
DB7 + ND +/- ND - - +/- ND 
4C8MS ++ ND +/- ++++ (kit) - - - ND 
EPR4219 ND -/+ + ND ND ND ND ND 
19C4MS ND + ND ++++ (kit) ND ND ND ND 
 
As the aim of this study was to create an assay detecting all isoforms of tenascin-C, 
selection of antibodies based on the epitope they recognised was critically important. 
Figure 5.5 summarises published or supplier data mapping the antibodies to the 
domains they recognise. This shows that the majority of the antibodies tested recognise 
conserved epitopes and thus could potentially be used in the total tenascin-C assay. 
The only two antibodies ruled out were 4C8MS and 19C4MS which recognised the 
alternatively spliced FNIII repeats B and C respectively. 
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Due to its availability, as a kind gift from Nascient Ltd, and based on the screening 
results showing its robustness, working in the most pairings in detection or capture 
roles, the NSCT-121 antibody was selected for further use. Furthermore, due to its 
greater availability at a high concentration, which would aid in conjugation reactions, 
it was also decided that NSCT-121 would be used as the detection antibody in the 
prospective pairing. In picking a capture antibody to pair with it a number of factors 
were considered which resulted in the final selection of the 9F8 antibody. These factors 
included the good performance of the pairing, which showed it to be one of the more 
sensitive and low background pairings for the detection of tenascin-C. Additionally, 
the 9F8 antibody proved economically favourable as it was available in bulk from the 
supplier Merck Millipore and at a price that was cost efficient to allow for maximal 
sample screening. This pairing would also, as aimed, detect total tenascin-C levels as 
the epitopes for both antibodies, in the FBG domain for NSCT-121 and the FNIII 
repeats 1-3 for 9F8, are constitutive domains and thus should be present in all forms 
of tenascin-C regardless of alternative splicing.  
Further work was carried out to verify the specificity of the NSCT-121 antibody. 
Purified tenascin-C or fibrinogen were coated onto 96 well plate wells and blocked 
with 2% BSA. The biotinylated antibody was titrated against it, from 50 to 0.78ng/ml, 
and detected with streptavidin-HRP. Fibrinogen was chosen as an appropriate non-
specific protein as NSCT-121 recognises the fibrinogen like globe (FBG) domain of 
tenascin-C which shares homology with terminal globular domains of fibrinogen 
(Doolittle, 1992). As such, it was essential to rule out cross-reactivity with this serum 
protein. The results of this assay, shown in figure 5.6a, show that NSCT-121 was able 
to detect tenascin-C at low ng/ml concentrations without any cross reactivity with 
fibrinogen. Further work was then carried out to develop the final sandwich assay, 
schematically outlined in figure 5.6b and methodologically described in section 2.9. 
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5.5.6 9F8-NSCT-121 tenascin-C sandwich ELISA validation  
The tenascin-C sandwich assay was then evaluated for detection of tenascin-C in 
serum samples. First, serum samples with or without 50 ng/ml purified tenascin-C 
added, were tested in a ‘swap out’ experiment. This involved systematically removing 
or replacing components of the assay with non-specific reagents, to ensure that signal 
obtained from tenascin-C spiked serum samples was specific and not the consequence 
of non-specific binding of the serum matrix. The results of this assay, shown in figure 
5.7a, demonstrate that a signal above background was observed only when both 
tenascin-C specific antibodies were used in the presence of tenascin-C spiked serum, 
tenascin-C prepared in buffer or serum on its own. This indicates that the assay 
specifically recognises the exogenous purified tenascin-C spiked into the samples, as 
well as endogenous tenascin-C present in the serum samples. No signal was detectable 
when using either NSCT-121 or 9F8 in combination with a non-specific IgG, and no 
reactivity with any other component of the assay, including plate or block, was 
detected. Additionally, the spike-recovery component of the assay also showed analyte 
recovery was not affected by the serum matrix. This was evident as compared to 
50ng/ml purified tenascin-C in buffer alone recovery of  tenascin-C from the spiked 
1/50 and 1/100 diluted serum was calculated as 98.5% ± 2.9% and 106.3% ± 4.2% 
respectively. This approximately 100% recovery for both dilutions demonstrates that 
the assay is not significantly affected adversely by the non-tenascin-C components of 
the serum which make up the sample matrix in the assay along with the diluent. 
In order to confirm that basal levels of tenascin-C observed in normal serum samples 
was the result of specific detection, normal serum samples were subject to a tenascin-
C depletion step prior to analysis in the tenascin-C ELISA. Samples were either 
prepared as normal or were preincubated in 96-well plates coated with tenascin-C 
specific NSCT-121 or a non-specific IgG. The result of this experiment, shown in 
figure 5.7b, demonstrated that pre-incubation with NSCT-121 resulted in a reduction 
in signal compared to the untreated control, whilst only a slight decrease was seen in 
samples pre-adsorbed with non-specific IgG. This suggested that signal obtained from 
normal serum samples in the tenascin-C sandwich ELISA was the result of a basal 
level of tenascin-C which could be depleted through pre-adsorption with tenascin-C 
specific antibody. 
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A third antibody-based inhibition assay was carried out as a final validation of 
tenascin-C sandwich assay specificity. Unlabelled 9F8, NSCT-121, or non-specific 
IgG were titrated into the assay samples in a concentration range from 5 to 0.07ng/ml. 
The result shown in figure 5.7c, showed that 9F8 and NSCT-121 dose-dependently 
reduced absorbance signal for both serum samples and buffer spiked with tenascin-C, 
whereas non-specific IgG had no effect on any of the samples tested. This strongly 
suggests that signal obtained in the tenascin-C sandwich assay was the result of 
specific binding of 9F8 and NSCT-121 to tenascin-C. 
Overall, the assays described above robustly demonstrate that the tenascin-C sandwich 
ELISA specifically recognises tenascin-C in tenascin-C spiked buffer and serum 
samples and that pooled serum from normal individuals contains a basal level of 
tenascin-C.  
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5.5.7 Tenascin-C sandwich ELISA characterisation  
Next, the sensitivity and dynamic range of the assay was assessed with a titration of 
purified tenascin-C from 100ng/ml to 0ng/ml, shown in figure 5.8a. A lower limit of 
detection of 0.78ng/ml was determined beyond which the tenascin-C dilutions were 
not reliably distinguishable from background levels. The linear dynamic range was 
determined to be between 0.78 to 50ng/ml and this was chosen as the concentration 
range for the assay standard curve going forward. From standard curves run across a 
number of plates an average signal to noise ratio of 29:1 was calculated by dividing 
the absorbance signal of the highest standard by the background buffer only readings. 
The sample dilution factor for the assay was also assessed to ensure samples would 
fall within the standard curve range and to mitigate any matrix effects. To do this a 
selection of normal serums containing varying basal levels of tenascin-C were serially 
diluted from 1/50 to 1/6400, the results for which are shown in figure 5.8b. Serum 
samples showed reasonable linearity of dilution and all fell below the 25ng/ml standard 
at a 1/50 dilution. As it had been used in previous optimisation it was thus determined 
that 1/200 was an appropriate sample dilution factor for the assay. 
As well as sample dilution, blood sample tube type was assessed. Work so far had 
utilised serum samples, which are produced by allowing the blood sample to clot 
before removing the clot and cells by centrifugation. However, plasma samples, to 
which anti-coagulation factors are added on sample collection to prevent clotting 
before centrifugation to remove cells, were also available. Several different anti-
coagulants exist with some of the most common including lithium heparin and EDTA. 
Separator tubes, containing a gel which prevents the cell pellet from mixing with the 
supernatant after centrifugation, also exist for both plasma and serum samples. These 
sample types can potentially impact assay results and thus screening was carried out 
of a selection of normal serums of different blood tube types to determine if any affects 
were observable. The results of this screen are shown in figure 5.8c and demonstrate 
that for all the tube types tested no significant difference in levels or distribution of 
tenascin-C were seen. Thus, tube type does not appear to significantly affect or 
confound tenascin-C detection by the assay.   
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Having shown good performance with human serum samples the ELISA was also 
tested for its compatibility for use with murine serum samples collected from the colitis 
experiments covered in chapters 3 and 4. However, murine serum diluted at the assay 
standard 1/200 or at 1/100, from both colitic and control mice, failed to produce a 
signal above background and was comparable to readings obtained for serum from 
Tnc-/- mice. This result was not entirely unexpected as the 9F8 capture antibody utilised 
in the assay was generated using human tenascin-C in a murine host. It is therefore 
unlikely that antibodies cross-reactive with murine tenascin-C would have been 
generated due to their autoreactivity to the host. In line with this the supplier did not 
recommend its use for the detection of murine tenascin-C with detection of human 
tenascin-C is only validated use.  
Alongside development of the tenascin-C sandwich assay carried out by myself a 
tenascin-C competition ELISA was also developed by Dr Mel Lewis at Axis Shield 
Diagnostics. A representative standard curve and the diagrammatic representation of 
the format of the assay are shown in figure 5.9a and 5.9b. In brief this competition 
assay involved the pre-mixing of labelled NSCT-121 and diluted sample before 
applying it to a recombinant FBG domain coated plate. Any tenascin-C in the sample 
would bind the tenascin-C during the pre-incubation and thus block its binding to the 
FBG domain on the plate. Thus, detection of the labelled NSCT-121 on the plate would 
provide an inverse readout of the amount of tenascin-C in the sample which the exact 
concentration of which could be calculated by utilising a standard curve of purified 
tenascin-C as in the sandwich ELISA. As this competition format of assay only utilises 
the binding of one antibody it can potentially detect distinct forms of tenascin-C, such 
as those in which the FBG domain and FNIII-repeat domains 1-3 have become 
detached, from the sandwich ELISA. As such, for comparative purposes the results 
from the screening of patient cohorts with this assay, also carried out by Dr Mel Lewis, 
are included for analysis in the sections below.  
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5.5.8 Total serum tenascin-C is significantly elevated in RA 
patient blood samples 
The tenascin-C sandwich ELISA was used to screen control, RA, and inflammatory 
diseased serum samples with the results shown in figure 5.10a. Results obtained from 
the screening the same cohorts with the tenascin-C competition ELISA, carried out by 
Dr Mel Lewis, are shown in figure 5.10b for comparison. Results for both assays are 
also summarised in table 5.4. Demonstrating a significant impact of assay format both 
assays detected a moderate amount of tenascin-C in the serum of healthy controls, with 
an average of 447ng/ml detected with the sandwich ELISA and 2164ng/ml with the 
competition ELISA. However, levels of tenascin-C detected by both assays were 
significantly higher in the serum of RA patients with average values of 768ng/ml and 
4112ng/ml in the sandwich and competition ELISAs respectively. For non-RA 
rheumatic diseases tested with the sandwich ELISA, although some patient groups 
showed a trend towards increased tenascin-C levels, none were significantly elevated 
compared to healthy controls. Conversely, for the competition ELISA, non-RA 
rheumatic disease cohorts showed significantly increased tenascin-C levels compared 
to controls, with the only exception being polymyalgia rheumatica patients. Using 
these screen results concordance between the two assays was also assessed, as shown 
in figure 5.10c, which demonstrated a significant moderate positive correlation (ρ = 
0.55, p<0.0001) in competition and sandwich ELISA tenascin-C levels.  
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Table 5.4: Summary total tenascin-C sandwich ELISA screen results alongside 
competition ELISA results, provided by Dr Mel Lewis. Shown are the number of 
samples screened with each assay per group as well as the group’s average tenascin-
C concentration in both assays. Early synovitis was not used for any of the non-RA 
grouped analysis due to the lack of definitive diagnosis. Significance was calculated 
compared to healthy donor controls using the Kruskal-Wallis test, ns = not significant. 
For groups with low n numbers significance was not determined (-). 













Healthy donors 93 447  124 2164  
Rheumatoid arthritis 150 768 <0.0001 156 4112 <0.0001 
Ipswich RF+ 73 895 <0.0001 82 4840 <0.0001 
Ipswich RF- 30 877 <0.0001 34 4800 <0.0001 
Mexico 40 521 ns 40 2034 ns 
Other 7 394 ns    
Scleroderma 8 655 ns 9 3766 0.0041 
Osteoarthritis 9 778 ns 9 3910 0.001 
Psoriatic arthritis  24 688 ns 26 3820 <0.0001 
Ankylosing spondylitis  13 460 ns 15 3626 0.0018 
SLE 7 531 ns 8 4477 0.0002 
PR 4 590 ns 5 3770 ns 
Vasculitis 6 400 ns 6 4243 0.0116 
OID 10 424 ns 12 3619 0.0057 
Sjögren’s syndrome 2 210 - 3 2730 - 
Dermatomyositis 2 310 - 2 2744 - 
Polymyositis 1 360 - 1 3706 - 
Fibromyalgia 2 360 - 2 3927 - 
JIA 1 520 - 2 4315 - 
Reactive arthritis 1 1100 - 1 6660 - 
Sarcoidosis 1 500 - 1 2904 - 
Early synovitis 3 810 ns 4 5081 0.0064 
Non-RA diseased (all) 81 586 ns 90 3834 <0.0001 
Non-RA (all) 174 512  214 2866  
AS, ankylosing spondylitis; SLE, systemic lupus erythematosus; PR, polymyalgia 
rheumatica; OID, other inflammatory disease; JIA, Juvenile idiopathic arthritis. 
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As with the ACPA assays stratification was attempted to determine if either assay was 
able to discriminate RA patient subgroups defined by either RF, CCP, or cTNC assay 
positivity. For the sandwich assay no significant differences in tenascin-C levels were 
seen for any of these stratification variables as shown in figure 5.11a. The result for 
the competition assay, shown in figure 5.11b, were similar although a significant 
increase (p=0.045) was seen in the CCP positive (average concentration 3880 ± 
2161ng/ml) compared to the negative (average concentration 4710 ± 2119ng/ml) 
subgroup. Further analysis demonstrated no significant correlation between either the 
absorbance levels in the CCP or cTNC assays and tenascin-C concentration in the 
sandwich ELISA (CCP ρ = -0.16, p=0.0527; cTNC ρ = -0.08, p=0.36). The analysis 
was similar for the competition assay with no significant correlation seen between 
cTNC levels and competition assay tenascin-C concentration (cTNC ρ = -0.11, 
p=0.20). However, in this case significance was found for a weak negative correlation 
with the CCP assay absorbance’s (CCP ρ = 0.28, p=0.0006). 
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5.5.9 Comparison of tenascin-C levels in total and splice 
variant specific assays 
Many studies investigating tenascin-C in blood samples have utilised splice variant 
specific assays. Therefore, the levels of tenascin-C detected using the total tenascin-C 
sandwich ELISA were compared to those obtained using assays that detect specific 
splice variants. Two of the most commonly used splice variant specific assays, the 
tenascin-C large FNIII-B or FNIII-C ELISA kits, produced by IBL International were 
selected for comparison. The FNIII-B kit utilises the alternatively spliced FNIII repeat 
B specific antibody, 4C8MS, for capture while the FNIII-C kit utilises the alternatively 
splice FNIII repeat C specific antibody, 19C4MS for capture. Both assays utilise the 
same detection antibody, 4F10TT, which recognises the conserved EGF-like repeat 
domain. The epitopes of the antibodies used in these assays are shown in figure 5.5.  
Both assays are performed as standard sandwich ELISAs, as outlined in section 2.11, 
and utilise as detection antibody; a mouse IgG1 Fab fragment conjugated to HRP for 
colourimetric detection utilising TMB. The FNIII-B assay standard covers 12.5 to 
0.20ng/ml whereas the FNIII-C assay from 24 to 0.38ng/ml. Representative standard 
curves for both assays are shown in figure 5.12a for FNIII-B and figure 5.12b for 
FNIII-C, which both showed good linearity. The bottom two standards were omitted 
to allow for additional sample quantification. In total 18 controls and 62 RA samples 
were screened with FNIII-B kit, and 8 controls and 30 RA samples were screened with 
the FNIII-C kit. The results for both the FNIII-B and FNIII-C kits, shown in figure 
5.12c and figure 5.12d respectively, showed a significant increase in tenascin-C levels 
in the RA groups compared to the healthy controls. For the FNIII-B ELISA the mean 
concentration of the controls was 121.4 ± 239.4ng/ml and this was elevated to 557.8 ± 
332.3ng/ml in the RA patients. For the FNIII-C ELISA the control average was 25.7 
± 23.4ng/ml and this increased to 77.3 ± 46.6ng/ml in the RA patients. 
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Results for samples tested with the IBL ELISAs were compared with the results 
obtained using the competition and sandwich ELISAs. For the sandwich ELISA a 
weak but significant positive correlation (ρ=0.3556, p=0.0012) was seen with the 
FNIII-B ELISA, as shown in figure 5.13a. A significant stronger positive correlation 
(ρ=0.7812, p<0.0001) was seen with the FNIII-C ELISA, shown in figure 5.13b. For 
the competition assay a significant moderate correlation (ρ=0.5086, p<0.0001) was 
seen with the FNIII-B assay, shown in figure 5.13c. Unlike the sandwich ELISA a 
similar moderate correlation (ρ=0.5795, p=0.0001) was also seen with the FNIII-C 
assay, shown in figure 5.13d. Finally, to compare the splice variants present a 
comparison was also made between the results from the FNIII-B and FNIII-C assays. 
This demonstrated a moderate significant positive correlation (ρ=0.4885, p=0.0019), 
as shown in figure 5.13e. 
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5.5.10 Total serum tenascin-C may be useful in the 
diagnosis of RA 
To test the clinical utility of serum total tenascin-C levels, ROC curves were generated 
from the screening data. The result for the sandwich ELISA, shown in figure 5.14a, 
demonstrated that the assay was able to discriminate RA patients from healthy controls 
with an AUC of 0.6835 (95% CI 0.6170 to 0.7501). Furthermore, this discrimination 
was shown to be statistically significant with p<0.0001. When other inflammatory 
diseases were included along with the healthy controls (non-RA group) in the analysis 
the sandwich assay retained the ability to discriminate RA patients from non-RA 
patients and healthy controls at a statistically significant level with p<0.0001. 
However, specificity was impacted with a decrease in the AUC to 0.6394 (95% CI 
0.5761 to 0.7027). Statistically the assay was still able to discriminate the RA patients 
from other rheumatic diseased patients with p=0.0262. However, the specificity of the 
assay was very poor with a low AUC of 0.5887 (95% CI 0.5149 to 0.6625) indicating 
a very limited ability for discrimination. To achieve a 95% specificity for RA 
diagnosis, cut off in tenascin-C levels was set to 850ng/ml when comparing to healthy 
controls and 1210ng/ml when comparing to the non-RA group. Using these cut offs 
the sensitivity of the assay was 38% (95% CI 30.62% to 45.98%) with a likelihood 
ratio of 8.83, and 16% (95% CI 10.99% to 22.70%) with a likelihood ratio of 3.48 for 
both group comparisons respectively.  
The same ROC analysis was carried out for the competition assay as shown in figure 
5.14b. Much like the sandwich ELISA the assay was able to significantly discriminate 
RA patients from both the healthy controls and non-RA groups (both p<0.0001). 
Additionally, for both groups the assay performed better than the sandwich assay with 
increased AUCs in both instances. However, the AUC of 0.7978 (95% CI 0.7449 to 
0.8508) obtained just the healthy donors as controls suffered a much bigger loss of 
specificity with the addition of the non-RA rheumatic disease group as reflected by a 
greater decrease in the AUC to 0.6738 (95% CI 0.6167 to 0.7309). Furthermore, unlike 
the sandwich assay the competition assay was not able to discriminate the non-RA 
rheumatic diseased patients on their own from the RA patients with an AUC of 0.5028 
(95% CI 0.4316 to 0.5741) and p=0.9414. To achieve a 95% specificity for RA 
diagnosis cut off in tenascin-C levels was set to 3606ng/ml when comparing to healthy 
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controls and 5622ng/ml when comparing against the non-RA group. Using these cut 
offs the sensitivity of the assay was 53% (95% CI 44.76% to 60.24%) with a likelihood 
ratio of 10.86, and 25% (95% CI 18.86% to 32.34%) with a likelihood ratio of 5.35 
for both group comparisons respectively. 
Finally, based on the healthy donor and RA patient group which was screened with the 
IBL splice variant assays a diagnostic comparison was made between all of the assays. 
Both of the IBL assays performed well being able to significantly discriminate the 
healthy donors from the RA patients with statistical significance at P<0.0001. The 
assays had AUCs of 0.8978 (95% CI 0.7981 to 0.9976) for FNIII-B and 0.85 (95% CI 
0.7205 to 0.9795) for the FNIII-C respectively. In this limited cohort this outperformed 
both the total tenascin-C sandwich and competition ELISAs which had lower AUCs 
of 0.7451 (95% CI 0.6260 to 0.8642) and 0.8378 (95% CI 0.7357 to 0.9399) 
respectively. It should be noted that due to less samples being screened in the FNIII-C 
assay this comparison is not perfect and more samples are needed to be screened with 
this assay to determine if it is truly superior. 
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5.5.11 Molecular forms of tenascin-C in healthy and 
diseased human serum 
The preceding sections of this chapter outline a sandwich ELISA I developed as well 
as a competition assay developed by a collaborator for the detection of tenascin-C in 
human serums samples. Both of these assays are robust tools for the detection of 
tenascin-C although due to methodological differences detect potentially differing 
forms of the protein due to potential fragmentation. Importantly for both these assays, 
unlike their commercial competition which were also tested, they detect total tenascin-
C levels irrespective of splice forms. The weak concordance and differing diagnostic 
performance of all these various assays suggests that increasing levels of certain 
subtypes, such as splice variants, does not simply reflect an increase in total tenascin-
C levels. As such, this would suggest that differing forms of tenascin-C must be present 
in human blood and that their abundance can vary independently of total tenascin-C 
levels. To investigate this further it was decided to attempt to purify and concentrate 
tenascin-C from human serum so that further biochemical analyses could be carried 
out. Current tenascin-C purification protocols generally rely on high volume, 
expensive, and lengthy chromatographic column-based methods and thus were 
deemed unsuitable for extraction of tenascin-C from the low volume and concentration 
serum samples available. As such, development of a novel IP protocol for tenascin-C 
using the NSCT-121 antibody was undertaken to allow for the future extraction and 
interrogation of tenascin-C from biological samples, including samples that had been 
tested in the tenascin-C ELISAs. 
Initially, to test the IP protocol, an RA serum sample was immunoprecipitated with 
NSCT-121 or non-specific IgG coated Dynabeads. The supernatants from these IPs 
were further immunoprecipitated with NSCT-121 to test the efficiency of the first IP.  
The eluents of all of the IPs as well as the washes were then tested in the total tenascin-
C sandwich ELISA the result of which is shown in figure 5.15a. This showed the 
successful IP of tenascin-C with clear enrichment in the NSCT-121 IP eluent and no 
tenascin-C present in the NS IgG IP eluent. Furthermore, low amounts of tenascin-C 
were detected in the NSCT-121 IPs wash and or supernatant suggesting the majority 
of tenascin-C was successfully captured. This was not observed for the NS IgG IP with 
significant amounts of tenascin-C still able to be depleted from its supernatant 
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suggesting no binding to this control occurred. The original serum sample was also ran 
in the assay as normal or supplemented with glycine to simulate the elution conditions. 
No difference was seen between the normal or glycine supplemented serum sample 
demonstrating that the elution conditions did not impact the ELISA results.  
To investigate the immunopreciptate further the NSCT-121 precipitate from a normal 
and RA patient sera was run on an SDS-PAGE gel alongside purified tenascin-C. 
Silver staining was then used to visualise the protein on the gel as shown in figure 
5.15b. The purified tenascin-C produced clear bands at 230 and 280 kDa as expected, 
whereas both of the IP samples produced a protein smear suggesting that the IP carried 
through other serum protein contaminants as well as tenascin-C. To confirm the 
presence of tenascin-C in the IP samples mass spectrometric analysis was performed 
on a gel band cut from the RA patient IP sample. This was cut at the same height as 
the high molecular weight (~280kDa) tenascin-C variant present in the purified 
samples which was also excised as a control for tenascin-C detection. The results of 
this analysis are shown in table 5.5 which showed that tenascin-C was readily 
detectable from purified tenascin-C gel band with it clearly the highest scoring hit. A 
few other ECM proteins were also detected which were suggested to be minor 
contaminants of the cell line purified prep. For the RA sera IP sample as expected 
contamination of abundant serum proteins was found with apolipoprotein B-100 and 
serum albumin featuring as top hits. However, tenascin-C itself was also identified as 
a top hit suggesting enough had been captured for detection. 
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Table 5.5: Proteins identified in mass spectrometric analysis of purified tenascin-C 
and RA sera tenascin-C IP gel bands (see figure 5.15b). The top 3 scoring proteins 
are listed for each. A total of 12 proteins were identified in the band 1 sample, and 
a total of 17 in the band 2 sample. 
 
Protein ID Protein name, species, and gene Mascot Score 
Band 1 280kDa band of purified tenascin-C  
P24821-4 Tenascin OS=Homo sapiens GN=TNC 9593 
O00468 Agrin OS=Homo sapiens GN=AGRN  273 
D6RGG3 Collagen alpha-1(XII) chain OS=Homo sapiens GN=COL12A1 234 
Band 2 280kDa band of RA sera IP  
P04114 Apolipoprotein B-100 OS=Homo sapiens GN=APOB  7802 
P24821 Tenascin OS=Homo sapiens GN=TNC  970 
P02768 Serum albumin OS=Homo sapiens GN=ALB  682 
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Following from this preliminary gel band analysis these experiments were repeated 
with additional normal and tenascin-C high RA serum samples. This time however, 
the IP beads were subjected to in solution trypsin digestion to avoid bias toward a 
specific molecular weight and so identify all forms of tenascin-C present, as well as 
any potential interacting partners. Using this approach tenascin-C was identified in all 
the NSCT-121 IPs from both normal and RA samples and in in none of the 
corresponding control IPs. As the gel digest had suggested however, the IPs were not 
pure with many serum proteins pulled down with the beads as well. The non-specific 
IgG control IPs confirmed these proteins as non-specific interactors and thus they were 
filtered from the analysis. The final protein list produced post filtering is shown in 
table 5.6. Other than tenascin-C the protein fibronectin was the only other protein 
identified in the samples screened. Fibronectin was identified in the control IPs but it 
did appear enriched in the NSCT-121 IPs consistently attaining much higher mascot 
scores in these samples. This suggested fibronectin is a potential interactor with 
tenascin-C in serum. Tenascin-C consistently attained a higher mascot score in the RA 
patient samples compared to the healthy donors suggesting, as expected, a higher 
concentration of tenascin-C present and thus more robust detection.  
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Table 5.6: Proteins identified in mass spectrometric analysis of normal and RA sera 
tenascin-C IPs. Results were filtered by mascot score, a measure of confidence of 
identification, and by comparison to a non-specific IgG control IP.  
 
Protein ID Protein name, species, and gene Mascot Score 
Sample 1 Normal donor serum 1  
F8W7G7 Fibronectin OS=Homo sapiens GN=FN1 1541 
J3QSU6 Tenascin OS=Homo sapiens GN=TNC 595 
Sample 2 Normal donor serum 2  
P02751 Fibronectin OS=Homo sapiens GN=FN1 2275 
J3QSU6 Tenascin OS=Homo sapiens GN=TNC 190 
Sample 3 RA patient serum 1  
J3QSU6 Tenascin OS=Homo sapiens GN=TNC 2073 
P02751 Fibronectin OS=Homo sapiens GN=FN1 3045 
Sample 4 RA patient serum 2  
J3QSU6 Tenascin OS=Homo sapiens GN=TNC 1361 
F8W7G7 Fibronectin OS=Homo sapiens GN=FN1 307 
Sample 5 RA patient serum 3  
P24821 Tenascin OS=Homo sapiens GN=TNC 2146 
P02751 Fibronectin OS=Homo sapiens GN=FN1 798 
 
To validate these findings western blotting of the IPs was carried out. Firstly, RA and 
normal serum NSCT-121 and control IPs were western blotted for tenascin-C 
alongside 0.1µg of purified protein. This blot, shown in figure 5.16a, demonstrated 
that the two major bands at approximately 200 and 280kDa seen with the purified 
protein are also present in both the normal and RA patient samples. Also like the 
purified protein in both cases the higher weight form appears to pre-dominate over the 
smaller isoform. Confirming the ELISA and mass spectrometry analysis, additionally 
a greater amount of tenascin-C is seen present in the RA sample compared to the 
normal sample. For both the control IgG IPs a strong smear is seen although this was 
hypothesised to be due to cross reactivity of the non-specific IgG present in the IP, 
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which was a mouse antibody, with the anti-mouse secondary used in the blot. A similar 
problem is not seen for the NSCT-121 IP as the NSCT-121 antibody is a human IgG 
and thus not recognised by the anti-mouse secondary.  
To check that both forms of tenascin-C were depleted equally the supernatants from 
the first IPs were subjected to an additional NSCT-121 IP and western blotted again 
for tenascin-C. As shown in figure 5.16b the first NSCT-121 IP was clearly sufficient 
to deplete both forms of tenascin-C with no bands seen in the NSCT-121 depleted 
supernatants from control or RA patients. As expected, the IgG IP did not deplete the 
sample tenascin-C and thus the follow up NSCT-121 IP was able to pull out tenascin-
C from these supernatants. The amount did appear slightly reduced however compared 
to the first NSCT-121 IPs. This could likely be due to incomplete supernatant recovery 
from the beads and subsequent loss of some tenascin-C in the wash steps due to weak 
non-specific bead binding.  
Having confirmed tenascin-C depletion, the fibronectin interaction was next 
investigated. To do this the first membrane presented in figure 5.16a was re-probed 
with an anti-fibronectin antibody, presented in figure 5.16c. This revealed fibronectin 
was present in all the IPs including the non-specific IgG IPs although this appeared 
enriched in the NSCT-121 IPs, corroborating with the mass spectrometry results. 
Comparing between the patient groups the form of fibronectin present appeared to 
differ with a major band at approximately 260kDa present in the control sample while 
a lighter form of around 250kDa seen in the RA sample. Additionally, less fibronectin 
seemed to be present in the RA patient sample compared to the healthy control. As the 
predicted band size of fibronectin was 263kDa it was hypothesised that this result for 
the RA patient sample may be due to proteolysis which may have also impacted 
antibody recognition or tenascin-C binding and thus resulted in the seemingly low 
levels detected in this sample. To investigate this further the original serum samples 
or an equivalent amount of the supernatant from the NSCT-121 depleted samples was 
blotted for fibronectin, as shown in figure 5.16d. This showed relatively equal amounts 
of fibronectin present in the original samples for the major 260kDa band although there 
was again differential banding seen in the RA sample. This took the form of an 
additional two bands at 250kDa, and 160kDa. The 260kDa band was the only major 
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band seen in the normal sample. This differences between the samples may have arose 
due to differential sample storage and freeze thaw cycles during previous usage, which 
has been shown to impact fibronectin fragmentation and western blotting (Griffiths et 
al., 1989). Overall, the NSCT-121 depleted supernatants both showed a slight 
reduction in fibronectin compared to the original serum samples although complete 
depletion like with tenascin-C was not observed. 
These preliminary findings on the forms and functions of tenascin-C in human serum 
will need further validation and characterisation in future. Furthermore, as well as the 
still unanswered questions on the forms of tenascin-C posed earlier in this chapter they 
additionally raise further questions, such as those around the nature of the tenascin-C 
and fibronectin interaction in serum. The IP protocol developed provides a good 
platform for answering these questions. Additionally, with tenascin-C’s often 
relatively low abundance in most other tissues this also provides a useful method 
applicable to a range of other biological sample sources as well.  
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5.6 Discussion 
5.6.1 cTNC5 assay performance and screen results  
The cTNC assay developed in this chapter specifically detected cTNC5 specific 
autoantibodies in human serum samples. This ELISA improved upon the protocol 
previously employed by Schwenzer and colleagues (Schwenzer et al., 2015) as it was 
less time intensive and had reduced complexity of assay buffers. Time saving steps 
included using commercially available streptavidin coated plates and biotin conjugated 
peptides which reduced plate coating from an overnight step to an hour incubation, 
and reduction in the sample and detection antibody incubation steps to one hour each 
from 1.5 to 2 hours for the Schwenzer assay. Buffers were simplified from the RIA 
buffer (1% BSA, 350 mM NaCl, 10 mM Tris–HCl, 1% Triton X-100, 0.5% Na-
deoxycholate, and 0.1% SDS) used by Schwenzer et al for the sample and detection 
antibody steps. This was replaced with the more simplified buffers, cTNC sample 
buffer (1M NaCl, 4.9mM disodium phosphate, 0.5% Tween 20, 2% BSA) and cTNC 
conjugate buffer (PBS, 0.05% Tween 20, 1% BSA), both made up of with less 
individual components. In terms of assay performance, low background was observed 
with most negative samples reading close to the absorbance observed for the no 
peptide control coat. Non-specific binding was noted for several samples, however, 
this was controlled for in the results by subtracting the absorbance obtained from the 
no peptide and rTNC5 coat controls. Only a small fraction of samples in the IgG anti-
cTNC5 assay, accounting for 3.6% of all samples tested, were rTNC5 positive. This 
was similar to the levels seen by Schwenzer and colleagues who found 2.5% of the 
RA sera samples they tested were rTNC5 positive. 
Results obtained from sample screening of the cohorts in this study were similar to 
those described by Schwenzer et al (2015). In their study of two confirmed RA cohorts 
they detected cTNC5 autoantibodies in 47% and 51% of patients which was similar to 
the percentage of anti-cTNC5 positive samples (51%) detected in the current study. 
Furthermore, the high specificity of cTNC5 autoantibodies to RA patients with very 
few observed in the healthy controls tested was common to both studies. The CCP 
results were also similar with 73.3% sensitivity in the current cohorts compared to 63.2 
and 83.6% seen in both the Schwenzer cohorts, which was in line with the 67-83% 
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range of sensitivities reported in the literature (Mathsson Alm et al., 2018). Likewise, 
CCP autoantibodies displayed high specificity for RA with no healthy controls testing 
positive. A mixed cohort of patients with non-RA rheumatic diseases was also 
included in the current study.  This cohort had low levels of cTNC5 autoantibody 
positive samples (9.3%), emphasising the specificity of the anti-cTNC5 autoantibody 
biomarker for RA. However, slightly more positive results (9.3% versus 3.7%) were 
detected in this group than in the healthy controls suggesting that a small proportion 
of non-RA rheumatic disease patients may have cTNC5 autoantibodies. A similar 
result was seen with CCP with a small proportion (7%) of non-RA rheumatic disease 
patients categorised as CCP positive.  
In addition to the IgG ACPA isotype, the cTNC5 and CCP assays were adapted for the 
detection of IgA autoantibodies, which have been shown to be present in some RA 
patients (Verpoort et al., 2006).  Like the IgG assay, IgA was specific for RA patients 
and none of the healthy donors tested positive for either CCP or cTNC autoantibodies. 
A significant proportion of the RA patients tested were positive for IgA autoantibodies, 
at 47.3%, and this was in line with other studies in the literature which have reported 
a prevalence of 52.9% (Lakos et al., 2008).  However, this was a lower sensitivity than 
seen with the IgG assay and all of the IgA positive samples were also CCP IgG 
positive, similar to what has been reported in the literature (Verpoort et al., 2006). 
cTNC IgA autoantibodies were much less prevalent with only 4.5% of RA patients 
positive, although again high specificity was observed with none of the healthy donors 
tested as positive. Interestingly, unlike for CCP, one of the cTNC IgA positive samples 
was not cTNC IgG positive although it was positive for both CCP IgA and IgG 
autoantibodies.  
5.6.2 Clinical utility of cTNC5 in diagnosis 
Overall the cTNC5 IgG assay exhibited a good diagnostic performance for RA in the 
cohorts tested although it was less sensitive than the CCP assay. In contrast to the 
studies by Schwenzer and colleagues (Schwenzer et al., 2015, Schwenzer et al., 2019), 
in the current study all anti-cTNC5 positive patients were also positive for anti-CCP 
autoantibodies. Therefore, there appeared to be no added benefit for additional testing 
for anti-cTNC5 alongside anti-CCP. The reported proportions of patients who are 
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CCP2 negative but cTNC5 positive is low at 1.7 (Schwenzer et al., 2017) to 4.9% 
(Schwenzer et al., 2015) and so it is possible that our cohort was not large enough to 
detect this small population. cTNC5 has also been investigated for its diagnostic 
potential in patients presenting with early synovitis as, like CCP autoantibodies 
(Nielen et al., 2004), cTNC5 autoantibodies have been shown to pre-date RA disease 
development, in some cases up to a decade before clinical symptoms appear 
(Schwenzer et al., 2015). The current study had a limited number of early synovitis 
samples, with only three analysed. However, one of these early synovitis patient 
samples was positive for cTNC5 and CCP suggesting that this individual was likely to 
develop RA. Recent studies in other clearly defined early synovitis cohorts have 
demonstrated that anti-cTNC5 autoantibodies can predict RA development, although 
in a less sensitive and largely overlapping manner to the CCP assay (Raza et al., 2016).  
These results might be anticipated in light of the fact the CCP assay contains a mix of 
artificially engineered peptides designed to capture the majority of ACPA for 
maximum sensitivity (van Venrooij et al., 2011). Thus, it is likely that the majority of 
cTNC5 specific autoantibodies are detected in the CCP assay as well. Similar results 
have been seen with other specific autoantigen ACPA assays which generally show 
reduced sensitivity compared to CCP (Bizzaro et al., 2007) and similar low frequencies 
in CCP negative patients (van Heemst et al., 2015).  
The diagnostic potential of detecting IgA autoantibodies should also be considered, as 
in recent years it has been recognised that determining autoantibody isotype may be 
diagnostically beneficial (Sieghart et al., 2018). The clinically used CCP3.1 assay is 
based on this principle, detecting both IgG and IgA CCP autoantibodies, with some 
evidence of improved sensitivity (dos Anjos et al., 2009). Whilst in the current cohorts 
studied a significant number of CCP IgA RA patients were identified there was no 
added benefit to observed sensitivity. This was also the case when taking the RF 
negative RA patients in isolation, in contrast to more recent literature reports that IgA 
detection may be particularly beneficial for the diagnosis of this group (Szekanecz et 
al., 2013). This likely reflects the low prevalence of CCP IgG negativity with IgA 
positivity that has been reported in the literature (Lakos et al., 2008, Svard et al., 2015). 
In contrast, a very slight diagnostic benefit was seen for IgA anti-cTNC5 
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autoantibodies with one RF negative RA patient tested as cTNC positive. This should 
be cautioned however as recent studies have suggested that IgA ACPAs increase with 
age in RA patients as well as healthy controls suggesting that the addition of IgA 
autoantibody detection may produce specificity problems (Berens et al., 2019). This 
was not observed in the current cohort tested with high specificity observed although 
more control samples as well as non-RA diseased samples would need to be tested to 
confirm this. 
5.6.3 Clinical utility of cTNC5 in patient stratification  
The benefit of detecting of ACPA fine specificities may not lie with diagnosis but in 
patient stratification. It is has already been shown that anti-CCP autoantibodies display 
some limited prognostic ability. This has included associations between CCP levels or 
positivity and aggressiveness of disease (Kastbom et al., 2004), mortality risk 
(Sihvonen et al., 2005), responsiveness to anti-TNF biologic therapy (Klaasen et al., 
2011), and rate of joint destruction (de Rooy et al., 2011). However, some of these 
associations are weak or with low predictive value and can vary by cohort making 
them of limited routine clinical use. It could also be argued that when looking solely 
at CCP positivity, a diagnosis  that includes >70% of all patients, is not particularly 
informative for clinicians, especially given the heterogeneous nature of RA even 
within these groups (Montgomery et al., 2013). As such, it has been proposed that 
further subdividing patients by ACPA fine-specificity may prove clinically 
informative. This is especially appealing if, in light of the heterogeneity of the 
condition, you consider RA as a syndrome encompassing a range of different 
aetiologies but a common clinical endpoint (Stanich et al., 2009). If such a view is 
taken it could be postulated that differing ACPA’s could be generated by different 
disease subsets and thus reflect differences in underlying disease mechanisms with 
prognostic implications.  
In this study cTNC5 was found to stratify patients by RF status. This is in agreement 
with other studies which have also shown an association between RF and cTNC5 
positivity (Raza et al., 2016). Likewise, an association between RF and CCP positivity 
has been previously reported in the literature (Murphy et al., 2017) and was also found 
in the current study. As such, the cTNC5 assay showed no added benefit for the 
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identification of seronegative patients. Additionally, in this study no other factors 
including age or treatment were found to correlate with cTNC5 positivity. This 
analysis was limited however by the differing or lacking clinical information available 
for the cohorts used. The heterogeneity of the patients further complicated analysis 
and made it harder to identify potential confounding factors when isolating sub groups. 
Previous studies have shown cTNC5 positivity is associated with smoking, the HLA 
shared epitope, and disease activity in the form of DAS28-CRP scoring (Schwenzer et 
al., 2015). Similar associations with smoking, the shared epitope (Krol et al., 2015) 
and DAS28 scoring (Fisher et al., 2011) have been observed for CCP as well. No other 
clinical characteristics, such as swollen joint counts, were found to correlate with 
cTNC5 levels and this finding is similar to studies of other fine-specificity ACPAs 
(Willemze et al., 2012).   
In light of this it has been hypothesised that ACPA fine specificities may associate 
more with extra-articular disease parameters relating to their potential association with 
different disease aetiologies or mechanisms (Montgomery et al., 2013). As expected 
based on this hypothesis the CCP test has shown no correlation with a range of extra-
articular disease parameters (Gonzalez-Lopez et al., 2014). Conversely, associations 
have already been found for some fine-specificities, for example ACPAs to 
citrullinated fibrinogen and vimentin have been found to be associated with increased 
atherosclerotic plaque burden (Sokolove et al., 2013). In regards to cTNC5 ACPA, an 
association has already been identified with a subgroup of RA patients suffering from 
periodontitis caused by the pathogen prevotella intermedia (Schwenzer et al., 2017). 
Periodontitis is a known risk factor for RA and it is hypothesised as a possible initiator 
of disease with the citrullination of host proteins by periodontal bacteria leading to 
ACPA generation and RA (Rosenstein et al., 2004). As such, it could be hypothesised 
that cTNC5 positivity may identify an RA subgroup in which treating periodontal 
disease may have particular benefit, although a recent small scale trial using this 
approach found no added benefit (Moller et al., 2019). 
Another angle of approach to patient stratification comes in the form of measuring 
specific ACPAs isotypes. In this study only a very small fraction of CCP IgA positivity 
was explained by cTNC5 suggesting it is not the primary target of the IgA response in 
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RA patients. CCP IgA positivity has previously been linked to smoking and it has been 
suggested it indicates a mucosal origin of the initiation of disease in these patients 
(Svard et al., 2015). As such, this result would suggest that cTNC5 is likely not a 
relevant autoantigen in this potential mucosal mode of pathogenesis.   
Overall these findings highlight the need for further studies of cTNC5 and other, 
perhaps yet unidentified, ACPA fine specificities in larger fully clinically described 
cohorts to determine if further serological stratification is possible. 
5.6.4 Performance of total tenascin-C ELISAs  
As well as the auto-antibody assays I also developed a sandwich ELISA to quantify 
levels of total tenascin-C in biological samples, that I examined in parallel with a 
competition assay developed by a collaborator. The total tenascin-C sandwich ELISA 
demonstrated good assay specificity, sensitivity, and linear range in comparison to 
competitors. Additionally, the assay was also benefited from compatibility of use with 
a variety of different blood tube types. This contrasts with some alternative assays such 
as the IBL tenascin-C FNIII-C assay for which the manufacturer states that lower 
results will be obtained for EDTA, citrate, and NaF plasma compared to serum or 
heparin plasma samples.  
Results from the anti-tenascin-C sandwich and competition ELISAs showed a 
reasonable correlation but the concentration range of tenascin-C detected with the 
competition assay was much higher than the sandwich ELISA. This was not 
particularly surprising as the use of a single antibody for recognition in the competition 
ELISA allows detection of proteolytically cleaved fragments of tenascin-C containing 
the intact FBG epitope. Whereas, in the sandwich ELISA both the 9F8 and NSCT-121 
epitope must be linked for recognition in the assay. Therefore, proteolytic cleavage in 
the intervening FNIII domains would result in loss of detection. A number of cleavage 
sites for various proteases have been mapped within this area, including MMP-2, 
MMP-7 (Siri et al., 1995), and meprinβ (Ambort et al., 2010), and thus cleavage by 
any of these would result in lack of recognition in the sandwich ELISA. Additionally, 
estimation of tenascin-C concentration could be further reduced in the sandwich 
ELISA as these cleaved fragments could also act as inhibitors in the assay. This could 
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occur as the fragments could occupy capture antibody binding sites and thus prevent 
non-cleaved fragments, which would be recognised by the assay, from binding. These 
potential cleavage affects are summarised in figure 5.17a. Furthermore, these cleavage 
issues are further complicated as the alternative spliced domains of tenascin-C are 
subject to differential cleavage and this therefore provides another variable influencing 
tenascin-C processing and thus potentially recognition. 
Another explanation of variation between the two assays could be due to the different 
binding modes of antibody to tenascin-C that can potentially occur. Antibodies have 
two antigen binding sites and tenascin-C as a hexamer would have potentially six 
antibody binding sites per oligomer. As such, in combination with proteolytically 
cleaved fragments a wide variety of binding can potentially occur including multiple 
antibodies binding per hexamer and crosslinking of hexamers by antibodies. The 
impact of these different binding modes on the ratio of antibody bound per tenascin-C 
hexamer are illustrated in figures 5.17b, c, and d. Additional complexity could also 
arise from the hypothesised oligomerisation of different splice variants or even with 
different tenascin family members (Jones and Jones, 2000). Together all of these 
factors could affect the amount of antibody sequestered in the competition assay as 
well as antibody:tenascin-C binding ratios in the sandwich ELISA and do so to 
differential degrees.  
The tenascin-C in the standard curve used for calculating concentration should also be 
considered in light of these potential differential form effects. HPLC analysis, 
performed by Dr Mel Lewis, indicated that the standard tenascin-C, which was purified 
from tissue cultured glioma cells, was oligomeric in nature. It has been shown that 
tenascin-C can differ by cell source (Giblin, 2018) and thus it is unknown whether this 
form accurately reflects the form or forms of tenascin-C present in the blood. Due to 
the issues highlighted above the commutability of this standard in either assay may be 
different and thus differential affect assay readout. Overall though it would be 
expected that the competition assay would have a greater variety of forms of tenascin-
C to detect which would thus explain its higher estimation of total tenascin-C 
concentrations.  
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5.6.5 Basal levels of total tenascin-C in human serum 
A wide range of total serum tenascin-C concentrations in health and disease obtained 
using various different assays have been reported in the literature. These are 
summarised in table 5.5. Concentrations range from as low as 0.09ng/ml, reported for 
the USCN ELISA, to as high as 33800ng/ml for the BIOABB ELISA. However, the 
majority of studies report an average tenascin-C concentration for healthy controls of 
696 ± 314ng/ml. This concentration is in reasonable agreement with the range of 
tenascin-C concentrations observed using the 9F8-NSCT-121 sandwich ELISA and 
far greater than those observed with both IBL splice variant specific ELISAs. 
Tenascin-C assays reported in the literature were all in a sandwich immunoassay 
format and therefore differences in concentrations between the sandwich and 
competition ELISA formats, as previously discussed, are applicable to these assays as 
well. Together, information from the current study and the literature suggest that a 
notable amount of tenascin-C is expressed and transferred into the blood in normal 
healthy individuals. The tissue or cellular source and functional significance of this 
serum tenascin-C remains to be elucidated. 
Those assays that differed substantially from the range described above and from each 
other were the BIOABB, USCN, and CusaBio commercial ELISAs. The BIOABB 
assay was described in a single publication and gave extremely high concentrations of 
tenascin-C concentration. In contrast, the CusaBio and USCN ELISAs gave much 
lower concentrations of tenascin-C. It is likely that poor assay performance or 
specificity were a potential cause of this low tenascin-C level and this has already been 
suggested as a problem with the USCN ELISA (Giblin, 2018). It is possible that these 
assays are not detecting total tenascin-C and, like many of the commercial assays 
identified, the epitopes of the antibodies used were not specified. Therefore, tenascin-
C splicing or other modifications may be affecting the results of the CusaBio and 
USCN ELISAs. However, results obtained using both of the IBL splice variant specific 
ELISAs were much higher than obtained with these assays.  
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Table 5.7: Summary of total serum tenascin-C levels reported in the literature in 
healthy and diseased patients. Results presented as median or mean serum 
concentration of tenascin-C in ng/ml ± standard deviation (SD) or standard error 
(SE) depending upon the published data available. The in house ELISAs comprise 
five distinct assays with differing methodologies and antibody combinations. 
 
Assay Reference Condition 
Tenascin-C 
concentration (ng/ml) 
In house ELISA 1 (Yamauchi et al., 1994) Healthy control Mean 860 ± 152 SD 
  Hepatitis  Mean 1371 ± 333 SD 
  Liver cirrhosis  Mean 1818 ± 484 SD 
  Hepatocellular carcinoma Mean 2455 ± 1153 SD 
In house ELISA 2 (Ylatupa et al., 1995) Healthy control Mean 730 ± 310 SD 
 
 
(Kaarteenaho-Wiik et al., 
1998) 
Healthy control Mean 750 ± 400 SD 
  Sarcoidosis  Mean 1390 ± 580 SD 
  Interstitial pneumonia  Mean 2810 ± 2970 SD 
  Bronchioloalveolitis Mean 950 ± 500 SD 
In house ELISA 3 (Riedl et al., 1995) Healthy control Mean 320 ± 170 SD 
  Colorectal cancer Mean 500 ± 420 SD 
 (Riedl et al., 2001) Healthy control Mean 320 ± 170 SD 
  Ulcerative colitis  Mean 1720 ± 1460 SD 
In house ELISA 4 (Kimura et al., 1993) Healthy control Mean 897 ± 250 SD 
  Carcinoma Mean 2546 ± 1746 SD 
 (Washizu et al., 1993) Healthy control Mean 837 ± 162 
  Carcinoma Mean 2039 ± 1969 
 (Yoshida et al., 1994) Healthy control Mean 1396 ± 368 
  Brain tumour Mean 1819 ± 1264 
In house ELISA 5 
(Latijnhouwers et al., 
1998a) 
Healthy control Mean 1110 ± 390 
  Psoriasis Mean 1270 ± 790 
Bayer Immuno 1 
analyzer assay 
(Ropers et al., 2000) Healthy control Mean 457 ± 176 SD 
 (Burchardt et al., 2003) Healthy control Mean 444 ± 171 SD 




(Didem et al., 2014) Healthy controls Median 0.09 
  Ovarian cancer Median 0.13 
 (Tastekin et al., 2014) Healthy control Mean 0.137 ± 0.026 SE 
  Breast cancer Mean 0.344 ± 0.042 SE 
 (Clancy et al., 2014) Healthy control Median 1131 
  Stroke Median 1277 
Table continued on next page 
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Table 5.7: Table continued from preceding page 
Assay Reference Condition 
Tenascin-C 
concentration (ng/ml) 
CusaBio ELISA (Karatas et al., 2013) Healthy control Mean 4.72 ± 1.77 SD 
  
Rheumatic heart valve 
disease 
Median 9.09 
 (Peng et al., 2018) Healthy control Mean 6.87 ± 2.63 SD 
  Depression Mean 14.37 ± 6.07 SD 
BIOABB ELISA (Orak et al., 2016) Healthy pregnant Mean 5020 ± 400 SE  
  Preeclampsia Mean 33800 ± 11700 SE 
Myriad RBM 
immunoassay 
(Bertenshaw et al., 2008) Healthy control Median 1090 
  Ovarian cancer Median 1910 
 (Bhattacharyya et al., 2016) Healthy control Mean 410.1 ± 150.4 SD 
  Systemic sclerosis  Mean 731.2 ± 371.5 SD 
 (van den Ham et al., 2018) Healthy control Mean 488 ± 149 SD 
Mesoscale 
immunoassay 
(O'Bryant et al., 2016) Healthy control Mean 44.1 ± 13.1 SD 
  Alzheimer’s disease Mean 37.7 ± 10.3 SD 
 
5.6.6  Levels of total tenascin-C in human serum with 
inflammatory disease 
In common with previous reports in the literature for splice variant specific tenascin-
C (Schenk et al., 1995, Page et al., 2012)  screening patient samples for total tenascin-
C showed elevated serum tenascin-C levels within the inflammatory disease cohorts 
studied. However, the significance of tenascin-C levels varied by assay used with the 
sandwich ELISA showing elevation within the RA cohort only whereas the 
competition assay demonstrated significantly higher tenascin-C levels in all 
inflammatory diseases tested except for polymyalgia rheumatica. This may reflect the 
higher number of RA samples tested which would give this group more power for 
statistical analysis versus the control group. The highest levels of tenascin-C for both 
assays were observed for the RA group suggesting that tenascin-C plays a greater role 
in this inflammatory disease than the others tested. Proteolytic cleavage resulting in 
loss of recognition in the sandwich ELISA, (as discussed above) may be another reason 
for the discrepancy between sandwich and competition assay results. Tenascin-C 
alternative splicing (Giblin and Midwood, 2015) as well as protease expression and 
activation, such as that of MMPs (Nissinen and Kahari, 2014), is known to be affected 
by disease states. Therefore, the differences between tenascin-C levels in the non-RA 
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diseased group obtained from the sandwich versus competition ELISAs may reflect 
the greater likelihood of epitope loss for the sandwich assay.  
For comparison, as in the healthy control samples the total tenascin-C levels of RA 
patients were found to be far greater than the specific splice variants detected by the 
IBL ELISAs. The correlations between splice specific variants and total tenascin-C 
were also found to be quite variable and in most cases weak. This suggests that splice 
specific tenascin-C is not a good read out of total tenascin-C levels in serum and this 
should be taken into account when considering the results of the IBL assays. 
Additionally, stark differences were also observed between the two IBL assays and 
thus between the levels of the different splice variants. This was evident with both 
assays results only showing a moderate correlation with the amount of the FNIII-C 
splice variant detected found to be much lower than the FNIII-B variant. While perhaps 
a reflection of differential assay performance, this could also suggest that the two 
exons are part of differential splicing modules resulting in different incorporation rates 
into tenascin-C and thus abundance. Alternatively, this could also suggest differential 
ability of the spliceoforms to make it into the circulation, perhaps due to the splicing 
conferring differential binding abilities or proteolytic processing.  
Consideration should also be given to how accurately tenascin-C levels in the serum 
actually mirror the tenascin-C found at the pathological site as no current studies have 
characterised how tenascin-C ends up in circulation. This is additionally hampered by 
the fact the majority of studies carried out on the tenascin-C found at the inflammatory 
site utilise non-quantitative methods of tenascin-C measurement such as IHC or 
western blotting. RA is one of the few diseases in fact where local amounts of tenascin-
C have been quantified with a studies investigating tenascin-C concentrations in knee 
synovial fluid utilising the IBL FNIII-C ELISA. These have revealed that control joints 
as expect contain very low amounts of tenascin-C with a median level of 7.7ng/ml 
whereas joints from RA patients have much higher levels with a median of 166.8ng/ml 
(Hasegawa et al., 2004, Hasegawa et al., 2007). While these studies did not investigate 
systemic tenascin-C the data presented above for the FNIII-C ELISA found that 
control and RA patients had lower average systemic tenascin-C concentrations of 25.7 
and 77.3ng/ml respectively. While this might not be representative for other diseases 
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or total tenascin-C this does indicate that systemic tenascin-C does not necessarily 
completely mirror the tissue levels of tenascin-C in disease.  
5.6.7 Clinical utility of total tenascin-C 
Both the competition and sandwich ELISAs were able to discriminate RA patients 
from healthy controls. However, they were both outperformed by the splice variant 
specific IBL assays in the limited amount of patients and donors tested with the IBL 
kits. This suggests that the FNIII-B and FNIII-C splice variants are more closely 
associated with the RA diseased state, fitting with the observation that differential 
tenascin-C splicing is seen with inflammatory disease (Giblin and Midwood, 2015). 
The ability of the total tenascin-C assays to diagnose RA also suffered with the 
inclusion of non-RA inflammatory disease group which significantly impacted both 
assays specificity. This reflects the general increase of tenascin-C seen in 
inflammatory disease suggesting it is more a marker of general inflammation than of 
a specific disease such as RA. This is supported by previous studies of splice specific 
tenascin-C which showed it correlated with the levels of the acute phase protein CRP, 
a general systemic marker of inflammatory responses (Schenk et al., 1995). 
In terms of RA patient subgroups using the tenascin-C levels measured in the sandwich 
assay no association between any of the groups for which data was available was 
identified. For the competition assay one subgroup association was found with 
seemingly higher levels of tenascin-C measured by this assay found in CCP negative 
patients. While this might simply be a reflection of the lower numbers of CCP negative 
patients in our cohort it could also due to a number of known differences between CCP 
positive and negative patients. For example, it is known that differences in synovial 
immune cell infiltration are seen with less lymphocytes and more extensive fibrosis 
seen in CCP negative patients (van Oosterhout et al., 2008). RA driven more weakly 
by lymphocytic infiltration would fit with heighted tenascin-C levels as it has it been 
shown that lymphocytes express lower levels of tenascin-C compared to other 
leukocytes, such as macrophages (Giblin, 2018). It has also been shown that tenascin-
C is able to drive fibrosis (Bhattacharyya et al., 2016) and so this may correlate with 
the increased fibrosis seen in the CCP negative patients. Other studies have shown that 
CCP negative RA patients achieve less disease remission than positive patients when 
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treated with the conventional disease modifying anti-rheumatic drug methotrexate 
(Wevers-de Boer et al., 2012, van Dongen et al., 2007). Previous studies have shown 
that methotrexate, unlike biologic therapies, was unable to reduce tenascin-C FNIII-C 
levels in RA patients (Page et al., 2012). Thus, it could be postulated that CCP negative 
patients have a more tenascin-C driven form of disease which is less receptive to 
methotrexate treatment. FNIII-C tenascin-C levels have also been shown to correlate 
with disease severity and response to biologic therapies, with some prognostic ability 
for predicting responsiveness to the biologic therapeutic infliximab shown (Page et al., 
2012). Future work with better clinically described cohorts would be is needed to see 
if this association is true for total tenascin-C as well.  
5.6.8 Forms of tenascin-C in human serum 
The results of the various assay formats, detecting different forms of tenascin-C, 
presented in this chapter highlight the heterogeneity of serum tenascin-C. The 
differences in isoforms of tenascin-C present in RA and healthy controls, as suggested 
by the IBL ELISAs, was also shown by western blotting. In both healthy control and 
RA patients two major molecular weight forms were seen at 200 and 280kDa. In 
addition, another, albeit less abundant, band was also observed in RA sera alone at 
approximately 210kDa suggesting the presence of a disease specific splice variant. 
Tenascin-C splicing is known to be regulated and promoted in a number of disease 
conditions including, inflammation, with functional consequences (Giblin and 
Midwood, 2015, Giblin, 2018). As such, further investigation of the forms identified 
here are warranted.  
Another, form of variation investigated in this chapter was the presence of tenascin-C 
interacting partners in serum. As a large multi-modular ECM molecule tenascin-C is 
known to bind a wide array of partners, from other ECM molecules, to soluble 
signalling factors, as well as a variety of cell surface proteins (Midwood et al., 2016). 
As such, its ability to retain binding to these factors and accompany them while 
circulating was of interest. Mass spectrometric analysis identified fibronectin as a 
serum binding partner in both healthy control and RA serum. Fibronectin is a 
ubiquitously expressed ECM component but is also secreted into the blood by liver 
hepatocytes to exist as a distinct form in the circulation (To and Midwood, 2011b). 
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Plasma fibronectin has been previously described as a tenascin-C interactor in vitro 
(Chung et al., 1995) and the data in this chapter would support that this interaction has 
in vivo relevance. The functional implications of this interaction remain to be 
elucidated; however, plasma fibronectin is known to form part of fibrin clots formed 
in response to tissue injury. Tenascin-C likewise has been shown to accumulate 
adjacent to tissue wounds less than 24hrs after wounding (Mackie et al., 1988). 
Moreover, tenascin-C has also been shown to promote fibrin accumulation and localise 
in close proximity to it in pulmonary fibrotic lesions (Brellier et al., 2011). As such, 
recruitment of circulating tenascin-C could present another means by which the protein 
is upregulated and plays a role at sites of tissue injury. The association with circulating 
fibronectin in this scenario may also aid in the rapid deposition of the protein as it has 
been shown fibronectin is needed for tenascin-C incorporation into the matrix (Ramos 
et al., 1998). Furthermore, a reciprocal aspect of this relationship has also been 
observed with less fibronectin accumulating in the granulation tissue of tenascin-C KO 
mice after dermal wounding (Forsberg et al., 1996).  
The fibronectin interaction may also have implications for the 9F8-NSCT-121 
sandwich ELISA, with the binding site of plasma fibronectin mapped to the 1-5 FNIII-
type repeats of fibronectin (To and Midwood, 2011a). This overlaps with the 9F8 
epitope on tenascin-C, which is located within the 1-3 FNIII-type repeats. As such, 
fibronectin binding to tenascin-C may compete with or completely inhibit recognition 
of tenascin-C by 9F8. This may be further affected by tenascin-C alternative splicing 
as the inclusion of additional FNIII-type repeats was shown to result in lower affinity 
to plasma fibronectin (To and Midwood, 2011a). 
Besides splicing and binding partners, additional aspects of tenascin-C variation while 
not directly investigated here should also be considered. This includes post 
translational modifications such as glycosylation, which has already been shown to 
vary by cell type (Mangan et al., 2019). This has potential implications for the 
molecular weight variant isoforms observed, which may have additionally been 
affected by their state of glycosylation. Citrullination may be another modification 
worth probing, as other RA citrullinated autoantigens such as fibrinogen have been 
detected in the circulation as part of immune complexes (Zhao et al., 2008). No 
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citrullination of circulating tenascin-C was detected in the current study although this 
may simply reflect technical limitations of the techniques employed.  
5.6.9 Study considerations and limitations 
Interpreting the results in this chapter a number of limitations and considerations 
should be made. Firstly, the patient and control cohorts investigated must be 
considered. Ascertainment bias could be a factor in the study, as CCP based assays are 
present in diagnostic guidelines and used routinely in the clinic for diagnosis of RA 
(Aletaha et al., 2010). Therefore, recruitment and classification as an RA patient within 
the cohorts studied is likely biased towards the CCP assay. This affect has been 
suggested in other studies using cohorts that recruited patients early in diagnosis before 
the CCP assay was used and showed a higher proportion of cTNC5 positive samples 
in the CCP negative groups (Schwenzer et al., 2019). In addition, when making 
comparisons of the current study to studies reported in the literature, the differences 
between study design and patient inclusion should be considered. For example, 
different results will be obtained when diagnostic accuracy is assessed in a study in 
which healthy donors are used as negative controls, versus a study using a more 
clinically representative population (Usher-Smith et al., 2016). This variation in test 
performance between different settings, referred to as the spectrum effect, were 
demonstrated in this study itself, with inclusion of non-RA diseased patients affecting 
the diagnostic ability of all the assays investigated. 
The general characteristics of the patients cohorts studied should also be considered. 
For example, the RA cohorts utilised in this study comprised mainly elderly patients 
with well-established disease. This likely impacted results as the CCP test is known to 
perform differentially in early versus established disease (Demoruelle et al., 2013). 
Likewise, age of disease onset is another factor known to influence ACPA prevalence 
which could also have impacted results (Boeters et al., 2017). Differences have also 
been observed between different geographic populations, for example differences in 
ACPA fine specificities has been shown between Malaysian and Swedish RA patients 
(Too et al., 2017). These regional differences suggest that while overall disease 
characteristics may be similar, different underlying genetic or environmental factors 
may be in play. This is of note due to the inclusion of geographically separated cohorts 
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in this study with samples derived from patient populations in Mexico, the UK, and 
Switzerland. No overt differences were observed between the RA cohorts investigated 
and the cTNC5 autoantibody response. In contrast differences were observed with the 
total tenascin-C ELISAs, with lower tenascin-C levels seen in Mexican versus UK RA 
patients, suggesting the potential influence of a regional environmental factor. A final 
uncontrolled variable in the cohorts was patient treatment or disease activity which is 
likely to have had a major impact on anti-cTNC5 and anti-tenascin-C assay results.  
For example, it has been reported that treatment with the steroid prednisolone 
abrogated the CCP assays ability to predict radiographic joint damage (Hafstrom et al., 
2014). Tenascin-C FNIII-C concentrations were likewise shown to be impacted by 
therapy with a decrease in tenascin-C levels observed with administration of biologic 
therapy (Page et al., 2012). Therefore, it is possible that the heterogeneity of patient 
treatment and disease activity could have affected the results.  
 Tenascin-C: A marker and driver of inflammation 
Chapter 6 – Final Discussion and Future Research 262 
Chapter 6 Final discussion and future research 
6.1 General discussion 
6.1.1 Role of tenascin-C in IBD 
Immune mediated inflammatory diseases (IMIDs) represent a growing medical 
problem globally with a high burden on both patients as well as society as a whole 
(Russell et al., 2011, Baumgart et al., 2019). Inflammatory bowel disease (IBD), as 
one of the most common IMIDs, is no different in this regard with increasing incidence 
and prevalence in the UK (Molodecky et al., 2012), with rising associated costs to the 
National Health Service, which are estimated to already be in excess of £1 billion per 
year (Ghosh and Premchand, 2015). As such, with health services faced by this 
mounting challenge, the need to properly understand the aetiology and disease drivers 
of this enigmatic condition is greater than ever.  
Much progress has been made in regard to this in recent decades with the identification 
of perturbations in epithelial barrier integrity and microbial dysbiosis which are now 
among some of the key factors implicated in disease pathogenesis (Chassaing and 
Darfeuille-Michaud, 2011, Antoni et al., 2014). In terms of disease drivers much 
progress has also been made with the identification of the key role of the pro-
inflammatory cytokine TNF being arguably the biggest landmark finding in recent 
decades (Neurath, 2014). However, the puzzle is still very much incomplete with other 
factors contributing to this complex disease still yet to be identified and characterised. 
The work of this thesis has focused on one such potential factor, the ECM glycoprotein 
tenascin-C.  
The ECM was once thought of as a static scaffold but is now well recognised as key 
modulator of cellular behaviour and function (Hynes, 2009). This includes behaviour 
in inflammatory disease as well as in health, with the recognition of its importance 
leading to research which is now opening up this previously untapped reserve of 
pathophysiologically relevant factors (Korpos et al., 2009, Sorokin, 2010). IBD is no 
exception to this with the role of the ECM and it’s pathological remodelling now 
implicated in a variety of disease processes, from the structural changes seen in 
fistulisation and stricture formation, to providing direct pro-inflammatory stimulation 
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to the pathological response (Shimshoni et al., 2015, Petrey and de la Motte, 2017). It 
is in this latter role which tenascin-C is implicated as a driver and propagator of the 
inflammatory response. Animal models of disease have implicated tenascin-C in this 
role in variety of diverse IMIDs, from RA (Midwood et al., 2009) to multiple sclerosis 
(Momcilovic et al., 2017), with the work of this thesis adding IBD to this list as well. 
This includes the work of chapter 3 which demonstrated tenascin-C’s upregulation in 
the damaged and inflamed mucosal tissue of the DSS colitis model. This was further 
corroborated by the work of chapter 4 which additionally provided evidence for 
tenascin-C’s direct role in the inflammatory pathology as indicated by the partially 
protective phenotype seen in Tnc-/- mice. 
While not addressed directly in this thesis a number of previous mechanisms for 
tenascin-C’s pro-inflammatory activity have been reported and shown to have in vivo 
pathological relevance in other models of inflammatory disease. As such, with the 
apparent usage of the same or similar pathological mechanisms across different IMIDs 
(Rahman et al., 2010), it can be reasonably speculated that these same mechanisms 
may explain some of the observations made with the DSS colitis model in this thesis 
as well. This includes tenascin-C’s ability to signal via the α9β1 and αVβ3 integrins 
(Kanayama et al., 2011, Shimojo et al., 2015), as well as the PRR TLR4 (Midwood et 
al., 2009). Indeed, links between these pathways and IBD already exist with the gene 
ITGAV, which codes for the αV subunit of the αVβ3 integrin, found to lie within in an 
IBD associated locus in a genetic association study (de Lange et al., 2017). 
Additionally, for TLR4 a significant body of work has already established this 
receptors link to the disease. This has similarly included genetic association studies 
which have found polymorphisms in the receptor associated with IBD in a number of 
diverse patient cohorts (Ao et al., 2015, Cheng et al., 2015). Furthermore, these 
associations have been found to have additional phenotypic correlations with some 
variants associated with more aggressive disease course and extraintestinal 
manifestations, such as arthritis (Dragasevic et al., 2017, Feki et al., 2017). TLR4 is 
found to be expressed at increased levels in both epithelial and lamina propria cells of 
IBD patients (Vamadevan et al., 2010). Additionally the macrophages in the latter 
population also show a hyperresponsiveness to TLR stimulation leading to production 
of a number of key IBD mediators, including TNF, IL-6, and IL-23 (Bain and 
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Schridde, 2018). Together these data indicate that the TLR4 signalling pathway, 
known to be activated by tenascin-C, displays a clear association with IBD 
pathogenesis which may explain the protective effects of tenascin-C’s loss in DSS 
colitis.  
It should be kept in mind however, that the role of tenascin-C in the inflammatory 
response has been shown to not always be so clear cut of a pathological nature. This 
has already been mentioned for the cases of chemically induced dermatitis (Koyama 
et al., 1998) and toxin induced glomerulonephritis (Nakao et al., 1998) in which Tnc-/- 
mice showed defective tissue regeneration. It is perhaps best exemplified in the case 
of osteoarthritis (OA) however, as it shares a similar localisation of pathology to the 
joint as RA, a disease in which tenascin-C’s role in driving has been already 
highlighted (Midwood et al., 2009). OA is characterised as a degenerative disease of 
the whole joint in which structural alterations and breakdown of the articular cartilage 
and subchondral bone leads to pain and joint dysfunction (Hunter and Bierma-Zeinstra, 
2019). In both spontaneous and surgical models of OA Tnc-/- mice showed slower 
cartilage repair and enhanced cartilage degeneration (Okamura et al., 2010). 
Furthermore, more recent studies have shown that injection of exogenous glioma cell 
line purified tenascin-C into the joints of a surgical OA model slowed joint 
degeneration (Matsui et al., 2018). This is surprising considering injection of similar 
amounts of recombinantly produced FBG domain of tenascin-C into joints has been 
shown to induce synovitis and joint damage (Midwood et al., 2009). This demonstrates 
the multifunctional nature of the different domains of tenascin-C and highlights its 
potential roles at different stages of the inflammatory response. 
Indeed, this duplicitous nature in fact mirrors a similar phenomenon which has been 
found for TLR4 signalling in models of IBD as well in which the receptor has been 
found to have protective functions. This has been evidenced in several studies of TLR4 
knockout (Tlr4-/-) mice in the DSS colitis model which found, counterintuitively based 
on its pro-inflammatory nature, that TLR4 deficiency actually worsened colitis 
(Rakoff-Nahoum et al., 2004, Fukata et al., 2005, Shi et al., 2019). This was attributed 
to the fact that, while the Tlr4-/- mice exhibited reduced granulocyte infiltration, their 
mucosal healing was perturbed leading to increased tissue damage and associated 
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intestinal bleeding, and bacterial invasion. Furthermore, this was found to mimic the 
phenotype of Myd88-/- mice suggesting that there affects were mediated via the 
myddosome extracellular signalling pathway, rather than the alternative intracellular 
TRIF pathway, by which TLR4’s protective signalling was acting (Rakoff-Nahoum et 
al., 2004, Araki et al., 2005). This was suggested to be due to TLR4’s ability to induce 
production of signalling factors, including prostaglandin E2 (PGE2) and granulocyte-
macrophage colony-stimulating factor (GM-CSF)(Shi et al., 2019), which have known 
roles in promoting intestinal tissue repair (Egea et al., 2013, Miyoshi et al., 2017). As 
the Tnc-/- mice did not show any deficiencies in mucosal healing, as evidenced in the 
DSS recovery model, this suggests that tenascin-C signalling does not contribute 
significantly to this pathway. Indeed, it could be argued that tenascin-C actually acts 
to tip the balance in TLR4 signalling towards a more pro-inflammatory and thus tissue 
damaging response, for example by its ability to promote TNF production in response 
to TLR4 stimulation (Piccinini and Midwood, 2012). Overall, this demonstrates the 
contrasting roles, factors, receptors, and signalling pathways can play at different 
stages of the inflammatory response and the importance of feedback loops and changes 
in signalling context. This is particularly important to consider when considering the 
possibility of targeting tenascin-C therapeutically. 
6.1.2 Tenascin-C as a therapeutic target in inflammatory 
disease 
In recent years great gains have been made with the introduction of antibody based 
biologic therapies targeting specific mediators of inflammatory disease and IBD is no 
different. Indeed, IBD was actually the first IMID to be targeted by these therapies 
with the trailblazer anti-TNF antibody infliximab first tested and shown efficacy in the 
treatment of a Crohn’s disease patient in 1993 (Derkx et al., 1993). Infliximab 
subsequently received its first in class marketing approval by the American Food and 
Drug Administration (FDA) in 1998 (Melsheimer et al., 2019) and since then the 
biologics field has rapidly grown as research has expanded the list of potential targets 
and improved antibody technologies. Currently three major classes of biologics are 
approved for the treatment of IBD which target TNF, IL-12/23, and α4 integrin 
receptors respectively with all having demonstrated good efficacy in clinical trials 
(Paramsothy et al., 2018). However, while a significant breakthrough, these therapies 
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still have shortcomings with for example 30% of patients failing to respond to anti-
TNF agents which increases further when accounting for patients who develop loss of 
responsiveness later in treatment (Yanai and Hanauer, 2011). Furthermore, these 
therapies also do not come without their downsides with an increased risk of infection 
or malignancy having been established for some of the therapies (Quezada et al., 
2018).  
With this current treatment landscape there is obviously clear unmet clinical need and 
thus opportunity for novel treatments to emerge. The work of this thesis would raise 
tenascin-C as one such potential candidate to pursue with chapter 4’s work showing 
its ablation is protective of disease. Indeed, tenascin-C already has a long-established 
relationship as a target of biologic therapy in the field of oncology where anti-tenascin-
C antibodies have been used to target radioactive iodine to gliomas in human patients 
as far back as 1988 (Lee et al., 1988, Spenle et al., 2015). Of greater relevance to IBD 
however is more recent efforts to develop an anti-tenascin-C therapy aimed at 
disrupting the FBG-TLR4 interaction and thus help dampen the proteins pro-
inflammatory activity. These efforts are currently focused on applying this therapy to 
RA where the role of TLR4 signalling in disease is well known with anti-TLR4 
biologic therapies also in development (Monnet et al., 2017) having shown efficacy in 
animal models (Kiyeko et al., 2016). These therapies raise concerns of potential 
adverse immunosuppression however, with a number of immunodeficiency syndromes 
associated with increased susceptibility to infection caused by defective TLR 
signalling (Maglione et al., 2015). Furthermore, this approach as was indicated by the 
findings in Tlr4-/- mice is unlikely to be efficacious in IBD. In regard to this a separate 
anti-TLR4 antibody used in a DSS colitis study has already demonstrated that this 
approach recapitulated the abrogated mucosal healing phenotype of the Tlr4-/- mice 
(Ungaro et al., 2009). As such, targeting the ligand tenascin-C presents itself as a 
potentially more amicable option for therapy.  
This approach has already demonstrated efficacy in an animal model, with a rat 
collagen-induced RA model showing significant reductions in both clinical and 
histological disease scoring with anti-tenascin-C antibody treatment (Aungier et al., 
2019). These early findings are promising and not just necessarily for RA with the 
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previous success of transfer of biologic therapies between IBD and RA seen with the 
anti-TNF therapies, attributed to common shared pathological mechanisms (Kuek et 
al., 2007). With the findings in this thesis of Tnc-/- mice protected in an IBD model 
similarly to how they were protected in a range of RA models this suggests that 
tenascin-C may be playing a role in another common disease mechanism. As such, 
therapies targeting this mechanism, diagrammatically summarised in figure 6.1, may 
have applicability across both conditions as well.  
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6.1.3 Clinical applicability of tenascin-C as a biomarker 
As has been explored in this thesis therapy is not the only area in which tenascin-C has 
shown promise for clinical application with its systemic form and autoantibodies 
against it candidate biomarkers as well. Biomarkers are of increasing clinical 
importance as objective tests for diagnostic and prognostic management of patients 
become ever more important as medicine switches to a more personalised approach 
(Committee, 2011). This is particularly true of complex diseases like IMIDs whose 
combination of non-specific symptoms and often lack of objective diagnostic and 
prognostic tests, especially in the early stages of disease, leads to a delay in diagnosis 
and impaired clinical management (Alonso et al., 2016). 
To this end tenascin-C has already been investigated as a biomarker in a variety of 
conditions, including cancer and heart disease (Midwood et al., 2011), as well as a 
range of IMIDs (Marzeda and Midwood, 2018). However, these analyses have been 
somewhat hamstrung by the lack of a simple, accurate, and robust assay for the 
measurement of total tenascin-C levels in biological samples. In chapter 5 of this thesis 
I have aimed to help address this issue with the development and characterisation two 
novel assays for measurement of tenascin-C and tenascin-C specific autoantibodies in 
human serum samples.  
Both of these assays demonstrate some degree of clinical utility, with significantly 
elevated levels of tenascin-C and autoantibodies against it found in RA patient 
samples. However, the lack of disease specificity seen with the total tenascin-C ELISA 
and reduced sensitivity in comparison with the current gold standards for the 
autoantibody test, suggest these assays are unlikely to find diagnostic utility in a 
clinical setting.  Instead, their utility is likely to be better realised in the stratification 
of patients with tenascin-C acting as a direct or proxy marker for specific disease 
mechanisms with potential clinical implications for patient management. Furthermore, 
as discussed earlier with the potential for these disease mechanisms to be shared 
between a range of IMIDs these tests could potentially also be applicable to a range of 
different IMIDs as well. Indeed, it could be envisaged that these tests might find use 
as companion diagnostics for anti-tenascin-C based therapies, allowing application of 
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the therapy to patients in which tenascin-C appears to be particularly elevated or 
involved in disease pathogenesis (Cutolo et al., 2019).  
6.2 Directions for future research 
Based on these as well as earlier conclusions on the roles and function of tenascin-C 
in inflammatory disease a number of key questions have arisen or remain to be 
answered. 
6.2.1 Function of basal expression of tenascin-C and non-
pathological roles 
One key question, which has remained unanswered since the generation of the first 
Tnc-/- mouse, is what function basal expression of tenascin-C in tissues serves. Chapter 
3 found a not insignificant amount of tenascin-C present in the resting colon which 
was found to localise to smooth muscle and a subepithelial band in the mucosa. 
Chapter 5 meanwhile found an equally not insignificant amount of tenascin-C present 
in normal healthy human serum. With the apparent health and normal tissue function 
of Tnc-/- mice no obvious function of either of these reservoirs of basal tenascin-C 
protein can be readily attributed. As such, is it safe to assume, as was postulated at the 
time of the generation of first Tnc-/- mouse, that this expression may simply be 
superfluous, perhaps a quirk of the evolution of the transcriptional regulation of genes 
(Erickson, 1993)? I would argue no, as was found back then, it may simply be the 
phenotypes are more subtle in locations or context yet to be examined or than can be 
readily detected utilising the current models and tools available.  
In regard to this a number of experiments can be proposed to help tease out these 
functions. Firstly, further characterisation of tenascin-C producing cells and 
transcriptional programs, under basal conditions, may aid in inferring function. This 
could be studied in current transcriptomic datasets with the mapping of co-expression 
networks around tenascin-C potentially able to infer function based on the known 
functions of its co-expressors and their shared regulatory networks (Li et al., 2017). 
Additionally, a much more costly approach would be to apply lineage tracing, to label 
tenascin-C producing cells in vivo, and single cell transcriptional approaches to further 
dissect these cells functions once isolated (Kester and van Oudenaarden, 2018). Both 
of these approaches could help in the teasing out of tenascin-C’s potential functions or 
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relevance in the colon. However, the source of the tenascin-C found in circulation 
proves a much more challenging prospect to determine, with its potential to be 
produced in any of the vascularised organs of the body. In this case generation of 
conditional tissue or cell type specific knockouts of tenascin-C combined with serum 
measurement of the protein may prove the only method of identifying the source. In 
particular, the smooth muscle cells of the vasculature as well as hepatocytes of the 
liver may prove prospective first targets with the former known to produce tenascin-C 
in close proximity to the circulation, and the latter known to produce the majority of 
serum proteins found within the blood.  
The roles of both of these basal reservoirs of tenascin-C protein may turn out still to 
be related to the inflammatory or immune response albeit in a non-pathological 
context. Indeed, this is another area of research worth pursuing further as while much 
work has been done on tenascin-C’s function in pathological inflammation it’s 
physiological role in the process has been less closely scrutinised. Indeed some studies 
have already hinted at perhaps perturbed immunity with the reduction in TNF and IL-
17 production by Tnc-/- mice (Piccinini and Midwood, 2012, Ruhmann et al., 2012). 
However, the exact impacts of these deficiencies in models of infection remains to be 
seen and dissected. Indeed, these studies themselves may prove important in 
evaluating the potential risks which tenascin-C targeting therapeutics might pose.  
6.2.2 Further dissection of tenascin-C’s specific roles in 
colonic inflammation 
While the work of this thesis has descriptively profiled tenascin-Cs localisation in DSS 
colitis further work remains to identify its specific roles in intestinal inflammation. 
These can somewhat be inferred from the phenotypes of Tnc-/- mice as well as tenascin-
C’s proven roles in other inflammatory disease contexts. However, with the context of 
the inflammatory response shown to be so important and the GI immune system so 
specialised, especially in contrast to the sterile environment of an RA joint, further 
work is needed to more precisely characterise tenascin-C’s role in intestinal 
inflammation. Indeed, in the studies undertaken in chapter 5 further analysis was 
planned with samples collected for the interrogation of colonic gene expression in both 
WT and Tnc-/- mice under basal and colitic conditions. Completion of this work would 
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give a first glimpse at the functional consequences of tenascin-C loss on specific 
inflammatory factors in the colon. Additionally, the DSS model is amendable to cell 
type specific analysis by applying flow cytometry to colon extracted cells (Weigmann 
et al., 2007). Again, by combining this technique with the Tnc-/- mouse a more 
comprehensive as well as quantifiable overview of the impacts of tenascin-C on the 
various cell indicated to be involved in IBD could be undertaken. Furthermore, 
isolation of cells types of interest by cell sorting would additionally allow for even 
more detailed analysis. This could come in the form of cell type specific transcriptional 
or proteomic analysis as well as ex vivo manipulation and experimentation, such as 
stimulation with exogenous tenascin-C. Another aspect of biology which could be 
probed with particular relevance to IBD is metabolomics, with the interaction between 
gut microbiome produced metabolites and immune cells a growing area of interest 
(Franzosa et al., 2019). Additionally, it is now well known that other inflammatory 
activation can produce profound changes in cell metabolism (O'Neill et al., 2016) and 
so it would be of interest to examine tenascin-C’s impact on this aspect of biology and 
how it might interact with IBD associated bacterial dysbiosis in the gut. 
Besides these experiments which can be carried out with the already established 
models future experiments could also look to expand upon these with additional IBD 
models. This could include the use of other inducible chemical models of colitis with 
different modes of pathogenesis. One example is trinitrobenzene sulfonic acid (TNBS) 
colitis which induces pathology by intra-rectal administration of the TNBS 
haptenizing agent which creates neo-antigens which induce an immunogenic reaction 
in the colon (Wirtz et al., 2017). Non-chemical models could also be investigated such 
as the T cell transfer model, in which a pro-inflammatory population of T cells 
depleted of Tregs are transferred to immunodeficient Rag1-/- mice which subsequently 
develop colitis (Ostanin et al., 2009). Both these models have greatly different 
mechanisms of action from DSS colitis, with different integral cell types and 
inflammatory mediators (Strober et al., 2002). These experiments could thus help 
unravel tenascin-C’s role in other immune compartments in intestinal inflammation. 
The T cell transfer model, being adaptive immune driven in contrast to innate driven 
DSS colitis, could be of particular interest in Tnc-/- mice given tenascin-C’s apparent 
immunosuppressive roles in terms of T cells (Mirzaei et al., 2018). Non-inducible 
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genetic models could also be investigated for tenascin-C involvement with Il-10-/- 
mice, deficient in the anti-inflammatory cytokine IL-10 required for gut immune 
homeostasis, probably the best known example (Kuhn et al., 1993). This model could 
additionally be further probed by generation of Tnc-/- Il-10-/- double knockout mice to 
examine tenascin-C’s role in this spontaneous disease model.  
Besides Tnc-/- mice, novel genetically engineered tenascin-C models could also be of 
benefit in teasing out tenascin-C’s roles in IBD. In particular a conditional knockout 
system for tenascin-C would be of great utility in a variety of ways. For a start this 
model could be used to generate cell type specific knockouts and reporter systems of 
tenascin-C in the gut. These could be used to confirm the key tenascin-C producers in 
vivo and whether tenascin-C’s impacts on certain cells is in an autocrine or paracrine 
manner during inflammation. Additionally, generation of inducible systems could 
allow for control of induction or ablation of tenascin-C expression which if carried out 
at different time points would allow for further picking apart tenascin-C’s roles in the 
different stages of inflammatory response. Besides knocking out tenascin-C knock-in 
mutants of the protein could also potentially be generated with key signalling sites 
inactivated or modified to assess their individual contributions to driving the 
inflammatory process. Indeed, such inactivating mutants have already been generated 
during the validation of the TLR4 and integrin IDG binding sites and thus would just 
need to be integrated into full length tenascin-C targeting vector to be utilised 
(Yokosaki et al., 1998, Zuliani-Alvarez et al., 2017). 
6.2.3 Comprehensive characterisation of the different forms of 
tenascin-C  
To fully understand tenascin-C’s functionality, in health as well as disease, a better 
understanding of its various forms and modifications will likely be necessary. 
Tenascin-C displays remarkable variety with variable splicing and a number of post-
translational modifications which have already been shown to impact its functionality 
(Giblin and Midwood, 2015). Further elucidation of these mechanisms will potentially 
provide explanations for a range of questions, such as how basally expressed tenascin-
C regulates its pro-inflammatory properties, with modifications modulating its 
functionality in different contexts. Much of the work thus far done in this regard has 
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been in in vitro settings particularly in models involving exposing cultured cell lines 
to purified tenascin-C or domain fragments derived from it. While proving informative 
these studies obviously lack important context including the exact forms of tenascin-
C present in the in vivo context of a complex 3D ECM.  
To answer these questions the immunoprecipitation assay developed in chapter 5 
should prove useful in allowing for the simplified purification of tenascin-C from 
biological samples for subsequent analysis. This was already partly begun in chapter 
5 for serum with molecular weight forms and binding partners probed for by mass 
spectrometry and western blotting. Far more detailed analysis is possible however with 
splice forms able to be probed with antibodies specific to the different alternatively 
spliced repeats. Additionally, PTM mapping by mass spectrometry looking at 
modifications such as glycosylation, phosphorylation, and citrullination would also be 
possible. Following the identification of these mapped modifications their 
functionality could then then be better explored. This might be best done initially in 
vitro with recombinant tenascin-C artificially modified to match in vivo forms before 
application to cell lines. Additionally, recombinant tenascin-C could itself be 
engineered to lack for example key modified residues to further establish their 
functionality by studying what occurs with their disruption. 
As well as informing studies of tenascin-C’s function probing its variation might also 
aid its further development as a biomarker as well by potentially identifying specific 
disease associated forms. In combination with the ELISAs developed in chapter 5 
these could be further investigated in better described prospective cohorts and might 
provide an additional measure by which to stratify patients into clinical subgroups.  
In summary these proposed additional investigations would help to further characterise 
tenascin-C’s role in health and disease and provide further mechanistic insight into the 
diverse nature of a highly variable protein. This greater understanding it is hoped could 
aid in the potential development of clinical tools based on tenascin-C for the treatment 
and management of chronic inflammatory disease. 
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Appendix 
Appendix I - Commercial buffer recipes 
TE buffer 
1mM EDTA, 10mM Tris-HCl pH8  
1x TAE buffer 
1mM EDTA, 0.1 % acetic acid, 40mM Tris 
10x PCR buffer 
500mM KCl, 200mM Tris-HCl pH 8.4 
5X First-Strand Buffer  
75mM KCl, 15mM MgCl2, 250mM Tris-HCl, pH 8.3 
Radioimmunoprecipitation assay (RIPA) buffer 
150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 25mM Tris-HCl 
pH7.6 
Ponceau S Solution 
0.1% Ponceau S, 5% Acetic Acid  
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Supplier  Species and isotype Working 
concentration 
Tenascin-C MTn-12 Sigma-Aldrich  Rat monoclonal IgG1 1µg/ml 
 NSCT-121 Nascient Ltd Human monoclonal IgG4 1µg/ml 
CD3 17A2 Biolegend Rat monoclonal IgG2b 10µg/ml 
B220 RA3-6B2 Biolegend Rat monoclonal IgG2a 1µg/ml 
CD11c HL3 Biolegend Armenian Hamster 
monoclonal IgG 
10µg/ml 
CD31 MEC13.3 Biolegend Rat monoclonal IgG2a 1µg/ml 
CD326 G8.8 Biolegend Rat monoclonal IgG2a 1µg/ml 
LYVE-1 ab14917 Abcam Rabbit polyclonal 10µg/ml 
Collagen IV ab6586 Abcam Rabbit polyclonal 1µg/ml 





Supplier  Species and isotype Working 
concentration 
or dilution 
Tenascin-C MTn-12 Sigma-Aldrich  Rat monoclonal IgG1 1µg/ml 
 NSCT-121 Nascient Ltd Human monoclonal IgG4 1µg/ml 
 B12 Nascient Ltd Mouse monoclonal IgG2a 10µg/ml 
 BC-24 Sigma-Aldrich  Mouse monoclonal IgG1 1µg/ml 
Fibronectin F14 Abcam Rabbit monoclonal IgG 0.27µg/ml 
β-Actin 13E5 Cell Signalling 
Technology 
Rabbit monoclonal IgG 1 in 5000 
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Supplier  Conjugate Working 
concentration 
Anti-rat IgG A-11006 Sigma-Aldrich  Alexa Fluor 488 2µg/ml 
Anti-rat IgG 112-065-167 Jackson 
Immunoresearch 
Biotin 2µg/ml 
Anti-rat IgG1 MRG1-58 Biolegend FITC 2µg/ml 
Anti-rat IgG2a MRG2a-83 Biolegend Alexa Fluor 594 2µg/ml 
Anti-rat IgG2b MRG2b-85 Biolegend Alexa Fluor 594 2µg/ml 
Anti-rabbit IgG A-11012 Biolegend Alexa Fluor 594 2µg/ml 
Anti-Armenian 
hamster IgG 
Poly4055 Biolegend Alexa Fluor 594 2µg/ml 
Anti-goat IgG SA5-10080 Thermo Fisher DyLight 594 2µg/ml 
Anti-human IgG A-11014 Thermo Fisher Alexa Fluor 594 2µg/ml 





Supplier  Conjugate Working 
concentration 
Anti-human IgG 926-32232 LI-COR Biosciences  IRDye 800CW 0.3µg/ml 
Anti-mouse IgG 926-32212 LI-COR Biosciences  IRDye 800CW 0.3µg/ml 
Anti-rat IgG 926-32219 LI-COR Biosciences  IRDye 800CW 0.3µg/ml 
Anti-rabbit IgG 926-68073 LI-COR Biosciences  IRDye 680RD 0.3µg/ml 
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Appendix IV - Genotyping and qPCR primers 
Target Gene Supplier Pair Sequence (5’-3’) 
Genotyping    
Tnc Sigma-Aldrich F GAAGTCACTAGAAACTAGTGGACAACTC 
  R AAGATGCCTGGCAGTAGCCAGGTCAC 
LacZ Sigma-Aldrich F GAAGTCACTAGAAACTAGTGGACAACTC 
  R CTCCATGCTTGGAACAACGAGCGCAGC 
qPCR    
Tnc PrimerDesign F GCCACAGCCTGCCTACTG 
  R GGTTAAGCCACAACGAGTTCC 
18S rRNA Sigma-Aldrich F GTAACCCGTTGAACCCCATT 
  R CCATCCAATCGGTAGTAGCG 
Il-6 Sigma-Aldrich F TTCCATCCAGTTGCCTTCTTG 
  R AGGTCTGTTGGGAGTGGTATC 
Il-10 Sigma-Aldrich F CCCTTTGCTATGGTGTCCTTTC 
  R GATCTCCCTGGTTTCTCTTCCC 
TNFα Sigma-Aldrich F CAGACCCTCACACTCAGATCATC 
  R GGCTACAGGCTTGTCACTCG 
Il-12a (p35) Sigma-Aldrich F TATCTCTATGGTCAGCGTTCC 
  R TGGTCTTCAGCAGGTTTCG 
Il-1β Sigma-Aldrich F GACGGACCCCAAAAGATGAAGG 
  R GTGATACTGCCTGCCTGAAGC 
Il-23a Sigma-Aldrich F CAACTTCACACCTCCCTAC 
  R CCACTGCTGACTAGAACTC 
Il-17a Sigma-Aldrich F TTTAACTCCCTTGGCGCAAAA 
  R CTTTCCCTCCGCATTGACAC 
TGF-β1 Sigma-Aldrich F CCACCTGCAAGACCATCGAC 
  R CTGGCGAGCCTTAGTTTGGAC 
Cxcl1 Sigma-Aldrich F ACTGCACCCAAACCGAAGTC 
  R TGGGGACACCTTTTAGCATCTT 
IFNγ Sigma-Aldrich F TCAAGTGGCATAGATGTGGAAGAA 
  R TGGCTCTGCAGGATTTTCATG 
Il-22 Sigma-Aldrich F ATGAGTTTTTCCCTTATGGGGAC 
  R GCTGGAAGTTGGACACCTCAA 
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